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Abstract 
Staphylococcus aureus is an important human pathogen. The emergence of 
multiple antibiotic resistant bacteria and lack of new antibiotics has highlighted 
the need for better understanding of staphylococcal physiology, molecular biology 
and virulence.  In S. aureus the agr quorum sensing (QS) system is a global 
regulator of virulence. In the agr system an autoinducing peptide (AIP) activates 
the histidine protein kinase (HPK), AgrC, leading to a switch from the production 
of colonization factors to exotoxins. The S. aureus agr system has diverged such 
that there are four different agr groups, each with a distinct AIP capable of 
activating its cognate AgrC but inhibiting the AgrC of the other groups. To 
investigate the molecular basis for the recognition of AIPs by AgrC, 
transmembrane topology modelling together with site-specific mutagenesis were 
used. The transmembrane topology of AgrC was predicted to consist of six 
transmembrane helices (TMHs) and three extracellular loops with both the N- and 
C-terminals on the cytoplasmic side. Since AIP-1 and AIP-4 differ by a single 
amino acid residue, the S. aureus AgrC1 and AgrC4 proteins were compared to 
identify extracellular amino acids likely to be involved in AIP recognition. Site-
specific mutagenesis was used to exchange the key AgrC1 and AgrC4 amino acid 
residues in extracellular loops 1 and 2.  The response of these AgrC mutants was 
evaluated using a novel bioluminescent AIP reporter. The data obtained showed 
that differential recognition of AIP-1 and AIP-4 depend primarily on three amino 
acid residues in loop 2, but that loop 1 plays an essential for activation but not for 
inhibition of AgrC.  The data obtained also revealed that a single mutation in the 
AgrC1 loop2 results in conversion of (ala
5
)AIP-1 from a potent antagonist to an 
activator, essentially forcing the evolution of a fifth agr group.   
Attempts to identify AgrC in the cytoplasmic membrane using Western blotting 
failed, but data obtained using  an N-terminal gfp tag showed that AgrC is evenly 
distributed through out the membrane.  
xiv 
Since the processing of AgrD by AgrB to generate an AIP requires at least 3 steps 
- two endopeptidase steps and the formation of a thiolactone bond to form the 
macrocycle, it is likely that other proteins are involved in the processing of AgrD 
and export of the AIP. To identify potential AgrB partners, yeast two hybrid assay 
was employed which revealed a potential role for the putative ABC transporter 
Rlp in the processing and/or secretion of AIP.   
In summary, the data presented define the key amino acid residues involved in 
AIP/AgrC interactions and imply a role for proteins such as Rlp in AIP synthesis 
and export. 
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1 General Introduction 
1.1 Staphylococci 
Staphylococcus aureus is a coagulase positive member of the genus 
Staphylococcus which comprises of low G + C (30-40 mol%), non motile, non 
spore forming Gram-positive cocci with a diameter of approximately 1 µm 
belonging to the family Staphylococcaceae.  The word staphylococcus is derived 
from the Greek word staphylos meaning a bunch of grapes and refers to the way 
that S. aureus divide in more than one plane, forming clusters resembling grape 
bunches under the light microscope (Kloos W.E., 1998).  
 
The staphylococci are usually facultative anaerobes, growing better under aerobic 
than anaerobic conditions, capable of both respiration and fermentation.  The cell 
wall of staphylococci contains both peptidoglycan and teichoic acid.  The diamino 
acid in the peptidoglycan is L-lysine and the interpeptide bridge consists of 
oligoglycine (depending on the species some glycine may be substituted by L-
serine or L-alanine).  The genus is susceptible to lysis by lysostaphin, which 
cleaves the interpeptide glycine bridge, and is relatively resistant to lysozyme.  
Most species grow in the presence of 10% wt/vol sodium chloride over a 
temperature range of 10ºC to 40ºC (Kloos W.E., 1998).  
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Over 30 species of staphylococci have been identified (Kloos W.E., 1998) and 
they can be divided into coagulase-positive (e.g.,, S. aureus) and coagulase-
negative (e.g.,, S. epidermidis) strains.  The natural habitat of the staphylococci 
habitats includes the nasal cavity (anterior nares and pharynx), skin, mammary 
glands, genitourinary and respiratory tract of their host (Kloos W.E., 1998).  
About 30% of the human population are permanent or intermittent carriers of S. 
aureus in their nasal cavities (Wertheim et al., 2005) and  generally have a benign 
relationship with their hosts.  However if the host is damaged by trauma, or the 
hosts immune system is weakened the staphylococci can gain access to the host 
tissue and adopt the lifestyle of a pathogen (they are opportunistic pathogens).  
 
1.2 Pathogenicity of S. aureus 
S. aureus is a very successful opportunistic pathogen, its importance as a human 
pathogen was first described in 1884 by the Scottish surgeon Alexandra Ogston 
who discovered S. aureus in pus from surgical abscesses (Ogston, 1984).  S. 
aureus is responsible for a wide range of diseases ranging from skin infections like 
boils, furuncles and cellulitis which are usually causes only a mild discomfort and 
the hosts immune system prevents the infections from becoming more severe 
(Lowy, 1998).  More serious and potentially life threatening infections like 
bacteraemia, necrotising pneumonia and toxic shock syndrome are usually 
associated with people with multiple risk factors, e.g., trauma victims, drug 
3 
abusers, the new born and burn victims and patients with implanted medical 
devices (Lowy, 1998).  Staphylococcal enterotoxins are also frequently associated 
with bacterial food poisoning.  
Being colonised with S. aureus provides a reservoir for infection and subsequently 
increases the risk of infection (Wertheim et al., 2005;Kluytmans et al., 1997)and 
most S. aureus infections are due to already the present strain (Williams et al., 
1959;Gordon and Lowy, 2008).  Colonisation also provides a source of S. aureus 
spreading to both health care and community settings. 
 
The first step in infection is breach of the skin or mucous barriers allowing S. 
aureus access to the adjoining tissue and bloodstream.  S. aureus establishes itself 
by binding to molecules such as collagen, fibronectin and fibrinogen.  This is 
mediated by a group of cell surface proteins called microbial surface components 
recognizing adhesive matrix molecules (MSCRAMMs, Table 1-1 and Figure 1-1) 
(Patti et al., 1994;Foster and Hook, 1998) and other adhesions, e.g., isdA.  These 
adhesins are also responsible for the establishment of S. aureus infection on 
surgical implants such as catheters following conditioning with molecules such as 
fibrinogen.  Once S. aureus has established itself in the tissue it is able to grow 
and evade the immune system.  Biofilm formation on host and prosthetic surfaces 
renders it less susceptible to antimicrobials and facilitates evasion of host defences 
(Donlan and Costerton, 2002).   
 
4 
The formation of small-colony variants (SCVs, these are a slow growing 
subpopulation with a distinct phenotype and pathogenic traits able to revert to the 
more virulent wild-type phenotype) is another way of evading host defences and 
may contribute to persistent and recurring staphylococcal infections (Proctor and 
Peters, 1998;Kahl et al., 1998;Proctor et al., 1995).  
 
IsdA is an iron-regulated surface protein which plays multiple roles in the 
virulence of S. aureus. IsdA binds fibrinogen and fibronectin , plays an important 
role in nasal colonisation (Clarke et al., 2004;Taylor and Heinrichs, 2002) and 
protects the cell against apolactoferrin (Clarke and Foster, 2008), a human iron-
binding glycoprotein protein with bactericidal properties. It also confers resistance 
against the free fatty acids and antimicrobial peptides making up a part of the 
innate defence of the skin by making the cells more hydrophilic (Clarke et al., 
2007). 
 
The production of microcapsules (most clinical strains are sero type 5 or 8) 
produced via the cap5 and cap8 gene clusters (O'Riordan and Lee, 2004) is 
another way S. aureus can evade the host immune system.  S. aureus also secrete a 
chemotaxis inhibitory protein and produces an extracellular adherence protein, 
which interfere with the recruitment of neutrophils to the site of infection.  In 
addition to evading the immune system, S. aureus also produces leukocidins that 
destroy leukoctyes by forming pores in their membranes (Foster, 2005) (Table 1-1 
and Figure 1-1). 
5 
 
After the establishment of an infection, S. aureus produces numerous exoproteins 
that enable it to invade and destroy host tissue and migrate to other sites within the 
host.  By interacting with and activating the host immune system and coagulation 
pathways, S. aureus is capable of inducing septic shock (Timmerman et al., 
1993;Heumann et al., 1994).  The production of so called superantigens, e.g., 
TSST-1 (Toxic shock syndrome toxin) and Enterotoxins A-J, cause a sepsis-like 
syndrome by initiating a positive feedback loop with the immune system and 
thereby over activating it, creating a so called cytokine storm (McCormick et 
al., 2001).  S. aureus has also been reported escape the endosome from both 
professional and non-professional phagocytes and start replicating inside the cell, 
which could allow it to escape the immune system and serve as a reservoir for 
reoccurring infections (Qazi et al., 2001;Ogawa et al., 1985;Drake and Pang, 
1988;Hamill et al., 1986).  
 
It should be mentioned that all the different virulence factors used in invading, 
evading and combating host defences are not necessarily present in all S. aureus 
strains.  Hence, different strains vary in there ability to form biofilms, evade host 
defences, resist phagocytosis and induce toxic shock.  Table 1-1 provides an 
overview of virulence factors, their frequency of occurrence and their regulation. 
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Figure 1-1: S. aureus surface proteins and exoproteins, their times of expression and location. 
In an infection the lag- and exponential-phase would be the colonisation phase and the 
stationary phase can be compared to an abscess or another site of infection where the 
bacteria will accumulate. Reproduced from (Gordon and Lowy, 2008) 
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Table 1-1: Virulence determinants regulated by SarA and agr, their function and their 
distribution in S. aureus. This is by no means a complete list but gives an overview of the 
arsenal of virulence factors at the disposal of S. aureus. Modified from (Peacock et al., 2002) 
and (Cheung et al., 2004). N/A = unknown; N/E = No effect; + = upregulated by ; - = down 
regulated by. 
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Name 
Distributi
on (%) 
Putative function agr SarA 
Exoproteins     
Aureolysin 100 Metalloprotease - + 
Enterotoxin B 7-9 Exotoxin with superantigen activity + + 
Enterotoxin C 10-11 Exotoxin with superantigen activity + N/A 
Į-hemolysin 99-100 Cytolytic pore-forming toxin + + 
ȕ-hemolysin 79-89 Tissue invasion, Sphingmyelinase + + 
Ȗ-hemolysin 89-97 Potentiation of host ccell lysis, 
Bicomponent leukocidin 
+ + 
į-hemolysin 69-80 Potentiation of ȕ-hemolysin,  
Cytolytic toxin 
+ + 
Exfoliatins A and B 6-22, 0-3 Exotoxins with superantigen activity + N/A 
FAME  Fatty acid modifying enzyme + + 
HysA, (Hyaluronate lyase)  Tissue invasion + N/A 
Lipase  Evasion of host defences + - 
Phospholipase C  Lysis of host cells + N/A 
Set8 Superantigen-like protein + N/A
Set9  Superantigen-like protein + N/A 
SplA, B, D and F  Proteases + + 
SspB  Cysteine protease N/A - 
Staphylokinase  Evasion of host defences + N/A 
TSST-1  Exotoxin with superantigen activity + + 
V8 protease (serine protease)  
Tissue invasion and modification of 
surface proteins 
+ - 
Panton valentine leukocidin  Bicomponent leukocidin + N/A 
CHIPS  Chemotaxis inhibitory protein   
MSCRAMMs     
Clumping factor A 98-100 Adhesin to fibrinogen N/E N/A 
Clumping factor B 100 Adhesin to fibrinogen N/E N/A 
Coagulase Binding to fibrinogen - +
FibA protein  Binding to fibrinogen   
Collagen-binding protein 32-52 Adhesin to collagen ± - 
Capsular polysaccharide type 5 
and 8 
16-26,55-
65 
Anti-phagocyte molecules + + 
Fibronectin-binding protein A 87-98 Adhesin for fibronectin - + 
Fibronectin-binding protein B  Adhesin for fibronectin - + 
Protein A 90-94 
Binds Fc domain of immunoglobulin 
and von Willibrand factor 
- - 
SdrC 100 Putative adhesin N/A + 
Vitronectin-binding protein   - N/A 
Map/Eap 93-96 
MHC ClassII analogous / 
eltracellular adherence proteins 
  
Other agr /sar regulated factors     
PBP3  Penicillin binding protein N/A - 
FemA  
methicillin resistance expression 
factor 
N/A + 
FemB  
methicillin resistance expression 
factor 
+ N/A 
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The growth phase dependent regulation of virulence factors in S aureus seen in 
vitro, where adhesins are expressed before haemolysins, proteases and other exo-
proteins, have also been shown to occur in vivo  (Novick, 2003).  The importance 
of agr in animal models has been demonstrated in various studies.  Thus, strain 
8325-4 ǻagr was demonstrated to be significantly less virulent than its wild type 
8325-4 parent strain in a mouse arthritis model (Abdelnour et al., 1993).  Cheung 
et al (1994) later showed that agr also played an important role in a rabbit 
endocarditis model using RN6390 with 4 out of 11 animals developing edocarditis  
for ǻagr compared to 9 out of 10 for the wild type strain at an inoculation dose of 
10
4
 CFU.  A significant role for agr in a rabbit osteomyelitis model both at high 
(t2x106) and at low dose (d 2x105 CFU) inocula, was also shown by the study of 
(Gillaspy et al., 1995). However Schwan et al. (2003) compared different murine 
models and found that agr
-
 strains are attenuated in the abscess and systemic 
models, but not in the wound model.  
 
1.2.1 MRSA 
With the introduction of penicillin in the 1940s, treating S. aureus infections 
which previously were difficult to treat became routine.  By the late 1940s and 
throughout the 1950s S. aureus, aided by selection pressure by the use, overuse 
and missuse of antibiotics, became resistant to penicillin.  Methicillin was 
introduced in 1959 to treat penicillin resistant S. aureus infections but by 1961 the 
first case of methicillin resistant Staphylococcus aureus (MRSA) was reported in 
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the United Kingdom (Jevons, 1961), soon thereafter MRSA was reported in other 
European countries, Japan, Australia and USA.  MRSA is now one of the leading 
causes of hospital acquired infections in the UK and most of the rest of the 
western world.  In 2007 alone MRSA was mentioned on the death certificates of 
1,593 patients in England and Wales (2008).  
 
Resistance to methicillin is conferred by the mecA gene which is a part of a mobile 
genetic element called staphylococcal cassette chromosome (SCC).  To date five 
different SCCmecs of different size and composition have been identified (type I-
V) (Witte et al., 2008).  The SCCmec is capable of horizontal gene transfer and is 
believed to have been transferred to S. aureus from a coagulase negative 
staphylococcus (Wisplinghoff et al., 2003).  
 
MRSAs have been divided into two groups; hospital associated (HA-MRSA) and 
community associated (CA-MRSA).  HA-MRSA infections are generally resistant 
to multiple antibiotics. 
 
 
In 1989 and 1991, the first cases of CA-MRSA were reported in the Australian 
indigenous community (Udo et al., 1993) and in 1999 several cases of aggressive 
MRSA infections occurred in USA (Gosbell et al., 2001), all without any 
established risk factors or prior exposure to a healthcare setting.  Since then cases 
of CA-MRSA skin infections and necrotising pneumonia have been reported in 
11 
other countries (Vandenesch et al., 2003).   Most CA-MRSA strains carry the 
truncated type IV SCCmec and are susceptible to a range of antibiotics. The 
presence of the Panton-Valentine Leukocidin (PVL) has been associated with CA-
MRSA, but its contribution to disease is still a highly debated subject. 
 
 
1.3 Quorum sensing  
The idea that bacteria can work together is not a new one, as far back as 1905 E.F. 
Smith stated: I think that the multiple of bacteria are stronger than a few and thus 
by union are able to overcome obstacles too great for the few (Smith EF, 1905). 
But it was not until 1962, that McVittie published on formation of fruiting bodies 
in Myxococus Xanthus (McVittie A et al., 1962), and presented evidence that a 
bacterial system utilising chemotactic substance was used for cell-cell 
communication and cooperation. These substances were first named pheromones 
by Karlson and Lusher (1959) (Karlson and Luscher, 1959). Nealson et al (1970) 
not only showed that Vibrio fischeri only produced light at high cell population 
density, but also the bacteria produced an extracellular substance that could induce 
bioluminescence at low cell densities. This is generally considered the discovery 
of quorum sensing (QS) (Nealson et al., 1970), a term that was not used until 1994 
(Fuqua et al., 1994). The secreted chemical was purified and shown to be an N-
acylhomoserine lactone (AHL) (Eberhard et al., 1981). During the 1990s 
pheromones were shown to be produced by a wide range of Gram-negative 
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bacteria including Erwinia carotovora, Pseudomonas aeruginosa and Serratia 
marcescens (Bainton et al., 1992b;Bainton et al., 1992a). Since the discovery of 
QS it has been found to control many other properties, other than 
bioluminescence, such as swarming, competence, sporulation, secondary 
metabolism, expression of virulence factors and various other processes (Jones et 
al., 1993;Passador et al., 1993;Swift et al., 1993;Zhang et al., 1993).  
For a molecule to be classified as a QS signal molecule four criteria have to be 
met: 1) the production of the molecule is dependent on growth phase, 
physiological conditions, or environmental changes; 2) The molecule accumulates 
extracellularly and is recognised by a specific receptor; 3) A clear cellular 
response is seen when the threshold concentration is reached and 4) The response 
is not just needed to metabolize or detoxify the QS signal molecule (Winzer et al., 
2002b). 
 
Besides AHLs, 4-quinolones, fatty acids and fatty methyl esters have been shown 
to be QS molecules in Gram-negative bacteria. In Gram-negative bacteria the 
small organic signal molecules generally diffuse across the cytoplasmic membrane 
and bind to an intercellular receptor molecule, the response regulator.  The 
activated response regulator, either directly or indirectly, regulates the expression 
of the target genes (Fuqua et al., 2001;Swift et al., 2001) (Figure 1-2). 
Gram-positive bacteria appear to preferentially use post translationally modified 
peptides as QS molecules. Three classes of these molecules are currently known: 
1) Oligopeptide lantibiotics (e.g., lactococcal nisin) (van, Jr. et al., 1993;Quadri, 
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2002) 2) sixteen membered thiolactone peptides (ring structure of five amino acids 
with or with out a tail, e.g., The staphylococcal autoinducing peptides (AIPs)) 
(Ji et al., 1997;McDowell et al., 2001;Chan et al., 2004) 3) and isoprenylated 
tryptophan peptides (e.g., Bacillus subtilis ComX) (Ansaldi et al., 2002;Okada et 
al., 2005). 
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Figure 1-2:  Quorum sensing in A) Gram-positive bacteria. The classic two component 
regulator system where the signal molecule binds to a sensor histidine kinase which activates 
a response regulator which then regulates the expression of the target genes (either directly 
or indirectly), and B) Gram-negative bacteria where the signal molecule binds directly to the 
receptor molecule which then regulates the expression of the target genes. Figure from (Lyon 
and Novick, 2004). 
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AIPs are secreted and activate a two component system by binding to a 
transmembrane receptor kinase leading to the phosphorylation of a response 
regulator.  The activation of the two component system leads to the regulation of 
the target genes via an intracellular response pathway (Figure 1-2).  
Streptomyces sp. uses Ȗ-butyrolactones for signalling (Takano et al., 2000) and is 
so far the only Gram-positive bacteria that has been found not to use peptides. 
 
The QS molecule AI-2 (furanosyl borate diester) is a QS molecules signalling 
molecule used by some gram-positive and gram-negative bacteria (Winzer et al., 
2002a;Xavier and Bassler, 2003). 
 
 
1.4 Two-component systems 
The staphylococcal quorum sensing system (agr), in common with many other QS 
systems, employs two-component systems to relay the external stimulus to the 
cytoplasm. Two-component systems (TCS) consist of a membrane bound sensor 
histidine kinase (HK) and a response regulator (RR).  The histidine kinase of the 
TCS is activated by an external stimulus which leads to the phosphorylation of the 
response regulator.  The phosphorylated RR regulates its target gene by binding to 
promoter / operator DNA. 
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Histidine protein kinases are divided into two different classes depending on the 
organization of their functional domains.  Class I type HPKs are the most common 
and contain an N-terminal membrane spanning sensor domain of variable length.  
The C-terminal domain makes up the so-called transmitter domain, which contains 
motifs (designated H, N, G1, F and G2) that are conserved in the histidine kinase 
super family.  A variant of this canonical type displays both a phosphor-accepting 
and a histidine phosphor-transfer domain (HPt) fused to the C-terminal end 
(Foussard et al., 2001).  The class II HKs are solely involved in chemotaxis 
responses (Foussard et al., 2001), and are not really relevant to the description of 
the agr QS locus. 
 
 
1.5 The agr locus 
A common QS system for many Gram-positives bacteria is the agr system and has 
been found not just in staphylococci but also in clostridia, lactocbacillus, bacillus, 
listeria, alkaliphilus, desulfitobacterium, moorella, ruminococcus, 
syntrophomonas, thermoanaerobacter (Winzer K, personal communication) and 
possibly more. 
 
In S. aureus the production of surface adhesin proteins and secreted virulence 
factors are primarily under the control of the agr operon, which consists of two 
transcripts, RNAII and RNAIII.  The RNAII mRNA contains four open reading 
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frames (ORFs), coding for AgrB, AgrD, AgrC and AgrA.   RNAIII is a regulatory 
RNA molecule and is the effector molecule of the agr QS system.  The regulatory 
RNA molecule RNAIII also contains a small ORF, hld, coding for į-haemolysin 
(Janzon et al., 1989). 
 
AgrCA is a classic two component system, where the agrC gene codes for the 
receptor histidine kinase, and agrA codes for the response regulator.  The agrB 
gene codes for a transmembrane cysteine protease that is involved in processing 
the AgrD propeptide into a mature autoinducing peptide (AIP), though the exact 
mechanism of this is still unclear. Type 1 staphylococcal signal peptidase (SpsB) 
is also thought to be involved by cleaving off the N-terminal leader of AgrD 
(Kavanaugh et al., 2007).  The AIP is predicted to bind to and activate AgrC 
which leads to phosphorylation of AgrA.  AgrA in its phosphorylated state binds 
to the region between the two promoters and activates transcription from both P2 
and P3 (Koenig et al., 2004) in conjunction with SarA.  Activation of transcription 
from the P2 promoter leads to a positive feedback loop.  The P3 promoter drives 
the transcription of RNAIII, the effector molecule of the agr system (Novick et 
al., 1993;Janzon and Arvidson, 1990).  Transcription of RNAIII results in a 
decrease in the production of surface factors  and an increase in the production of 
other extracellular virulence factors (Novick et al., 1993) (Figure 1-3).  
 
The agr locus contains a hypervariable region spanning the region from mid agrB 
over agrD and into agrC (Figure 1-3) (Ji et al., 1997). The variability in this 
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regions primary amino acid sequence leads differences in the of the N-terminal 
region of AgrB, AgrD and the C-terminal domain of AgrC.  This in turn leads to 
the production of four different AIPs and their cognate AgrCs.  Based on the 
structure of these AIPs S. aureus can be divided into four agr groups (I-IV) (Ji et 
al., 1997;McDowell et al., 2001).  Each AIP specifically activates their native 
AgrC and is an antagonist for the other groups AgrC; this is known as cross 
inhibition. AIP-1 is however a weak activator of AgrC4 and AIP-4 is a moderate 
activator of AgrC1 (Lyon et al., 2002). 
 
19 
 
 
 
hld
RNAIII
positive and negative regulation
of target genes
P3P2
agrA agrC agrD agrB
P2 transcript
AgrC
Cell membrane
Auto inducing peptide
(1) AgrD processing(2) Peptide sensing
AgrA AgrA
P
(3) AgrA activity
AgrB
SarA
Hypervariable region
 
 
Figure 1-3: The agr locus and agr activation. Orange box shows the hypervariable region. (1) 
AgrB processes AgrD into active AIP (2) The AIP activates AgrC and AgrA is 
phosphorylated (3) P-AgrA binds to the agr promoter P2 leading to a positive feedback loop 
and P3 leading to transcription of RNAIII and hld. 
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1.5.1 AgrB 
AgrB is a membrane cysteine peptidase required for processing of AgrD to 
generate active AIP (Ji et al., 1995;Ji et al., 1997).  AgrB cleaves off the C 
terminal tail of AgrD (Qiu et al., 2005).  It is predicted, by a combination of 
hydrophobicity and PhoA fusion analysis, to contain six transmembrane domains.  
Four of these domains are hydrophobic and two are hydrophilic containing highly 
positively charged amino acid residues which are involved in the proteolytic 
cleavage of AgrD (Zhang et al., 2002). 
 
Figure 1-4: The two dimensional structure of AgrB1. Amino acids conserved among the 
different agr groups are marked in black (Qiu et al., 2005). 
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The group specific processing of AgrD by AgrB is thought to be less stringent 
than that of activation of AgrC by AIP , with AgrB1 and AgrB3 being able to 
process both AgrD1 and AgrD3 but not AgrD2 (Ji et al., 1997).  The regions 
responsible for the group specific processing of AgrD for AgrB1 and AgrB have 
been identified.  For AgrB1 the first transmembrane helix (TMH) and the first 
extracellular loop are important, whereas for AgrB2 it is two hydrophilic segments 
consisting of M67 to G75 (TMH2) and A126 to K141 (TMH4 together with 
cytoplasmic loop 2) (Zhang and Ji, 2004).  It has been shown that alanine 
substitution of the histidine residue at position 77 (H77) and cysteine residue at 
position 84 (C84) totally eliminate the ability of AgrB1 to process AgrD1 to form 
the mature AIP (Qiu et al., 2005).  
 
1.5.2 AgrD 
AgrD is processed by AgrB, and there is some indication that the signal peptidase 
1 SpsB is involved (Kavanaugh et al., 2007), to yield AIP (Ji et al., 1995). This 
involved 3 steps, two endopeptidase steps and one cyclization (Figure 1-5).  
 
For AgrD to be processed it has to be anchored in the membrane via the N-
terminal amphipathic leader (Zhang et al., 2004) where upon the C-terminal tail is 
cleaved off by AgrB (Zhang and Ji, 2004) this step is believed to be the catalyst 
for the formation of the thiolactone ring. The AIPs derived from the different 
AgrDs are all agonists for their cognate AgrCs and cross inhibit the other AgrC 
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groups (Ji et al., 1997;McDowell et al., 2001), with the exception of AIP-4 which 
is also a moderate activator of AgrC1 and AIP-1 which is a weak activator of 
AgrC4 (Lyon et al., 2002), this may partially be due to the fact that AIP-1 and 
AIP-4 only differ by one amino acid residue at position 5, aspartic acid in AIP-1 
and tyrosine in AIP-4. Structure function analysis of AIPs has shown that if the 
aspartic acid in position 5 of AIP-1 is changed to an alanine the resulting AIP 
derivitive, (ala
5
)AIP-1, is an inhibitor of all four S. aureus agr groups (McDowell 
et al., 2001). 
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Figure 1-5: The domains and primary sequences of AgrD1-4. In order to yield active AIP two 
endopeptidase reactions and the formation of a thiolactone bond between the central cysteine 
(marked in red) and the C-terminal amino acid residue of the AIP, yielding the macrocycle. 
Note: AIP-1 and AIP-4 are closely related and only differ by one amino acid residue at 
position 5 (D to Y). Modified from (Lyon et al., 2002). 
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1.5.3 AgrC 
AgrC is a member of the class 10 receptor histidine protein kinases (HPKs) (Grebe 
and Stock, 1999) and consists of an N-terminal transmembrane sensor domain, 
that is a part of the agr hypervariable region (Figure 1-3), and a C-terminal HPK 
domain (Lina et al., 1998) that is highly conserved among the staphylococci.  The 
N-terminal sensor domain is responsible for the group specific recognition of AIPs 
(Wright, III et al., 2004).  AgrC is predicted to be found in the membrane as a 
dimer, but the structure of AgrC has yet to be solved.  Lina, et al (1998) 
suggested, on the basis of hydrophobicity analysis and PhoA fusions, that it 
consisted of 5 transmembrane helices (Lina et al., 1998).  Later in silico 
prediction, however, suggests that AgrC consists of six TMHs and three outer 
loops (Geisinger et al., 2008), a topology model that is also supported by findings 
using PhoA fusions (Lina et al., 1998).  These extracellular loops are found in the 
N-terminal sensor domain of AgrC.  Chimeric studies of AgrC have indicated that 
the recognition specificity is located in the C-terminal part of the sensor domain 
(Wright, III et al., 2004). 
 
1.5.4 AgrA 
AgrA is a member of the LytR response regulator family and when 
phosphorylated, binds to a consensus sequence consisting of two direct repeats 
(TA AC CA GTTN AG TG), that are separated by a 12-13 bp spacer region 
(Nikolskaya and Galperin, 2002).  Two of these elements have been identified in 
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the P2-P3 intergenic region of the agr operon and RNAIII, one in the P2 promoter 
and one in the P3 promoter.  AgrA binds to the P2 promoter with a higher affinity 
than to the P3 promoter (Koenig et al., 2004) hence; auto-activation of the P2 
promoter precedes P3 activation (Cheung et al., 2004).  The regulator SarA 
interacts with, or is displaced by AgrA and enhances AgrA induced transcription 
from both promoters in an as yet unknown manner (Cheung et al., 1997;Rechtin et 
al., 1999;Morfeldt et al., 1996).  The crystal structure of AgrA bound to DNA has 
recently been solved and has revealed a novel structure of a 10 strand ȕ-fold that 
intercalates.  Unlike other major groove DNA binding proteins, AgrA binds to a 
single face on the DNA, covering nearly 16 bp, inserting long loops into the major 
grooves making direct single base contacts, Figure 1-6 (Sidote et al., 2008). 
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Figure 1-6: Dimer of the C-terminal DNA binding domain of AgrA bound to DNA. (Sidote et 
al., 2008) 
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1.5.5 RNAIII 
RNAIII is a 514 nucleotide regulatory RNA molecule and is the effector molecule 
of the agr-operon; it has a highly conserved secondary structure, although the 
primary sequence varies, among staphylococcal species (Novick et al., 1993).  
RNAIII is a highly abundant, very stable RNA molecule with a half life of more 
than 45 min (Huntzinger et al., 2005) that folds into a complex secondary structure 
(Benito et al., 2000). Besides being a regulatory RNA, RNAIII also contains a 
short CDS containing the hld gene encoding į-haemolysin (Janzon et al., 1989) 
(Figure 1-7). 
 
The exact mechanism of how RNAIII works is not yet fully understood but it is 
believed that functions as an antisense molecule, regulating translation of both 
individual exoproteins / toxins and pleiotropic regulators (e.g., SarT, SarS and 
Rot) (McNamara et al., 2000;Tegmark et al., 2000).  RNAIII directly down 
regulates translation of protein A (Novick et al., 1993;Benito et al., 2000), and up 
regulates translation of Į-haemolysin by binding to the hla mRNA by hindering 
the formation of a secondary translation blocking structure (Morfeldt et al., 1995) 
(Figure 1-7). 
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Figure 1-7: 2D structure of the functional molecule RNAIII (Benito et al., 2000;Novick, 2003). 
The hld coding region is highlighted in solid blue and potential upstream translatable region 
in dashed blue. Red shading shows sequence that is complementary with the hla mRNA. 
Green shading shows sequence complementary with spa mRNA translation initiation region. 
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1.5.6 Role of agr In Vivo 
The growth phase dependent regulation of virulence factors in S aureus seen in 
vitro, where adhesins are expressed before haemolysins, proteases and other exo-
proteins, have also been shown to occur in vivo (Novick, 2003).   The importance 
of agr in animal models has been demonstrated in various studies.  Thus, strain 
8325-4 ǻagr was demonstrated to be significantly less virulent than its wild type 
8325-4 parent strain in a mouse arthritis model (Abdelnour et al., 1993).  Cheung 
et al (1994) later showed that agr also played an important role in a rabbit 
endocarditis model using RN6390 with 4 out of 11 animals developing edocarditis  
for ǻagr compared to 9 out of 10 for the wild type strain at an inoculation dose of 
10
4
 CFU.  A significant role for agr in a rabbit osteomyelitis model both at high 
(t2x106) and at low dose (d 2x105 CFU) inocula, was also shown by the study of 
(Gillaspy et al., 1995). However Schwan et al. (2003) compared different murine 
models and found that agr
-
 strains are attenuated in the abscess and systemic 
models, but not in the wound model.  
 
The results from various animal models seem to indicate that agr plays an 
important role in vivo; also most clinical isolates of S. aureus are agr
+
 , but the 
occurrence of strains which either express agr poorly or not at all (Fowler, Jr. et 
al., 2004;Sakoulas et al., 2002) seems to raise questions about the role of agr in 
human disease.  Traber et al (2008) carried out a study of 146 clinical isolates 
which showed that 15 % were non-haemolytic (often used as an agr indicator), a 
few of these could be complemented with WT agr but some were not 
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complementable; indicating that factors outside the agr locus are responsible for 
the phenotype.  They also showed that the agr
-
 strains isolates are most likely 
mutants that have appeared during the infection (Traber et al., 2008).  This is 
supported by agr having been shown to be important during early stages of an 
infection (Wright, III et al., 2005b). 
 
Using a mouse abscess model Wright et al. (2005a) showed that agr was activated 
a few hours after injection of S. aureus. This burst lasted for a few hours and then 
subsided again, but a second burst of agr activity was observed approximately 72 
hours after injection (Wright, III et al., 2005a). This cessation of activity and the 
second burst can not be explained by the traditional model for agr activation but 
several environmental factors also influence the agr response.  Low oxygen 
concentration inhibits the expression of RNAIII via the staphylococcal respiratory 
response (SrrAB) (Pragman et al., 2004). The general stress response factor ıB, 
which reacts to a variety of different environmental stress factors, influences the 
agr response via SarA (Cheung et al., 1999) and it has been shown that a ıB 
deletion mutant has decreased virulence in the murine model for septic arthritis 
(Jonsson et al., 2004) but not in a murine subcutaneous skin abscess model 
(Horsburgh et al., 2002).  MgrA (also known as Rat or NorR) is a regulator 
repressor of agr (Truong-Bolduc et al., 2003) via SarX and has been shown to 
sense reactive oxygen and nitrogen species (Chen et al., 2006). 
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1.6  The SarA family 
The staphylococcal SarA family is a family of DNA binding regulatory protein 
which are all homologous to the SarA regulatory protein.  It has 11 members and 
can be divided into three subfamilies: 1) Single domain proteins; to this subfamily 
belong  SarA, SarR, SarT, SarV, SarX and Rot which are 115 to 141 amino acid 
residues long and form active dimer.   2) Double domain proteins; to this 
subfamily belong SarS, SarU and SarY which are 247 to 250 long amino acid 
residues and are active as monomers with a structure that resembles a dimer from 
the single domain family.  They have two homologues but not identical domain, 
and 3) MarR homologues; this subfamily consists of  MgrA and SarZ which are 
147 and 148 amino acid residues long respectively and form active dimers (Table 
1-2 and Figure 1-8).   
 
The crystal structures have been solved for several of the SarA homologues and it 
is reasonable to assume that within the subfamilies the structure is similar.  The 
structures show that the SarA family are winged helix proteins, where the single 
domain subfamily is a homo-dimeric winged helix structure possessing a central 
helical core and two winged helix motifs (Liu et al., 2001;Liu et al., 2006).  The 
two domain subfamily is a monomeric structure forming a similar structure to the 
dimer of the single domain subfamily of two winged motifs, linked by a well 
ordered loop (Liu et al., 2006;Liu et al., 2001;Li et al., 2003;Chen et al., 2006).  
Members of the MarR homolog subfamily still form dimeric winged helix 
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structures but have more sequence similarity to the Gram-negative bacterial MarR 
proteins than to the other small SarA proteins (Ingavale et al., 2005). 
 
 
SarS
MgrA1
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W1
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Figure 1-8: Comparison of (A) SarA (Liu et al., 2006), SarR (Liu et al., 2001) (single domain 
subfamily), (B) SarS (Li et al., 2003) (Two domain family) and (C)MgrA  (Chen et al., 2006) 
(MarR homologue) winged helix structure. The different secondary structures (Į-helices Į1-7 
ȕ-sheets ȕ1- and wings W1 and W2) and important features are marked; Linker and the 
cysteine involved in oxidation sensing in MgrA. 
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Table 1-2: The SarA protein family their subfamilies and regulatory functions. 
*
MgrA is also 
known as Rat or NorR. 
 
Protein Subfamily Putative function Reference 
SarA Single Domain 
Activates genes via agr and agr 
independent pathways 
 
SarR Single Domain 
Negative regulator of sarA and 
activator of agr 
(Cheung et al., 
2004) 
SarT Single Domain 
Activator of sarS and repressor of 
Į-heamolysin 
(Cheung et al., 
2004) 
SarV Single Domain 
Regulator of autolysis repressed 
by SarA and MgrA 
(Manna et al., 
2004) 
SarX Single Domain 
Negative regulator of agr 
activated by MgrA 
(Manna and 
Cheung, 2006a) 
Rot Single Domain 
Repressor of toxin expression, 
works oppersit to agr 
(Said-Salim et 
al., 2003) 
SarS Double Domain Activator of protein A 
(Tegmark et al., 
2000) 
SarU Double Domain Activates agr 
(Cheung et al., 
2004) 
SarY Double Domain Unknown  
MgrA
*
 MarR homologue Regulator of autolysis and agr 
(Truong-Bolduc 
et al., 2003) 
SarZ MarR homologue Activates hla 
(Kaito et al., 
2006) 
 
Structural data suggest that the SarA family all bind to DNA in a similar fashion, 
with the helix-turn-helix binding to the major grooves and the winged motif 
binding to the minor groves of the DNA. 
 
In contrast to the similarity in binding domains, the activation domains differ 
among the family members.  Based on the structures of SarA, SarS, SarR and 
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MgrA five different mechanisms of regulation have been proposed: 1) For MgrA 
an oxidation sensing mechanism for the cysteine (C12) residue has been proposed 
(Chen et al., 2006); 2) Bending of target DNA to facilitate contact with the 
regulatory protein (Cheung et al., 2004); 3) The formation of a complex of three 
SarA dimers encased in DNA blocking transcription from the promoter (Liu et al., 
2006); 4) Formation of heterodimer (for the single domain subfamily) between 
compatible family members (e.g., SarA and SarR) that interferes with the function 
of the homodimers (Cheung et al., 2004);  5) Competitive displacement of one 
homodimer by another (e.g., SarR displacing SarA from the agr promoter) 
(Manna and Cheung, 2006b). 
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Figure 1-9: Modelling of (A) SarR (Liu et al., 2001) and (B) MgrA (Chen et al., 2006) binding 
to DNA. In both cases it is the fourth Į-helix (Į4) that fits in the major grooves of the DNA 
and the wings (W1) binds to the minor grooves.  
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1.6.1 SarA 
SarA is the best studied protein in the SarA family.  It is transcribed from the sarA 
locus which consist of sarA and three promoters (P1, P2 and P3) (Bayer et al., 
1996) and is required for optimal expression of agr (Cheung and Projan, 1994).  
Transcription peaks in the late exponential phase (Manna and Cheung, 2001) and 
controls over 100 genes (Dunman et al., 2001).  This regulatory effect is either 
through agr by binding to the agr promoter region, directly binding to the 
promoter of the target gene (e.g., hla and spa) or by stabilising mRNA during the 
logarithmic growth phase (Cheung et al., 2004;Roberts et al., 2006;Liu et al., 
2006) (Table 1-1).  Various studies have identified the SarA binding site in the agr 
promoter region using footprinting (Chien and Cheung, 1998;Chien et al., 
1999;Rechtin et al., 1999) and the 7 bp consensus binding sequence (ATTTTAT) 
has been proposed based on promoter selection assay (Sterba et al., 2003). 
 
Mutation studies of SarA revealed that substituting the Y18, E29, E36, K54, L74 
or F80 for alanine reduces SarA ability to bind to DNA.  Substituting R84 or R90 
within the winged motif with alanine completely abolished SarAs ability to bind 
to DNA.  In contrast substituting D88, E89 (part of the DER conserved motif), C9 
or K23 with alanine did not alter SarAs ability to bind to DNA, but rendered SarA 
inactive and unable to complement a ǻsarA phenotype (Liu et al., 2006).  
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1.6.2 Other SarA homologues 
1.6.2.1 Single domain SarA homologues 
SarR is a 115 amino acid residue protein that binds to the sarA promoter and 
represses the expression of SarA (Manna and Cheung, 2001).  SarR also 
influences agr indirectly by repressing SarA but is also capable of binding directly 
to the agr promoter region (Manna and Cheung, 2006b).    
 
SarT is a 118 amino acid residue protein and is repressed by sarA and agr.  SarT 
represses hla and up-regulates spa by activating transcription of sarS (Schmidt et 
al., 2001;Schmidt et al., 2003). 
 
SarV is a 116 amino acid residue protein.  Its expression is very low under in vitro 
growth conditions and is repressed by MgrA and SarA (Manna et al., 2004).  SarV 
mutants are more resistant to detergent, or cell wall antibiotic-mediated lysis than 
wild type S. aureus and over expression lowers the parent strains resistance to 
lysis (Manna et al., 2004).  Therefore, sarV might be a part of the mgrA and sarA 
controlled autolysis pathway in S. aureus. 
 
SarX is 141 amino acid residue long and is the largest of the single domain SarA 
homologues.  SarX is an auto regulator that, in conjunction with MgrA, up-
regulates its own expression.  SarX is also a repressor of agr (Manna and Cheung, 
2006a) 
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Rot was first reported to be 166 amino acid residues in length (Said-Salim et al., 
2003) but was later reported to be 133 amino acid residues (Manna and Ray, 
2007).  Rot is  a repressor of toxin synthesis and up-regulates cell wall protein 
synthesis and has been shown to affect the transcription of 168 genes (Said-Salim 
et al., 2003).  Rot is a positive regulator of sarS  (Said-Salim et al., 2003) and 
SarA and SarR have been shown to bind to the rot promoter region (Hsieh et al., 
2008). Rot is transcribed throughout the different growth phases and is only 
modestly influenced by agr and SigB (Hsieh et al., 2008).  RNAIII has been 
shown to interact directly with rot mRNA and to inhibit rot translation (Geisinger 
et al., 2006), indicating that a major part of agr-dependent regulation of rot is post 
transcriptional. 
1.6.2.2 Two domain SarA homologues 
SarS (also called SarH1) is the most studied of the two domain subfamily of SarA 
homologues.  It is 250 amino acid residues long and activates spa and represses 
hla transcription (Tegmark et al., 2000;Cheung et al., 2001;Cheung et al., 2001).  
Transcriptional analysis show that sarS is repressed by agr and MgrA (Tegmark et 
al., 2000;Cheung et al., 2001) and activated by ClpXP protease (Frees et al., 
2005) and SarT(Schmidt et al., 2003). 
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SarU is 247 amino acid residues long and is transcribed divergently from sarT.  
SarU is an activator of agr and is repressed by SarT (Manna and Cheung, 2003).  
Since SarT is repressed by agr and SarU activates agr but is repressed by SarT, 
the agr locus could be activated by this positive feedback loop, in addition to the 
activation effected by AgrA and SarA. 
 
SarY is a hypothetical SarA homologue and has only been predicted in scilico so 
far.  It is predicted to be 247 amino acid residues (Manna and Cheung, 2003). 
 
1.6.2.3 MarR homologues 
MgrA, also known as Rat or NorR is the best studied of the MarR homologues.  It 
is 147 amino acid residues in length and is a dimer in its functional form (Truong-
Bolduc et al., 2003;Chen et al., 2006).  MgrA was initially identified as a 
regulator of autolysins (Ingavale et al., 2003;Manna et al., 2004).  MgrA also 
regulates hla (up regulated) and spa (down regulated) expression in both an agr 
dependent (by up regulating transcription of RNAIII) and an agr independent 
manner (Ingavale et al., 2005).  Besides having a regulatory effect on agr, MgrA 
also has an effect on the SarA homologue SarS and SarX (Ingavale et al., 2005).  
Besides these effects MgrA has been observed to positively regulate capsular 
polysaccharide synthesis (Luong et al., 2003).  MgrA is also involved in 
regulation of antibiotic resistance and has been reported to positively regulate the 
efflux pumps NorA and AbcA (Truong-Bolduc et al., 2003;Truong-Bolduc and 
40 
Hooper, 2007) and to negatively regulate three other efflux pumps NorB, Tet38 
and NorC (Truong-Bolduc et al., 2005;Truong-Bolduc et al., 2006).  
Transcriptional analysis of mgrA has shown that MgrA effects 355 genes, 175 of 
which are positively regulated and 180 which are negatively regulated (Luong et 
al., 2006).  The phenotype of a mgrA mutant is very like that of an agr mutant. 
 
SarZ is 148 amino acid residues and like MgrA is a member of the MarA 
subfamily of SarA homologues (Cheung et al., 2004).  It has been shown to be a 
positive regulator of hla and sarZ mutants have decreased virulence in both a 
silkworm and a mouse infection model (Kaito et al., 2006). 
 
All these different DNA binding proteins interact with each other, and many also 
directly or indirectly interact with agr, results in a complex virulence regulon in S. 
aureus. In Figure 1-10 the sar-agr regulatory network as it is currently 
understood. 
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Figure 1-10:The sar-agr regulatory network, figure adopted from (Cheung et al., 2008). 
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1.7 Other virulence regulating TCSs 
The SaeRS (Giraudo et al., 1994;Giraudo et al., 1999) TCS is the second major 
global regulator of the S. aureus virulon. Its regulation of virulence factor 
production is agr independent but agr and sae mutually upregulates each other. 
Transcription of sea  is influenced by various environmental stimuli such as salt 
concentration, pH, glucose and antibiotics (Novick and Jiang, 2003). 
 
The arl TCS is a regulator of autolysins and the norA efflux pump (Fournier and 
Hooper, 2000). It is up-regulated by agr and repressed the transcription from the 
P2agr promoter, hence making up an autorepression circuit (Fournier et al., 2001). 
Consequently, its effect on exoprotein production is probably through agr, but it 
acts independently on protein A production (Fournier et al., 2001). 
 
The SrrAB (also know as SrhRS) TCS is involved in the regulation of the S. 
aureus virulon and energy metabolism under microaerobic conditions (Yarwood et 
al., 2001;Throup et al., 2001). agr and srr cross-inhibit each other, and srr links 
the agr system to the energy metabolism of S. aureus (Novick, 2003). 
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1.8 Aims of the project 
S. aureus is an incredible versatile pathogen which is proving increasingly 
difficult to control using the antimicrobials available. Antivirulence agents present 
a possible way of controlling infections without the selection pressure of 
conventional antibiotics. This study aims to elucidate some of the molecular 
mechanisms of the agr system which offers potential as an antimicrobial, 
antivirulence target, as follows: 
  
x Use available prediction programs to determine the likely transmembrane 
topology of AgrC 
o To identify which amino acid residues are likely to play a part in 
the group specific activation of AgrC 
x Develop and validate an easy to use AIP bioreporter 
o Requirements: no agr background, no need for additional 
substrates and high signal to background ratio 
x Determine the contribution of each amino acid residue to the group 
specific activation of AgrC 
x Identify the AgrC protein and elucidate the location and distribution of 
AgrC in the cytoplasmic membrane 
x Investigate whether proteins other than AgrB are involved in AgrD 
processing   
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A detailed knowledge of the molecular mechanisms involved in the agr response 
should aid the rational design of inhibitors which control infection through 
attenuation of virulence 
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2 Materials and Methods 
The bacterial strains, plasmids and primers used in this study are listed in Table 
2-1 to Table 2-3.  
Table 2-1: Strains 
Name Genotype reference 
Staphylococcus aureus strains 
RN4220 rsbU- Kreiswirth et al. 1983, 
Nature 305, 709712 
RN6390B Wild type,  Patel A. H. et. al. 1992, 
Gene 114,25-34 
8325-4 Wild type 8325 cured of prophages Novick R.P. 1967, Virology 
33,155-166 
ROJ37 RN6390B ǻagr::ErmB #1 ermR This study 
ROJ38 RN6390B ǻagr::ErmB #2 ermR  This study 
ROJ39 RN4220 x ĭ11(ROJ37) #1 ermR This study 
ROJ40 RN4220 x ĭ11(ROJ37) #1 ermR This study 
ROJ48 ROJ40 pǻagr-lux (SCO) #1 tetR ermR This study 
Escherichia coli strains 
C41 BL21(DE3) F- ompT gal hsdSB (rB-mB-) dcm lon 
ȜDE3 and an uncharacterised mutation described in the 
reference (Miroux, B. and Walker, J.E. 1996 J. Mol. 
Biol. 260, 289298) 
Avidis 
C43 as C41 but cured for pMW7(OGCP) Avidis 
TOP10 F- mcrA ¨(mcr-hsdRMS-mcr-BC) ĳ80lacZ ¨M15 
¨lacX74deoR recA1 araD139¨(ara-leu) 7697galU 
galK rpsL (StrR)endA1 
nupG 
Invitrogen 
TOP10F F(lacIq,Tn10(TetR))mcrA ¨(mcr-hsdRMS-mcr-BC) 
ĳ80lacZ ¨M15 ¨lacX74deoR 
recA1 araD139¨(ara-leu) 7697galU galK rpsL 
(StrR)endA1 nupG 
Invitrogen 
JM109 F traD36 proA+B+ lacIq ǻ(lacZ)M15/ ǻ(lac-proAB) Yanisch-Perron C. et. al. 
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glnV44 e14- gyrA96 recA1 relA1 andA1 thi hsdR17 1985 Gene 22,103-119 
DHM1 F- cya-854 recA1 endA1 gryA96 (nalR) thi1 hsdR17 
spoT1 rfbD1glnV44(AS) 
Proc. Natl. Acad. Sci. USA 
Vol. 95, pp. 57525756, 
May 1998 
 
BTH101 F- cya-99 araD139 galE15 galK16 rspL1 (strR) hsdR2 
mcrA1 mcrB 
Proc. Natl. Acad. Sci. USA 
Vol. 95, pp. 57525756, 
May 1998 
 
Saccharomyces cerevisiae Strains 
PJ69-4A MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4' 
gal80' LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-
lacZ 
James P. et al 1996 
Genetics 144 (4): 1425-
1436 
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Table 2-2: Plasmids 
Name Genotype reference 
pCR2.1 TOPO cloning vector kanR bla Invitrogen 
pSK5630 Shuttle vector cat bla (Grkovic et 
al., 2003) 
pSK5632 Expression shuttle vector cat bla (Grkovic et 
al., 2003) 
pMAD Shuttle vector for gene replacement in low GC gram-
positive bacteria ermC bla 
(Arnaud et 
al., 2004) 
pǻagr-tetM agr up and down stream regions tetM Klaus Winzer 
pǻagr-ErmB agr up and down stream regions ermB This study 
pǻagr-lux agr up and down stream regions tetM luxABCDE Klaus Winzer 
pǻagr-dual agr up and down stream regions tetM gfp luxABCDE Klaus Winzer 
pGAD424 Col E1 and 2P origin GAL4-AD LEU2 bla Clonetech 
(Bartel et al 
1993) 
pGBT9 Col E1 and 2P origin GAL4-BD TRP1 bla Clonetech 
(Bartel et al 
1993) 
pGAD424-agrB Col E1 and 2P origin GAL4-AD::agrB LEU2 bla Alan 
Cockayne 
pGAD424-agrD Col E1 and 2P origin GAL4-AD::agrD LEU2 bla Alan 
Cockayne 
pGBT9-agrB Col E1 and 2P origin GAL4-BD::agrB TRP1 bla Alan 
Cockayne 
pGBT9-agrD Col E1 and 2P origin GAL4-BD::agrD TRP1 bla Alan 
Cockayne 
pGBT9-S.a.lib S. aureus Newman strain genomic library fused to the 
GAL4-BD in pGBT9. TRP1 bla 
Alan 
Cockayne 
pBluescript SK + High copy cloning vector Fermentas 
pBSK-AgrC1A pBluescript SK + agrC1 agrA  
pBSK-AgrC4A pBluescript SK + agrC4 agrA  
pSKermP2 pSK5630 ermB P2agr-agrC1 agrA This study 
pAgrC1agrA pSKermP2 agrC1 agrA This study 
pAgrC2agrA pSKermP2 agrC2 agrA This study 
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pAgrC3agrA pSKermP2 agrC3 agrA This study 
pAgrC4agrA pSKermP2 agrC4 agrA This study 
pAgrC1A101TagrA pSKermP2 agrC1A101T agrA This study 
pAgrC1T104VagrA pSKermP2 agrC1T104V agrA This study 
pAgrC1S107VagrA pSKermP2 agrC1S107V agrA This study 
pAgrC1A101TT104VagrA pSKermP2 agrC1A101TT104 agrA This study 
pAgrC1A101TS107VagrA pSKermP2 agrC1A101TS107 agrA This study 
pAgrC1T104VS107VagrA pSKermP2 agrC1T104VS107V agrA This study 
pAgrC1loop2gr4agrA pSKermP2 agrC1A101TT104V107V agrA This study 
pAgrC4T101AagrA pSKermP2 agrC4T101A agrA This study 
pAgrC4V104TagrA pSKermP2 agrC4V104T agrA This study 
pAgrC4V107SagrA pSKermP2 agrC4V107S agrA This study 
pAgrC4T101AV104TagrA pSKermP2 agrC4T101AV104T agrA This study 
pAgrC4T101AV107SagrA pSKermP2 agrC4T101AV107S agrA This study 
pAgrC4V104TV107SagrA pSKermP2 agrC4V104TV107S agrA This study 
pAgrC4loop2gr1agrA pSKermP2 agrC4T101AV104TV107S agrA This study 
pAgrC4S35LagrA pSKermP2 agrC4S35L agrA This study 
pAgrC4Y39FagrA pSKermP2 agrC4Y39F agrA This study 
pAgrC4L38FY39FagrA pSKermP2 agrC4L38FY39F agrA This study 
pAgrC4G42VagrA pSKermP2 agrC4G42V agrA This study 
pAgrC4loop1gr1agrA pSKermP2 
agrC4R31KK33YS35LI38FY39FG42VV44SL45TS46LV
48L agrA 
 
This study 
pGfp-AgrC pSKermP2 gfp-agrC1 agrA (N-terminal gfp fusion to 
agrC1) 
This study 
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Table 2-3: Primers. * indicates primer is 5 phosphorylated. 
Name Sequence 
DagrtstF 5'-GATTTACAATTGAATACGCCG 
DagrtstR 5'-CTGTCAATTTGATAGCGGG 
TetMseq1 5'-GGATATCAGGTTACCACTG 
TetMseq2 5'-CCACGCTTCCTAATTCTG 
ErmB-F 5'-AATTGGCATGAATTCGGTCTTGCGTATGGTTAACCC 
ErmB-R 5'-TTTACTCGAGTAGAATTATTTCCTCCCGTT 
pSK-FOR 5'-TCGTATGTTGTGTGGAATTG 
pSK-REV 5'-GCTGCAAGGCGATTAAGTTG 
pGBTf 5-TGCCGTCACAGATAGATTGG 
pGBTr 5-CCTGAGAAAGCAACCTGACC 
Drlp_up-F 5'-*ATTAATCAATAATGTTTTAAATAT 
Drlp_up-R 5'-TACAGGATCCCAATATTGATTTTCATGCGT 
Drlp_dwn-F 5'-TACAGAATTCCAGTAGTTATTGCAGTTATTTT 
Drlp_dwm-R 5'-*TTTCTTCACATCTATCCCTA 
DhutI_up-F 5'-TACAGGATCCCAGCCGTAGCCAAAATACTAGCC 
DhutI_up-R 5'-TACAGAATTCAAAGCATAAAATAATTAGAAAGC 
DhutI_dwn-F 5'-TACAGAATTCATCATTCATTATTTATCACCT 
DhutI_dwn-R 5'-TACAGGATCCGTTGAGTGGTGATCCAAAAG 
Drlp_up-F 5'-*ATTAATCAATAATGTTTTAAATAT 
Drlp_up-R 5'-TACAGGATCCCAATATTGATTTTCATGCGT 
Drlp_dwn-F 5'-TACAGAATTCCAGTAGTTATTGCAGTTATTTT 
Drlp_dwm-R 5'-*TTTCTTCACATCTATCCCTA 
  
agrCA1+4-R 5'-ACAAATAAGCTTCGCCGTTAACTGACTTTATTA 
agrC1-F 5'-AGTAATGGATCCGAGTGTGATAGTAGGTGGAAT 
agrC2-F 5-AGTAATGGATCCGTTATTTTAGAAAGTGTGTAGC 
agrC3-F 5-AGTAATGGATCCGAGAAAGTGTGATAGTAAGTG 
agrC4-F 5'-AGTAATGGATCCCAGAAAGTGTGATAGTAAGTG 
  
agrC4loop1gr1-F 5'-*TATTTTTTCATCATAGTAATTTCGACATTATCGTTA 
agrC4loop1gr1-R 5'-*GTCAAGTTTACTGTACTTGATACCACT 
S35L-F 5'-*AAATTGGACTATTTGTATATCACG 
L38F-F 5'-*AAATCTGACTATTTTTATATCACG 
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Y39F-F 5'-*TATTTGTTTATCACGGGTATTACG 
G42V-F 5'-*TATTTGTATATCACGGTTATTACG 
L38F_Y39F-F 5'-*TATTTTTTTATCACGGGTATTACG 
Loop1-R1 5'-*ACTGTATTTGATACCACTAATAAT 
loop1-R2 5'-*GTCAGATTTACTGTATTTGATACC 
  
agrC1wt-R 5'-*ATATAACTATATACATGTAGTTAGC 
agrC1 A101T-F 5'-*ATACATATATCACCAAAATTTCTGAT 
agrC1 T104V-F 5'-*ATGCATATATCGTCAAAATTTCTGAT 
agrC1 S107V-F 5'-*ATGCATATATCACCAAAATTGTTGAT 
agrC1 A101T T104V-F 5'-*ATACATATATCGTCAAAATTTCTGAT 
agrC1 A101T S107V-F 5'-*ATACATATATCACCAAAATTGTTGAT 
agrC1 T104V S107V-F 5'-*ATGCATATATCGCCAAAATTGTTGAT 
agrC1 A101T T104V S107V-F 5'-*ATACATATATCGCCAAAATTGTTGAT 
  
agrC4wt-R 5'-*ATATAACTATATACATGTAATTTGC 
agrC4 T101A-F 5'-*TCGCATATATTGTCAAAATCGTTGAT 
agrC4 V104T-F 5'-*TCACATATATTACCAAAATCGTTGAT 
agrC4 V107S-F 5'-*TCACATATATTGTCAAAATCTCTGAT 
agrC4 T101A V104T-F 5'-*TCGCATATATTACCAAAATCGTTGAT 
agrC4 T101A V107S-F 5'-*TCGCATATATTGTCAAAATCTCTGAT 
agrC4 V104T V107S-F 5'-*TCACATATATTACCAAAATCTCTGAT 
agrC4 T101A V104T V107S-F 5'-*TCGCATATATTACCAAAATCTCTGAT 
  
Gfp-N-F  GACATCGGATCCGTTAACAAGGAGGAATAAAAAATG 
Gfp-N-R GACATCGAATTCTTTGTATAGTTCATCCATGCCATG 
agrC1-N-F GACATCGAATTCGTGGAATTATTAAATAGTTATAATTTTG 
agrCA1-N-R GACATCAAGCTTTTATATTTTTTTAACGTTTCT 
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2.1 Growth Media and antibiotics 
All growth media was sterilised by autoclaving at 121ûC, 20 min at 15 p.s.i. unless 
otherwise stated. 
2.1.1 Luria Bertani medium 
Luria Bertani (LB) broth was prepared as described by Sambrock et al (1989) and 
consisted of 10 g/L tryptone (Oxoid) 5 g/L yeast extract (Berton, Dikinson and 
company) and 10 g/L NaCl (Fisher Scientific). LB agar was prepared by the 
addition of 15 g/L No. 1 Bacteriological Agar (Oxoid) to LB broth. 
 
2.1.2 Tryptic Soya Broth 
Tryptic soya broth was prepared as 15 g/L of Tryptic Soya Broth (Berton, 
Dikinson and company). TSB agar was prepared by the addition of 15 g/L No. 1 
Bacteriological Agar (Oxoid) to TSB broth. 
2.1.3 B2 medium 
B2 broth consisted of 10 g/L Bacto Casamino  Acids (Becton, Dickinson and 
company) 25 g/L Yeast Extract (Becton, Dickinson and company) 1 g/L K2HPO4 
(Sigma) 25 g/L NaCl (Fisher Scientific). After autoclavation the sterilised medium 
was supplemented with 25 ml/L of filter sterilised 20% glucose (sigma). 
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2.1.4 LK medium 
LK broth consists of 10 g/L Tryptone (Oxoid) 5 g/L Yeast extract (Becton, 
Dickinson and company) and 7 g/L KCl (sigma). LK agar was prepared by 
addition of 15 g/L No. 1 Bacteriological Agar (Oxoid) to LK broth 
 
2.1.5 CYGP medium 
CYGP broth was prepared as described by Ji et al. (1995) and consists of 10 g/L 
Casamino acids (Becton, Dickinson and company) 10 g/L Yeast Extract (Becton, 
Dickinson and company) 5 g/L Glucose (Sigma) and 5.9 g/L NaCl (Sigma) 
supplemented by 40 ml/L ȕ-Glycerophosphate (1.5M). 
 
2.1.6 YPD medium 
YPD broth was prepared as described in Yeast Protocol Handbook (Clontech, 
2001) and contains 20 g/L Peptone (Becton, Dickinson and company) and 10 g/L 
Yeast extract (Becton, Dickinson and company). After autoclavation the medium 
was supplemented with 50 ml/L 40% Glucose wt/vol. YPD agar was prepared by 
adding 20 g/L Technical agar No. 3 (Oxoid) to YPD broth. 
 
2.1.7 YMM medium 
YMM broth was prepared as described in Yeast Protocol Handbook (Clontech, 
2001) and contains 6.7 g/L Yeast Nitrogen base w/o amino acids (Becton, 
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Dickinson and company) After autoclavation the medium was supplemented with 
50 ml/L 40% Glucose wt/vol. 
YMM agar was prepared by adding 20 g/L Technical agar No. 3 (Oxoid) to YMM 
broth. 
 
2.1.8 Antibiotics 
Growth media for Escherichia coli was supplemented as required with: ampicillin 
(Amp) at 100 µg/ml, chloramphenicol (Cm) at 30 µg/ml, tetracycline (Tet) at 10 
µg/ml or kanamycin (Kan) at 50 µg/ml. Growth media for Staphylococcus aureus 
was supplemented as required with the following: Erythromycin (Ery) 10 µg/ml, 
chloramphenicol (Cm) at 10 µg/ml or tetracycline (Tet) at 10 µg/ml. 
 
 
2.1.9 Yeast medium supplements 
Growth media for Saccharomyces cerevisiae was supplemented as required with 
the following: L-Methionine (20 Pg/ml) (Sigma), Uracil (20 Pg/ml) (Sigma), L-
Histidine-HCl (20 Pg/ml) (Sigma), Adenine Sulphate (20 Pg/ml) (Sigma), L-
Tryptophan (20 Pg/ml) (Sigma), L-Leucine (30 Pg/ml) (Sigma) 
For X-gal YMM agar: 80Pg/ml X-gal, 20 Pg/ml L-Methionine, 20 Pg/ml Uracil, 
20Pg/ml Adenine Sulphate and 1:10 10X BU salts (70g/L Na2HPO47H2O and 30g 
g/L NaH2PO4, pH 7). 
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2.2 Microbial growth conditions 
E. coli and S. aureus were grown at 37ûC unless otherwise stated. E. coli and S. 
aureus liquid cultures were grown in broth with agitation at 200 rpm unless 
otherwise stated.  
S. cerevisiae were grown at 30ûC. S. cerevisiae liquid cultures were grown in 
broth with agitation at 250 rpm unless otherwise stated. 
Optical density of bacterial or yeast cultures was measured at 600 nm (OD600), 
using a Pharmacia LKB Novaspec II spectrometer. 
 
2.3 Manipulation of DNA 
2.3.1 DNA restriction enzymes 
Restriction enzymes were obtained from Promega, UK. DNA restriction digest 
contained 0.5-1 µg of DNA, 1U of restriction endonuclease and 1 x buffer 
(supplied by manufacture) made up to a final volume of 30-40 µl with sterile 
distilled water. Digests were incubated for between 2 to 18 h at the appropriate 
temperature. Restriction enzymes and cut off ends from PCR products were 
removed from the reaction using a QUIquick PCR purification kit as described in 
the manufacturers instructions (Qiagen Ltd, UK). For digested plasmid desired 
fragment was isolated on a 0.7-1% wt/vol agarose gel and gel purified as 
described in section 2.3.8  
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2.3.2 DNA Ligation 
Ligation of DNA was carried out using either T4 DNA ligase supplied by 
Promega UK or Quick T4 DNA Ligase supplied by New England BioLabs (UK) 
Ltd. Purified DNA inserts were ligated to purified vector DNA in a ratio of 3:1. 
The ligation reaction mix also contained 1 x T4 DNA ligase buffer (supplied by 
manufacture) and 1 U T4 DNA ligase in a final volume of 10 µl made up with 
sterilised distilled water. Reactions were incubated overnight at 16ûC.  
PCR products with phosphorylated 5 ends were ligated using Quick T4 ligase 
(NEB, UK). The ligation reaction mix contained approx. 25 ng DNA 1 x Quick 
Ligation Buffer and 0.5 µl Quick T4 DNA ligase in a final volume of 10 µl made 
up with sterilised distilled water. Reactions were incubated 5 min at room 
temperature (approx. 22ûC) 
 
2.3.3 Synthesis of oligonucleotide primers 
Oligonucleotide primers were synthesised at the Biopolymer Synthesis and 
Sequencing Unit, Queens Medical Centre, University of Nottingham or at Sigma-
Genosys (Suffolk, UK) 
2.3.4 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) DNA amplifications were performed as 
described by (Sambrook et al., 1989). PCR reactions for cloning and mutagenesis 
were carried out in 50 µl volumes using 1 U of Phusion High-Fidelity DNA 
polymerase (Finzymes supplied by NEB UK), 1 x HF Buffer, 200µM dNTPs 
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(Promega), 0.5-1 µM of each primer, 1 pg  10 ng DNA template and sterilised 
distilled water to the final volume of 50 µl. Reaction mixtures were heated to 98ûC 
for 30 s to denature template. Primers were annealed at 48 - 60ûC for 20s and the 
product extended at 72ûC for 20 s per 1 kb DNA to be amplified. Denaturation, 
annealing and extension cycles were repeated 25-35 times. A final extension time 
of 5 min at 72ûC ensured completion of all strands.  
Screening PCR and some cloning PCR reactions were carried out in 25-50 µl 
volumes using 1 U of Taq thermostable DNA polymerase (Promega UK.), 1 x 
PCR buffer (supplied with enzyme), 1 µM of each primer, 10-500 ng template 
DNA, 1,5 mM MgCl2 and 0,2 nM dNTP (Promega UK.) Reaction mixtures were 
heated to 95ûC for 2 min to denature the template. Primers were annealed at 48-
60ûC for 30 s and the product extended at 72ûC for 1 min per 1 kb DNA to be 
amplified. Denaturation, annealing and extension cycles were repeated 25  30 
times. A final extention time of 5 min at 72ûC ensured completion of all strands.  
The reactions were carried out in a Hybaid PCR Express Thermo (Hybaid, 
Ashford, UK). The elongation time and annealing temperatures were varied 
depending on the primers used, the stringency levels required and specified in the 
relevant results chapter. 
 
2.3.5 Site directed mutagenesis by PCR 
All site directed mutagenesis reactions was carried out using Phusion
®
 Site-
Directed Mutagenesis Kit (Finnzymes, Espoo, Finland) in accordance to the the 
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protocol supplied by the manufacture using phosphorylated primes designed 
according to the maufactures description (Finnzyme, Espoo, Finland). For 
template pBSK-AgrC1A and pBSK-AgrC4A (Table 2-2) was used. 
 
2.3.6 Purification of PCR products 
PCR products were purified by either agarose gel electrophoresis or using a 
QIAquick PCR purification kit as described by manufacturers (Qiagen UK). 1 x 
volume of PCR product was mixed with 5 x volume of PBI buffer (supplied by 
manufacture), the mix were transferred to a spin column and spun at 14,000 rpm 
for 1 min and the flow though discarded. 750 µl of PE buffer (supplied by the 
manufacture) were added to the column and it was spun for 1 min at 14,000 rpm 
and the flow through discarded. The column was then spun for 1 min at 14,000 
rpm to remove residues of the PE buffer and the dry column were inserted to a 1.5 
ml microcentrifuge tube and 30  50 µl of 1/10 EB buffer (supplied by 
manufacture) was added. The column was incubated at room temperature for 1 
min and spun at 14,000 rpm for 1 min. The eluate contain the purified PCR 
product. 
 
2.3.7 DNA agarose gel electrophoresis 
Agarose gels were prepared and run as described in (Sambrook et al., 1989). Gels 
were prepared in 1 x TAE (40 mM Tris acetate, 2 mM EDTA, pH 8,5) to a final 
concentration of 0.7  1 % wt/vol agarose. To enable visualisation of the DNA, 
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ethidium bromide was added to the molten agarose at a final concentration of 0.4 
µg / ml before the gel was poured. Samples were prepared in loading buffer (6 x 
stock: 0.4% orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% 
Ficoll® 400, 10mM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0) supplied by 
Promega UK) and gels run in 1 x TAE at 80  100 V. A UV transluminator was 
used to visualise the DNA and bands were excised as required. DNA markers, 1 
kb or 100 bp ladder (Promega UK), were used at 0.5 µg pr lane. 
 
2.3.8 Purification of DNA from agarose gels 
DNA was extracted from agarose gels using either QIAquick gel purification kit 
(Qiagen UK) or Wizard
®
 SV Gel and PCR Clean-Up System (Promega UK) as 
described by the manufacturer. Briefly, the desired bands were cut out of the 
agarose gel and put in a 1.5 ml micro centrifuge tube.  Both systems work by 
dissolving the gel in a buffer by heating it to 60ûC for 10 min in 30 µl of buffer 
QC pr 10 µg gel for QIAquick and 10 µl of Membrane Binding solution per 10 mg 
gel for SV gel. For the QIAquick system 10 µl of isopropanol per 10 mg of gel 
were added and mixed by vortexing. The dissolved gel was transferred to filter 
spin columns incubated at room temperature for 1 min and spun at 13,000 rpm for 
1 min. The flow through was discarded and 700 µl of either PE buffer (QIAgen) or 
Membrane Wash Solution (Promega) was added and the columns were spun at 
13.000 rpm for 1 min and the flow through discarded. The wash was repeated with 
500 µl Membrane Wash Solution for the Wizard
® 
SV system and spun at 13,000 
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rpm for 5 min and the flow through discarded.  Columns were spun for 1 min to 
remove the last residues of the wash buffers and transferred to new labelled 1.5 ml 
microcentrifuge tubes. 30  50 µl of sterile destilled water or 1/10 Buffer EB 
(supplied by manufacture) was added directly to the membrane and the columns 
were incubated at room temperature for 1 min and spun at 13,000 rpm for 1 min. 
The eluted DNA was stores at 4ûC. 
 
2.4 DNA sequencing 
DNA sequencing was conducted at Geneservice (Cambridge, UK). Specific 
primers were used in the sequencing reactions, details of which are given in the 
appropriate chapter section. 
 
2.5 DNA Sequence Analysis 
DNA sequence data was analysed using Chromas Lite 2.0 (Technelysium Pty Ltd) 
and VectorNTI 10 Advance 10 (Invitrogen). When required, DNA sequences were 
obtained from the National Centre Biotechnology Information (NCBI) 
[http://www.ncbi.nlm.nih.gov]. Databases were also searched for sequence 
similarity using the basic alignment search tool (BLAST) on the NCBI webpage 
[http://www.ncbi.nlm.nih.gov/BLAST/]. 
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2.6 Protein identification 
Protein identification was conducted at Biopolymer Synthesis and Sequencing 
Unit, Queens Medical Centre, University of Nottingham.  
 
2.7 Manipulation of Escherichia coli 
 
2.7.1 Electro-competent cells  
Electro-competent E. coli JM109, TOP10 and C41 cells were prepared as 
described by (Ausubel et al., 1988). Briefly, 1 l of LB broth was inoculated with 
10 ml of an overnight E. coli culture. The culture was incubated at 37ûC, shaking 
at 200 rpm until an OD600 of 0.5  0.8 was reached. Following incubation on ice 
for 15  20 min, the cells were harvested by centrifugation at 5000 x g, 4ûC for 10 
min. Cells were then washed in 1 l of ice-cold sterile distilled water, recentrifuged, 
washed with 500 ml ice-cold sterile distilled water, then resuspended in 20 ml ice-
cold 10 % vol/vol glycerol. Cells were centrifuged once again prior to 
resuspension in a final volume of 1 ml of ice-cold 10 % vol/vol glycerol. Aliquots 
of 40 µl were transferred to cold microcentrifuge tubes and flash frozen in liquid 
nitrogen before storage at -80ûC. 
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2.7.2 Rubidium Chloride competent E. coli 
Chemically competent E. coli JM109 cells were prepared as described by 
(Kushner, 1978). An E. coli overnight culture was used to inoculate 50 ml LB to 
an OD600 of approx 0.05 in a 500 ml Erlenmeyer flask. Cells were incubated at 
37ûC, shaking at 200 rpm until an OD600 of 0.6  0.7 was reached. Following 
incubation on ice for 15 min, the cells were harvested by centrifugation 3000 x g 
for 15 min, the supernatant poured of and the cell pellet dried by inverting the 
falcon tube on a paper towel. Cells were resuspended by moderate vortexing in 17 
ml RF1 (see below for recipe) and incubated on ice for 15-30 min. Cells were 
centrifuged again and resuspened in 4 ml RF2 (See below for recipe) and 
incubated on ice for 15 min. Aliquots of 400 µl were transferred to cold 
microcentrifuge tubes and flash frozen in liquid nitrogen before storage at -80ûC. 
 
Table 2-4: RF1 
Compound Amount/ litre Final concentration 
RbCl 12 g 100 mM 
MnCl2ǜ4H2O 9.9 g 50 mM 
Potassium Acetate 30 ml of a 1M stock pH 7.5 30 mM 
CaCl2ǜ2H2O 1.5 g 10 mM 
Glycerol 150 g 15% wt/vol 
Adjust the pH to 5,8 with 0.2 M acetic acid.  
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Table 2-5: RF2 
Compound Amount/ litre Final concentration 
MOPS 20 ml of a 0.5 M stock pH 
6.8 
10 mM 
RbCl 1.2 g 10 mM 
CaCl2ǜ2H2O 11 g 75 mM 
Glycerol 150 g 15% wt/vol 
Adjust pH to 6,8 with NaOH. 
2.7.3 Transformation of Ecoli 
2.7.3.1 Electroporation 
Ligation mix to be electroporated into competent cells was dialysed against sterile 
distilled water for 30 min using 0.025 µm Millipore filters (Millipore Corporation, 
USA) to remove any salts. Electrocompetent cells were thawed on ice and 2-5 µl 
dialysed ligation mix or 1  2 µl plasmid DNA added to the 40 µl aliquot. The 
mixture was incubated on ice, for 1 min before transferring a 2 mm 
electroporation cuvette (BioRad), on ice. A BioRad Gene Pulsar was used, 
according to manufacturers instructions, to deliver an electric pulse of 2.5 kV 
(25µF, 200ȍ). The cuvette was immediately removed and 1 ml of LB broth was 
added immediately to the electroporation cuvette. After incubation for approx 2 h 
at 37ûC (unless otherwise stated) 100  200 µl of the bacterial suspension was 
spread on to an appropriate selective plate. 
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2.7.3.2 Heat shock transformation 
Cells were removed from the freezer and thawed at room temperature until just 
liquid, and placed back on ice. 200 µL aliquots were mixed with 1-10 µL of DNA 
and incubated on ice for 20 min. Cells were heat shocked by placing tubes in a 
42ûC water bath for 90s, and then chilled by returning to ice immediately.  
Cells were recovered by adding 500 µL of LB and incubated shaking at 37ûC for 
approx 1 h and plated on LB plates containing appropriate antibiotic 
 
 
2.8 Manipulation of Staphylococcus aureus  
2.8.1 Preparation of plasmids DNA 
For purification of plasmid DNA from S. aureus a QIAprep Spin Miniprep Kit 
(Qiagen UK) was used with modification to the protocol. Briefly, 2-3 ml of a S. 
aureus overnight culture was harvested in a by centrifugation 14,000 rpm 1 min. 
The pellets was resuspended in 250 µl P1 buffer (supplied by the manufacturer) 
and 5 µl of a 5 mg/ml Lysostaphin (Sigma) was added, mixed and incubated at 
37ûC for 30 min. 250 µl P2 buffer (supplied by the manufacturer) was added and 
mixed by gently inverting the tube 3-4 times, 350 µl N3 buffer was added and tube 
gently inverted 3-4 times to facilitate total mixing. Mixture was centrifuged for 10 
min at 14,000 rpm to precipitate genomic DNA and cell debris. Supernatant was 
gently poured on to a spin column and spun at 14,000 rpm for 1 min and flow 
through was discarded. 750 µl of buffer PE (supplied by manufacturer, Ethanol 
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added) was added and column centrifuged again for 1 min at 14,0000 rpm. Flow 
through discarded and column spun again at 14,000 rpm for 1 min to get rid of 
wash buffer residues. Spin column was transferred to a new micro centrifuge tube 
and 30  50 µl of a 1:10 dilution of EB buffer was added. Columns were incubated 
at room temperature for 1 min and plasmid DNA recovered by centrifugation at 
14,000 rpm for 1 min.  
 
 
2.8.2 Preparation of genomic DNA  
Genomic DNA was recovered from S. aureus using a QIAGEN DNeasy Tissue kit 
with a modified protocol. Briefly, S. aureus cells were grown at 37ûC for 4  6 h 
or statically overnight in LB or TSB and 2-3 ml culture was harvested by 
centrifugation at 14000 rpm for 1 min. The pellet was resuspend in 180 µl enzyme 
lysis buffer by vortexing and 5 µl of a 5 mg/ml lysostaphin in dH2O (Sigma) plus 
5 µl of a 1 mg/ml RNaseA in dH2O (Sigma) was added and the cells were 
incubated for 30 min at 37ûC. 25 µl Proteinase K (supplied by manufacturer) and 
200 µl Buffer AL was added and samples mixed by vortexing and incubated at 
70ûC for 30 min. 200 µl of 100% ethanol was added and samples mixed 
thoroughly by vortexing. The mixture was transferred to DNeasy mini column 
sitting in a 2 ml collection tube and centrifuged at 8000 rpm for 1 min. The flow 
through and collection tube were both discarded. The column was transferred to a 
new 2 ml collection tube and 500 µl buffer AW1 was added and columns were 
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centrifuged at 8000 rpm for 1 min. The flow through and collection tube were 
again discarded. The column was transferred to a new 2 ml collection tube and 
500 µl buffer AW2 was added and columns were centrifuged at 13,000 rpm for 3 
min. The flow through and collection tube were agsin discarded. The column was 
transferred to a 1.5 ml microcentrifuge tube and 200 µl Buffer AE was added 
directly onto the column membrane, incubated for 1 min at room temperature and 
genomic DNA recovered by centrifuging the column at 8000 rpm for 1 min. 
 
 
Enzyme lysis solution: 
20mM Tris pH 8.0 
2mM EDTA 
1.2% vol/vol Triton X-100 
Store at room temperature. 
 
2.8.3 Preparation of electro-competent S. aureus 
Electro-competent S.aureus RN4220, RN6390B and ROJ48 cells were prepared as 
described by (Schenk and Laddaga, 1992). Briefly, an overnight culture of the 
desired strain was grown in 30 ml of B2 broth for no more than 15 h. This 
overnight culture was used to inoculate 200 ml of pre-warmed B2 broth to an 
OD600 of approx. 0.25. The culture was incubated at 37ûC, shaking at 200 rpm 
until an OD600 of 0.35  0.4 was reached (approx 1  1.5 h). All of the washes and 
66 
incubations were done a room temperature unless otherwise stated. The cells were 
harvested by centrifugation at 10.000 x g for 10 min. Cells were then washed in 30 
ml of sterile distilled water, recentrifuged, washed with 30 ml sterile distilled 
water. Centrifuged again and resuspended in 10 ml 10 % vol/vol glycerol. This 
step was repeated with resuspension in 5 ml of 10 % vol/vol glycerol and 
incubated at room temperature for 15 min. Cells were transferred to 1.5 ml 
microcentrifuge tubes and centrifuged once again at 10.000 x g prior to 
resuspension in a final volume of 1.5 ml of 10 % vol/vol glycerol. Aliquots of 80 
µl were stored at -80ûC. 
 
2.8.4 Electroporation of S. aureus cells 
Electrocompetent cells were removed from the freezer and thawed at room 
temperature prior to use. The cells were mixed with approx 1 µg of plasmid DNA 
was added to 70 µl of electrocompetent S. aureus cells and transferred to  a 0.2 
mm electroporation cuvette (BioRad). A BioRad Gene Pulsar was used, according 
to manufacturers instructions, to deliver an electric pulse of 2.3 kV (25µF, 100ȍ). 
The cuvette was immediately removed and 1 ml of B2 broth was added. After 
incubation for approx 2 h at 37ûC (unless otherwise stated) 100  200 µl of the 
bacterial suspension was spread on to an appropriate selective plate, the rest of the 
cells were spun at 13.000 rpm for 1 min, supernatant discarded and resuspended in 
200 µl B2 broth and spread in an appropriate selective plate. 
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2.8.5 ĭ11 transduction 
Phage ĭ11 transduction of Staphylococcus aureus was carried out as described by 
P. Chan, Sheffield Uni (1996) as follows: 
2.8.5.1 Phage Lysate preparation  
Briefly, an S. aureus over night culture in TSB of 8325-4 or ROJ37 was grown at 
37ûC. The overnight culture was used to inoculate 25 ml freshly prepared TSB 
containing 10 mM MgSO4 and 10 mM CaCl2 to an OD600 of 0.05 in a 100 ml 
conical flask and incubated shaking 200 rpm at 37ûC until an OD600 of 0.2 (approx 
1 h). 10 ml of culture was subcultured in a fresh conical flask and 1 ml of ĭ11 
stock (kindly supplied by Dr. Alan Cockayne) was added. Both cultures, with and 
with out phage, was incubated for a minimum of 4 h, until lysis was apparent by 
comparing phage containing culture with uninfected control, at 37ûC with shaking 
at 200 rpm. Phage containing culture was centrifuged 10 min at 5000 rpm to 
remove unlysed cells and other cell debris. Supernatant, containing the lytic 
phage, was filter sterilised and labelled lysate A. The lysis step was repeated using 
1 ml of Lysate A instead of 1 ml ĭ11stock. The resulting lysate was labled Lysate 
B. 
 
2.8.5.2 Determination of phage titres 
Titres of ĭ11 lysates was determined as follows. A 10 ml overnight culture of S. 
aureus 8325-4 was grown in TSB broth. 0.25 ml of the overnight culture was used 
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to inoculate 25 ml of fresh TSB and incubated shaking at 37ûC to an OD600 of 0.2 
after 2 h. 100 ml TSB bottom agar was (10 g/L agar No 1) melted, cooled down to 
approx 50ûC and and 5 ml of a sterile 1 M CaCL2 solution was added, plates 
poured and left to solidify. At the same time TSB top agar (7 g/L agar No 1) was 
melted and cooled to 50ûC before 1 ml of sterile 1 M CaCL2 and 1 ml of sterile 1 
M MgSO4 was added. The top agar was kept melted while TSB bottom agar 
solidified. 100 ml of the TSB top agar was seeded with 20 ml early log phase S 
aureus 8325-4 (OD600 approx 0.2) and 5 ml of the mixture was evenly distributed 
on top of a TSB bottom agar plate and left to solidify. A series dilution of the ĭ11 
lysate to be tested was made and 10 µl of each dilution spotted on the the freshly 
made plates. When lysate was absorbed plates was incubated at 37ûC over night. 
The number of plaques on each plate was counted and the number of plaque 
forming units per ml was calculated.  
 
2.8.5.3 Phage transduction 
S. aureus RN6390B cells were phage transduced as described by P Chan. An 
overnight culture of RN6390B was grown in 20 ml LK broth. The cells were 
harvested by centrifugation for 10 min at 10000 rpm and resuspended in 1 ml LK 
broth. Both a sample and a control were mixed. Sample consisted of 500 µl cells, 
1 ml LK with 10 mM CaCl2 and 500 µl ĭ11 lysate B. Control consisted of 500 µl 
cells and 1.5 ml LK with 10 mM CaCl2. Both sample and control was incubated 
first 25 min stationary and the 15 min shaking at 37ûC. After incubation sample 
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and control was transferred to an ice bucket and 1 ml of ice cold 0.02 M sodium 
citrate was added. Both Sample and control was centrifuged for 10 min at 10000 
rpm at 4ûC and resuspended in 1 ml ice cold 0.02 M sodium citrate and incubated 
on ice for 2-3 h. Aliquots of 100 µl was spread on selective LK plates containing 
0.05% wt/vol sodium citrate. Plates were incubated at 37°C for 12-72 h and 
transduction of the desired DNA was verified by Southern blot. 
 
2.9 Manipulation of Saccharomyces cerevisiae 
2.9.1 Lithium acetate transformation 
Co-transformation of two-hybrid plasmids into Saccharomyces cerevisiae strain 
PJ694A was performed as described by (Gietz et al., 1992). Briefly, 1 ml of YPD 
broth was inoculated with several 2-3 mm colonies of PJ69-4A and vortexed 
vigorously for approx 5 min. The cell suspension was transferred into a conical 
flask containing 50 ml of YPD broth and incubated over night (approx 17 h) at 
30ûC with shaking at 250 rpm. 30 ml of the overnight culture was transferred to a 
conical flask containing 300 ml of YPD, OD600 0.2  0.3. The culture was 
incubated for 3 h at 30ûC shaking at 230 rpm until OD600 of 0.4  0.6 was reached. 
The culture was transferred to 50 ml falcon tubes and centrifuged at 1000 x g for 5 
min at room temperature. The supernatant was discarded and the cells resuspended 
and pooled in sterile TE, final volume of 40 ml and centrifuged again at 1000 x g 
for 5 min, room temperature. The supernatant was discarded and the cells were 
resuspended in 1.5 ml of freshly prepared sterile 1 x TE / 1 x lithium acetate. 
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Approx 0.1 µg of each two-hybrid plasmid and 0.1 mg of herring testes carrier 
DNA were mixed in a fresh 1.5 ml tube and 0.1 ml of competent S. cerevisiae 
PJ69-4A cells was added and the suspension mixed by vortexing. 0.6 ml of PEG / 
lithium acetate solution was added and the tubes were vortexed for approx 10 s 
and incubated at 30ûC shaking at 200 rpm for 30 min. 70 µl of DMSO was added 
and the suspension mixed well by gently inverting the tubes. The transformation 
mixture was heated to 42ûC for 15 min and chilled on ice for 1-2 min. Cells were 
centrifuged at 14000 rpm for 5 s and the supernatant removed. Cells were then 
resuspended in 0.5 ml of sterile 1 x TE buffer and aliquots of 100 µl of 10
0
, 10
1
, 
10
2
, and 10
3
 times dilutions were plated onto selective YMM plates. The plates 
were incubated at 30ûC for 2-4 days. 
 
2.9.2 Preparation of plasmid DNA from S. cerevisiae 
Preperation of plasmids from was done as described in (Holm et al., 1986)S. 
cerevisiae PJ69-4A containing two-hybrid plasmids was patched on YMM 
MUHA (Yeast minimal medium with methionine, uracil, histidine and alanine) 
plates and incubated at 30ûC for 3-4 days. Approx 10 mm
2
 of the patches was 
scraped off and resuspended in 50 µl TE buffer in a 1.5 ml microcentrifuge tube. 
10 µl of lyticase solution (5 U/µl lyticase (sigma) in TE buffer), to lyse the yeast 
cells, was added to each tube and vortexed. Tubes was incubated for 30  60 min 
at 37ûC shaking, 200 rpm. 10 µl 20% SDS was added and tubes was vortexed for 1 
min and the cells subjected to a freeze thaw cycle (-20ûC) before vortexing. 130 µl 
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of TE, pH 7, was added to each tube to bring the volume up to 200 µl. Next 200 µl 
of phenol:chloroform:isoamyl alcohol (25:24:1) was added and tubes was 
vortexed for approx 5 min and centrifuged at 14000 rpm for 10 min. The upper 
aqueous phase was transferred to a fresh micro centrifuge tube and 8 µl of 10 M 
ammonium acetate and 500 µl of 96% vol/vol ethanol were added to precipitate 
the DNA. The tubes were incubated at -70ûC for 1 h and centrifuged at 14000 rpm 
for 10 min. The supernatant was discarded and the pellet dried completely before 
being resuspended in 20 µl dH2O.  
 
2.9.3 Yeast two-hybrid screening 
Interactions between the fusion proteins expressed by the two-hybrid vectors 
transformed into the yeast S. cerevisiae PJ69-4A were evaluated as follows. For 
library screening for intactions with AgrB the co-transformants was plated onto 
selective plates YMM MUA (Yeast Minimal media + Methionine +Uracil 
+Alanine) which not just selects for the two plasmids but also for interactions 
between AgrB and the protein expressed from the library plasmid. 150 colonies 
which showed potential interaction were picked and streaked onto more stringent 
plates YMM MUA X-gal, YMM MUH and YMM MU, with YMM MU being the 
most stringing and incubated at 30°C for 72 h. Colonies showing positive for 
interactions, by turning blue on X-gal and growing on the most stringent selection 
medium, were restreaked on YMM MUA plates and incubated for 72 h at 30°C, 
this was repeated twice to make sure that each cell only contained one copy of the 
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library plasmid. Plasmid DNA was isolated from overnight cultures of streaks 
showing positive for interactions. Insert of the library plasmid was PCR amplified 
using primers pGBTf and pGBTr (Table 2-3). 5 µl the resulting PCR fragments 
was digested with the restriction enzyme HaeIII and cut and uncut PCR products 
were run on a 1% analytical agarose gel. PCR products revealing the same 
restriction pattern was assumed to have come from identical library inserts. Two 
of each PCR product showing an identical restriction pattern was sent for 
sequencing to identify the insert. 
 
2.9.4 Analysis of Yeast Two-Hybrid data 
Sequence data was analysed using both blastn and blastx (2006) and the 
VectorNTI 10.0 software packet (Invitrogen)  
 
2.10  Southern blot 
Southern hybridisation was carried out as described in Sambrook et al. (1989). 
 
2.10.1 DIG labelling of DNA probe 
Probes for southern blots were labled with digoxygenin (DIG) using PCR DIG 
Labelling Mix (Roche Applied Science, UK) as recommended by the 
manufacture. Briefly, a PCR reaction was carried out using using 1 U of Taq 
thermostable DNA polymerase (Promega UK.), 1 x PCR buffer (supplied with 
enzyme), 1 µM of each primer, 10-500 ng template DNA, 1.5 mM MgCl2 and 200 
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µM dNTP (10 µl) PCR DIG Labelling Mix and sterile dH2O to 100 µl. The 
reaction mixture was heated to 95ûC for 2 min to denature the template. Primers 
were annealed at 48-60ûC for 30s and the product extended at 72ûC for 1 min. 
Denaturation, annealing and extention cycles were repeated 25  30 times. A final 
extention time of 5 min at 72ûC ensured completion of all strands.  
 
2.10.2  Digestion of DNA and gel electrophoresis 
 
Genomic DNA isolated from S. aureus strains RN6390B and RN4220, were 
digested with PstI and loaded on a 0.7% agarose gel. The gel was run for 3h at 100 
V (approx 3.5 V/cm). After electrophoresis the DNA agarose gel was pre-treated 
with 250 mM HCl for 10 min, shaking gently at room temperature to depurinate 
the DNA. The DNA was denatured by submerging the gel in Denaturation 
solution (0.5 M NaOH, 1.5 M NaCl) for 2 x 15 min, gently shaking at room 
temperature and the gel was rinsed with sterile dH20. Gel was submerged in 
Neutralisation solution (0.5 M Tris-HCl, 1.5 M NaCl)  for 2 x 15 min gently 
shaking at room temperature and equilibrated in 20 x SSC (3M NaCl, 0.3 M 
sodium citrate, pH 7.0) for 10 min. DNA was transferred onto a positively charged 
Nylon membrane (Roche, USA) using the setup illustrated in Figure 2-1. The gel 
was placed on top of a piece of Whatman 3MM paper soaked in 20 x SSC and 
placed on a bridge resting in a shallow reservoir of 20 x SSC. A piece of 
positively charged Nylon membrane the size of the gel was placed on top of the 
gel and a gel size piece of Whatman paper was placed on top. A total of 4 gel size 
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pieces of blotting paper (Sigma) was placed on top and the blotting sandwich was 
finished of by placing a glass plate and a weight (approx 500g) on top of the 
sandwich. The DNA was left to transfer overnight.  
 
 
Figure 2-1: Schematic of a southern blot transfer set up 
 
2.10.3 Hybridization 
The blotting sandwich was disassembled and the DNA was cross linked to the still 
damp membrane by exposing the membrane to UV light for 2 min, DNA side up. 
The membrane was rinsed in distilled water and left to air dry. The dry blot was 
placed in a glass roller bottle, 20 ml of prewarmed DIG Easy hyb (Roche, USA) 
was added and the blot was incubated in a hybridisation oven at 42ûC for 30 min. 
In the mean time the prepared DIG labelled DNA probe was denatured by heating 
in a boiling water bath for 5 min and quenching on ice for 2 min and the probe 
was added to 7 ml DIG Easy hyb (Roche). The DIG Easy hyb from the 
prehybridisation step was discarded and the 7 ml DIG Easy hyb containing the 
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labelled probe was added to the roller bottle contaning the membrane. The 
membrane with probe was left to hybridise overnight in at 42ûC in a hybridisation 
oven. 
The hybridisation mix was poured into a 50 ml falcon tube and stored at -20C. The 
blot was rinsed in low stringency buffer (2 x SSC, 0.1% SDS) and 50 ml of low 
stringency buffer was added and the blot was washed at 65°C for 30 min. The 
buffer was poured of and replaced with 50 ml of preheated of high stringency 
buffer (0.5 x SSC, 0.1% wt/vol SDS) and the blot incubated at 65°C for 2 x 15 
min.   
2.10.3.1 Detection of hybridised bands 
The membrane was equilibrated in 50 ml washing buffer (0.1 M maleic acid, 0.15 
M NaCl; pH 7.5; 0.3% Tween) for 2 min, the washing solution was poured of and 
50 ml of blocking solution (1 x Blocking Solution (Roche, USA) in 0.1 M maleic 
acid, 0.15 M NaCl; pH 7.5) and incubated at room temperature for 1 h. The 
blocking solution was removed of and replaced 20 ml antibody solution (1:10000 
alkaline phosphorase conjugated anti-digoxigenin ab in blocking solution) and 
incubated for 30 min at room temperature. The antibody solution was discarded 
and the membrane was washed 2 x 15 min in 50 ml washing solution. The 
membrane was equilibrated in 20 ml detection buffer (0.1 M Tris-HCl, 0.1 M 
NaCl, pH 9.5) for 3 min. The membrane was placed on an acetate sheet and 1.5 ml 
of a 0.25 M CDP-Star solution was evenly distributed over the membrane 
before another sheet of acetate was placed on top and the membrane was 
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incubated at room temperature for 5 min. The blot was visualised by taking a 
picture of the membrane using a light camera (EG&G BERTHOLD Luminograph 
LB980). 
2.11  Membrane protein preparation 
Crude membrane protein preparations were prepared as follows. A volume 
equevilent to an OD600 of 5 was pelleted from an overnight culture of S. aureus 
RN6390B, ROJ38 or ROJ38 pAgrC1agrA and the supernatant removed. The 
pellet was resuspended in 250µl of in PBS 80 µg/ml Lysostaphin by vortexing and 
incubated for 30 min at 37°C. Cooled on ice and sonicated for 2 x 15 s at 6-8 
MSE. Centrifuged for 10 min at 13.000 g and the supernatant removed (soluble 
proteins). The Pellet was washed with 1 ml PBS, centrifuged at 13.000 g for 10 
min resuspended and in 200 µl 1X SDS-PAGE sample buffer. 15 µl was loaded in 
each gel lane. 
2.11.1 Elugent extraction of membrane proteins 
Elugent extracts were prepared as described for membrane protein preperations 
with the pellet in the last step being resuspended in 100 µl 2 % vol/vol Elugent 
(Calbiochem, MERCK, UK,), instead of 1X SDS-PAGE buffer, and incubated at 
37°C for 30 min  and centrifuged at 13.000 g for 10 min. The pellet was 
resuspended and in 200 µl 2X SDS-PAGE sample buffer. 15 µl was loaded in each 
gel lane.  
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2.12  SDS-polyacrylamide gel electrophoresis 
SDS-PAGE was conducted using the method of  (Laemmli, 1970). 10 % 
acrylamide gels were prepared using 3.3 ml BioRad Protogel (30:08),  1.25 ml 3 
M Tris-HCL pH 8.8, 4.8 ml sterile distilled water, 100 µl 10 % wt/vol sodium 
dodecyl sulphate (SDS), 75 µl 10 % wt/vol ammonium persulphate and 5 µl 
NNNN-tetramethylethylene diamine (TEMED). The mixture was then poured 
into a BioRad Mini-protean II casting tray, and overlaid with water saturated with 
butanol to minimise shrinkage of the gel due to evaporation. Upon polymerisation 
of the separating gel the butanol saturated water was discarded and the stacking 
gel was poured onto the separating gel. The 5 % acrylamide stacking gel was 
prepared using 750 µl Protogel (National Diagnostics, USA), 1.5 ml 0.5 M Tris-
HCl pH 6.8, 60 µl 10 % wt/vol SDS, 10.3 ml water, 150 µl 10 % wt/vol 
ammonium persulphate and 6 µl TEMED. 
Samples for analysis was mixed with an equal volume of 2 x sample buffer (0.25 
M Tris-HCl, pH 6.8, 20 % vol/vol Glycerol, 4 % wt/vol SDS. 0.001 % wt/vol 
bromphenol blue, 100 mM DTT) and then boiled for 10 min. Samples were then 
loaded on to the gel, and the gel run at 150 V in Tris-glycine running buffer (2.88 
% wt/vol glycin, 0.6 % wt/vol Tris, 0.2 % wt/vol SDS, pH 8.3). Gels were run 
until the dye present in the sample buffer tracked to the bottom of the gel. 
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2.13  Coomassie staining of polyacrylamide gels 
SDS-PAGE gels were first fixed in destain solution (20 % vol/vol methanol; 7.5 % 
vol/vol acetic acid) for 10-15 min, then stained with Coomassie Brilliant Blue (20 
% vol/vol methanol; 7.5 % vol/vol acetic acid, 0.025% Coomassie Brilliant Blue 
R250) and the subsequently destained in destain solution  to reveal the protein 
profile and reduce background staining. 
 
2.14  Protein identification 
Protein identification of bands from Coomassie stained SDS-PAGE gels was 
conducted by MALDi TOF or QTof mass spectroscopy at Biopolymer Synthesis 
and Sequencing Unit, Queens Medical Centre, University of Nottingham. Whole 
SDS-PAGE gels were delivered together with an image of the gel with the bands 
to be sequenced marked. 
2.15  Western blotting 
Western blotting was carried out as described in Sambrook et al., (1989). 
Proteins to be analysed by Western blotting were first separated by SDS-PAGE 
(2.12).  Proteins were the transferred onto a BioTrace®NT nitrocellulose 
membrane (PALL life sciences, USA) using a BioRad II Mini-Cell and 
Electroblotting Module according to the manufacturers instructions. Transfer was 
carried out at 140 mA for 1.5 h at room temperature in Western blotting buffer 
(2.88 % wt/vol glycin, 0.6 % wt/vol Tris-HCL). 
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Blots were removed from the apparatus and blocked in PBS (pH 7.4) containing 5 
% wt/vol skimmed milk powder overnight at 4ûC then incubated with primary 
antibody (1:500 dilution of rat antiserum immunised with the C-terminal fragment 
of AgrC) in PBS 5 % wt/vol skimmed milk powder for 1 h.  Blots were subjected 
to 2 x 15 min washes in PBST (PBS pH 7.4 with 0.05% vol/vol Tween20) and 
then probed with the same buffer containing the secondary antibody (1:2000 rabit-
anti-rat alkaline phosphatase conjugated (DAKO A/S, Denmark) in PBST) for 1 h. 
Blots were once again washed 2 x 15 min in PBST prior to being developed using 
ECL substrate (GE healthcare). Positive reactions were visualised by exposure 
to autoradiograph film (Kodak). 
 
2.16  Bioluminescence agr activity assay 
Reporter strain containing plasmids pSKermP2 with either wild type agrC or 
mutated agrC and agrA were grown o/n @ 37°C in CYGP medium supplemented 
with appropriate antibiotics. In the morning cultures were diluted 1/25 and grown 
@ 37°C for 2h after which 10 µl of the cultures were diluted 1/50 into wells in a 
96 well microtiter plates containing a series dilution of AIP obtained from Dr. 
Weng Chan (CBS, University of Nottingham). Each plate contained two sets of a 
series dilution of AIP in triplicates. CYGP containing the appropriate antibiotic 
was then added to a total volume of 200 µl.  The microtiter plates were then 
incubated in an Anthos Lucy 1 luminometer (Labtech) where light measurements 
and OD492 were taken every 30 min for 24h. 
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Data were plotted as Relative Light Units pr cell density (RLU/OD) over time. 
EC50 and IC50 values were extracted from the sigmoidal dose-response curves 
using the PRISM2 PROGRAM (Graphpad). All assays were carried out at least in 
triplicate. 
 
2.17  Light camera pictures 
Pictures of plates with luminescent bacteria and southern blots were taken with an 
EG&G BERTHOLD Luminograph LB980 light camera connected to a computer 
using Luminograph LB980 v. 2.6 software. 
 
2.18 Fluorescence microscopy 
Pictures of  S. aureus and E. coli carrying the plasmid pGfp-AgrCA were obtained 
using a Nikon eclipse TE2000-S (Nikon) fluorescence microscope linked to a 
computer running IPlab v3.7 (Scanalytics Inc, BD Biosciences, USA). 
Manipulation of the obtained pictures was done using IPlab v3.7. 
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3 Structure function study of the interactions of the 
histidine kinase sensor AgrC and AIP ligands 
 
3.1  Introduction 
 
The production of many surface proteins and secreted toxins in Staphylococcus 
aureus is controlled in a quorum sensing-dependent manner via the agr (accessory 
gene regulator) system. This system is activated by a diffusible signal peptide 
termed an Auto-Inducing Peptide (AIP) which is predicted to bind to and activate 
the histidine sensor kinase, AgrC. Four different AIPS have so far been identified 
(Figure 3-1), dividing S. aureus into four groups. Each groups native AIP 
activates its own AgrC and inhibits activation of those of other groups, a process 
known as cross-inhibition (Ji et al., 1997;McDowell et al., 2001). Activation of 
AgrC by an AIP leads to the phosphorylation of the response regulator AgrA, 
which binds to the intergenic promoter region and activates both agr promoters P2 
and P3, leading to increased transcription from both promoters. The P3 transcript 
is the functional RNAIII which is responsible for the regulation of the genes in the 
agr regulon (Balaban and Novick, 1995;Ji et al., 1995;McDowell et al., 2001).  
 
AgrC was first predicted to have five transmembrane domains and two extra-
cellular loops by Lina et al (1998) based on data obtained using PhoA fusions and 
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Kyle-Doolittle hydrophobicity plots. Recently this suggested model has been 
questioned.  
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Figure 3-1: Structures of AIPs, (top) AIP-1 and AIP-4 and the structure of the modified AIP, 
(ala
5
)AIP-1. In blue is shown the difference between AIP-1 which has an aspartic acid at 
position 5 and AIP-4 which has a tyrosine at positions 5.  The alanine substitution of position 
5 (ala
5
)AIP and is known to be a potent inhibitor of all known agr groups  (McDowell et al., 
2001;Lyon et al., 2002) shown in red. 
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The initial aim of this work was to construct and validate an easy to use and 
reliable reporter to the study of AIP mediated activation and inhibition of AgrC, 
and to identify the key amino acids involved in these processes. For this purpose 
AgrC1/AIP-1 and AgrC4/AIP-4 were chosen due to their high degree of similarity 
of both AIPs and AgrCs. Only the amino acid in position five differs between the 
AIPs, aspartic acid (a polar acidic amino acid) in AIP-1 and tyrosine (a polar 
neutral amino acid) in AIP-4. 
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3.2 Results 
3.2.1 Prediction of the transmembrane topology of AgrC 
 
To gain insight into the key amino acid residues in AgrC likely to be involved in 
AIP recognition, the transmembrane topology of AgrC was first modelled using 
online prediction tools. 
AgrC is encoded by the third gene in the agr P2 transcript. The size of the agrC  
gene depends on the agr group; agrC1 is either 1245 bp or 1293 bp,  agrC2 is 
1116 bp,  agrC3 and agrC4 are 1293 bp. The agrC gene products are either a 371, 
414 or 430 amino acid residue transmembrane proteins predicted to have 
molecular weight of 42.45 kDa, 48.0 kDa or 49.89 kDa. AgrC consists of two 
major domains, an N-terminal membrane spanning sensor domain and a C-
terminal cytoplasmic histidine kinase domain, each approximately making up half 
the protein. 
 
3.2.1.1 Selection of prediction server 
To derive the most likely AgrC topology, the online prediction tools listed below 
were used (See http://www.expasy.org/tools/#topology and http://saier-144-
37.ucsd.edu/memsat.html).  
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Table 3-1: Transmembrane topology prediction servers available online and used for the 
transmembrane topology prediction for staphylococcal AgrC in this study. 
Name Web address (as of 08/2008) Reference 
DAS (Stockholm 
University, 
Sweden) 
http://www.sbc.su.se/~miklos/DAS/ 
(Cserzo et al., 
1997) 
PredictProtein 
(Columbia 
University, USA) 
http://www.predictprotein.org/ 
(Rost et al., 1996) 
 
SOSUI  (Nagoya 
University, 
Japan) 
 
http://bp.nuap.nagoya-u.ac.jp/sosui/ 
(Hirokawa et al., 
1998) 
TMAP 
(Karolinska 
Institut; Sweden) 
http://bioinfo4.limbo.ifm.liu.se/tmap/index.html 
(Persson and 
Argos, 
1994;Persson and 
Argos, 1996) 
TMHMM (CBS; 
Denmark) 
http://www.cbs.dtu.dk/services/TMHMM-2.0/ 
(Sonnhammer et 
al., 1998;Krogh 
et al., 2001) 
TMpred 
(EMBnet-CH) 
http://www.ch.embnet.org/software/TMPRED_form.html 
(Hofmann and 
Stoffel W., 1994) 
 
TopPred (France) 
http://mobyle.pasteur.fr/cgi-
bin/MobylePortal/portal.py?form=toppred 
(von Heijne G., 
1992;Claros and 
von, 1994) 
 
MEMSAT (USA) http://saier-144-37.ucsd.edu/memsat.html 
(Jones et al., 
1994) 
 
HMMTOP 
(Hungarian 
Academy of 
Sciences) 
http://www.enzim.hu/hmmtop/html/adv_submit.html 
(Tusnady and 
Simon, 2001) 
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The predicted amino acid sequence for S. aureus Newman AgrC1 was evaluated 
via each of eight prediction programs listed in Table 3-1.  
 
A summary of the results is shown in Table 3-2 (for full results see Appendix A). 
For DAS two different cut off values are given by default giving two different 
possible predictions. For MEMSAT, a 7 TMH was given as the favoured structure 
but the score shown in the final result corresponded to the 6 TMH shown. 
HMMTOP was the only topology prediction server that predicted both the N- and 
the C- terminal to be extracellular. 
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Table 3-2: Summary of transmembrane topology predictions from selected online programs. 
Name of server, number of predicted transmembrane helices (TMH) and which amino acids 
are likely to be located in the TMH are shown for each program.  
Prediction 
server 
name 
No 
of 
TMH 
Amino acid predicted to be in the TMH (N to C) 
  TMH1 THM2 THM3 THM4 THM5 THM6 
THM7 THM8
TMHMM 
v2 
6 7-29 49-71 
78-
100 
110-
132 
145-
167 
188-
204 
  
toppred 6 8-28 54-74 
84-
104 
109-
129 
149-
169 
182-
202 
  
TMpred 6 9-27 53-72 
79-
103 
113-
132 
149-
168 
184-
205 
  
Tmap 6 11-39 50-78 
83-
106 
112-
140 
150-
178 
188-
216 
  
SOSUI 7 6-28 34-56 60-82 
85-
107 
110-
132 
148-
170 
182-
204 
 
PHDhtm 6 12-30 41-65 70-94 
110-
133 
149-
167 
183-
201 
  
DAS (1.7) 6 18-37 47-62 
67-
113 
119-
142 
158-
177 
193-
212 
  
DAS (2.2) 8 19-36 48-60 69-82 89-98 
105-
111 
120-
141 
159-
176 
194-
211 
MEMSAT 7 9-27 35-51 58-74 
87-
103 
110-
132 
149-
168 
182-
205 
 
MEMSAT 6 4-30 56-72 
79-
103 
110-
132 
149-
168 
182-
205 
  
HMMTOP 6 7-30 39-62 
79-
103 
110-
133 
150-
169 
182-
205 
  
 
88 
From the eight prediction programs, six gave one possible AgrC transmembrane 
topology model and two gave two alternatives. 
 
Information from multiple programs should help with an overall prediction and of 
the eleven predicted topologies, eight gave a six TMH topology, two gave a seven 
TMH topology and one predicted an eight TMH model. Based on this comparison, 
the age of the prediction programs and Möller et als (2001) large study of various 
prediction servers and evaluation of their accuracy using sequences from proteins 
with known structure, where the TMHMM 2.0 was shown to be the most accurate 
service available at the time of the article, (Moller et al., 2001) TMHMM 2.0 was 
used for the further studies of the AgrC membrane topology and the AgrC-AIP 
structure function study. 
 
3.2.2 Predicted transmembrane topology of several 
staphylococcal AgrCs 
The next step in this study was to predict the transmembrane topology of different 
AgrC using sequences from available staphylococcal genomes 
(www.ncbi.nlm.nih.gov/ sites/entrez?db=genome). Sequences used in this study 
were five S. aureus AgrC1s, three S. aureus AgrC2s, three S. aureus AgrC3s, 
three S. aureus AgrC4s (None of the S. aureus genomes published is agr group 
four so the three sequences were selected by a gene search for AgrC and identified 
by the AgrD sequence as agr group four), two S. epidermidis AgrCs, one S. 
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haemolyticus AgrC, and one S.saprophyticus AgrC.  The results are shown in 
Figure 3-2 to Figure 3-4 
 
S. aureus AgrC1 
Modelling the two different attenuated AgrC1 (414 aa: NCTC 8325 and USA300 
and 430: Newman, COL and USA300_TCH1516, Source; NCBI, accession no. 
YP_500745, YP_494642, YP_001332979 and YP_001575910) from completed S. 
aureus genomes resulted in two different predicted transmembrane topologies, 
both with six transmembrane spanning helices and three extracellular loops with 
the N- and C-terminal amino acid residues located on the cytoplasmic side of the 
membrane.  This six TMH structure for the 430 amino acid residue AgrC1 is 
consistent with data obtained using PhoA fusions which indicated that 
33
Y, 
105
K 
and 
176
A is located on the outside of the membrane (Lina et al., 1998) (Figure 3-3 
A). 
 
S. aureus AgrC2 
Since AgrC2 (Accession no. Mu50: NP_372562, Mu3: YP_001442613 and N315: 
NP_375146) DNA sequence is shorter than the other three groups it is predicted to 
have four TMH resulting in two extra-cellular loops with N- and C-terminal ends 
of the protein on the cytoplasmic side of the membrane (Figure 3-3 B). 
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S. aureus AgrC3 
The AgrC3 sequence (Accession no. Mw2: NP_646779, MRSA252: YP_041488 
and MSSA476: YP_044054) has 430 amino acids and the prediction suggested six 
TMH and three extracellular loops with N- and C-terminal ends of the protein on 
the cytoplasmic side of the membrane (Figure 3-3 C).  
 
S. aureus AgrC4 
The AgrC4 sequence (Accession no. RN4850: ABB29292 ,H460: ABB17521 and 
H417: ABB17515) has 430 amino acids and the prediction suggested six TMH 
and three extracellular loops with N- and C-terminal ends of the protein on the 
cytoplasmic side of the membrane (Figure 3-3 D).  
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Figure 3-2: Predicted six transmembrane helices and three extracellular loops topology of 
AgrC1 and AgrC4. Circled amino acids are those that differ between AgrC group 1 and 4. * 
represents published PhoA fusions (Lina et al., 1998) and all collaborated the structure 
predicted by TMHMM 2.0 shown in the figure. 
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Figure 3-3: Predicted extracellular loops for S. aureus. A) AgrC1 from S. aureus Newman, 
COL and USA300 TCH1516 all have annotated genes coding for a 430 aa AgrC1. AgrC1 
from S. aureus 8325 and USA300 both have annotated genes coding for a 414 aa AgrC1. B) 
Extracellular loops 1 and 2 for AgrC2. Due to the shorter annotation of the agrC2 gene 
AgrC2 is only predicted to be 371 amino acids and contain four TMH insteas of six as 
predicted for AgrC1, AgrC3 and AgrC4. C) Predicted extracellular loops 1 to 3 for AgrC3. 
D) Predicted extracellular loops 1 to 3 for AgrC4. 
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Staphylococcus epidermidis AgrC 
The S. epidermidis AgrC (Accession no. ATCC12228: NP_765192 and RP62A: 
YP_189058) is 429 amino acid long and has only ~51-54% sequence homology 
with S. aureus AgrCs with most variation in the N-terminal sensor domain. It is 
predicted to have seven TMH with the N-terminus and three loops on the 
extracellular side and the C-terminal histidine kinase domain on the cytoplasmic 
side of the membrane (Figure 3-4 A).   
 
Staphylococcus haemolyticus and Staphylococcus saprophyticus AgrC 
Both S. haemolyticus and S. saprophyticuss AgrC (Accession no. YP_252909 and 
YP_300930) are 431 amino acids and share ~52% and 47% sequence homology 
with S. aureus AgrC respectively.  Both are predicted to have six TMH and three 
extracellular loops with both N-terminal and C-terminal ends on the cytoplasmic 
side of the membrane (Figure 3-4 B and C).  
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Figure 3-4: Predicted extracellular loops of A) S. epidermidis B) S. hemolyticus and C) S. 
saprohyticus. 
 
For all the predicted staphylococcal AgrC structures loop3 contains 14 amino 
acids residues and loop 2 is 9-14 amino acid residues, where as loop 1 varies a 
great deal more, from 3 to 19 residues.  
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3.2.2.1 Alternative open reading frames for AgrC1 confer 
identical transmembrane topology 
That there are two different genes coding for two different size AgrC1s both 
activated by the same AIP seems highly unlikely.  Sequence analysis of the 
available agrC1 genes from fully sequenced genomes revealed that there are 
alternative open reading frames for AgrC1 in both S. aureus 8325 and USA300, 
both having annotated AgrC1s of 414 amino acid residues giving 8325 and 
USA300 AgrC1s of 430 amino acid recidues, which is comparable with Newman, 
COL and USA300 TCH1516 and all AgrC3 and AgrC4s.  Besides that it seems 
unlikely that there are two AgrC1s, more importantly this new AgrC1 is 
predicted to posses the same transmembrane topology as the AgrC1 from 
Newman, COL, USA300 TCH1516, AgrC3 and AgrC4. 
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Figure 3-5: A) graphic representation of agrD, agrC and agrA from S. aureus 8325 and 
USA300 with the two different size open reading frames for AgrC1; agrC1 being the 
annotated ORF from NCBI (www.ncbi.nlm.nih.gov) and agrC1? being the larger ORF 
predicted using VectorNTI (Invitrogen, CA, USA) which has the same transmembrane 
topology as AgrC1 from strains Newman, COL and USA300 TCH1516 and AgrC3 and 
AgrC4. B) The general transmembrane topology of S. aureus AgrC1, AgrC3 and AgrC4. 
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3.2.3 Identification of amino acids residues involved in the 
group specific activation and inhibition of AgrC 
 
3.2.3.1 Construction of an AIP bioreporter 
 
To facilitate identification of the amino acid residues involved in the AgrC/AIP 
interactions, a reliable low background AIP-bioreporter was needed, into which 
plasmids expressing agrC variants could easily be introduced.  The initial strategy 
was to use suicide plasmids containing the gfp gene and the luxABCDE operon 
(pǻagr-dual, Figure 3-6) or just the luxABCDE operon (pǻagr-lux, Figure 3-6 and 
Figure 3-7) under the control of the P3agr promotor, tetM and the 1kb up- and 
down-stream regions of the agr locus to replace the entire agr locus. This was 
achieved by transforming the plasmids directly into S. aureus RN4220, resulting 
in single cross overs (SCO). The intention was to then transduce the engineered 
agr locus into S. aureus RN6390B using ĭ11 and to force a second recombination 
event resulting in the complete replacement of agr with the gfp-luxABCDE / 
luxABCDE reporter genes. 
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Figure 3-6: Plasmids used in the construction of the agr P3-luxABCDE reporter strain 
ROJ48. Plasmid pǻagr-dual was constructed by Klaus Winzer. Plasmid pǻagr-lux was made 
by excising the gfp gene using SmaI and PvuII. pǻagr-ermB is a derivative of pǻagr-tetM 
(constructed by Klaus Winzer, not shown) where the tetM gene has been excised using 
restriction enzymes XhoI and EcoRI and replaced by the ermB gene using the same 
restriction sites. The ermB gene was PCR amplified from pEC4 (Bruckner, 1997).  
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RN4220 transformants were screened by PCR for the presence of the tetM cassette 
on the chromosome.  Four of the transformants which contained the tetM cassette 
were used to make ĭ11 lysates. The lysates were used to transduce S. aureus 
RN6390B and the resulting transductants were screened by PCR for the tetM 
cassette.  However this strategy failed to produce the desired double cross overs 
(DCO), at least at a frequency that was suitable for our screening methods (data 
not shown). 
 
To make the screening process easier a ǻagr::ermB stain was made by 
transforming pǻagr-ermB (Figure 3-6 and Figure 3-7) into RN4220, and PCR 
screening colonies growing on LB containing 5µg/ml erythromycin for the 
presence of the ermB gene on the chromosome. ĭ11 lysates were prepared from 
four transformants positive for the ermB gene.  The lysates were used to transduce 
S. aureus RN6390B.  Transductants were screened by Southern blot for double 
cross over events, i.e., strains where the agr locus had been replaced by the ermB 
gene.  A Southern blot of 6 transductants and their RN4220 SCO donor strains 
showed two of the transductants were DCOs (Figure 3-8). 
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Figure 3-7: Diagram of the steps involved in the construction of the bio-reporter ROJ48. 
First a complete agr deletion was made in S. aureus RN4220 using plasmid pǻagr-ermB 
yielding the strain ROJ39. The plasmid pǻagr-tet-lux containing the luxABCDE operon 
under the control of the P3agr promoter was then introduced into ROJ39 yielding the final 
bio-reporter ROJ48. 
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Homologous recombination can occur when DNA duplexes align at regions of 
homologous sequence. It involves 5 steps 1) alignment of the homologous DNA 
duplex, 2) cleavage of a single strand from each duplex, 3) strand invasion, 4) 
sealing, resulting in a so called Holliday intermediate and 5) resolving of the 
Holliday structure. This can happen in two different ways one leading either to 
two molecules identical to the two starting molecules (e.g.,, a plasmid and a 
circular bacterial chromosome) or leading to the integration of the plasmid into the 
chromosome (Figure 3.7).  
For gene replacement using suicide plasmids two of these events are necessary. 
The first recombination event will integrate the whole plasmid into either of the 
homologous regions (in figure 3.7 either in fructokinase of the orfX). The 
second (between the two other homologous regions) will delete the gene / region 
flanked by the two regions (figure 3.7 top) (Stryer L, 1997). 
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Figure 3-8: Southern blot of PstI digested genomic S. aureus DNAs and plasmid controls. A) 
Probed with ~1kb DIG labelled DNA upstream of agrA probe B) Probed with ~1kb DIG 
labelled downstream of agr probe. Red arrows indicate lanes with single band indicating a 
double cross over. 
Lane 1: Marker (not DIG labelled). 2: RN6390B. 3: pǻagr-ErmB 4:RN4220 pǻagr-ErmB #1. 
5: RN6390B X ĭ11(RN4220 pǻagr-ErmB #1) #1. 6: RN6390B X ĭ11(RN4220 pǻagr-ErmB 
#1) #2. 7: RN4220 pǻagr-ErmB #2. 8: RN6390B X ĭ11(RN4220 pǻagr-ErmB #2) #1. 9: 
RN6390B X ĭ11(RN4220 pǻagr-ErmB #2) #1. 10: RN4220 pǻagr-ErmB #3. 11: RN6390B X 
ĭ11(RN4220 pǻagr-ErmB #3) #1. 12: RN6390B X ĭ11(RN4220 pǻagr-ErmB #3) #2. 13: 
RN4220 pǻagr-ErmB #4. 14: RN6390B X ĭ11(RN4220 pǻagr-ErmB #4) #1. 15: RN6390B X 
ĭ11(RN4220 pǻagr-ErmB #4) #2 
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This Southern blot shows two RN6390B transductants where only one of each 
flanking region is a different size to that of the parent RN6390B strain, indicating 
that they are DCOs.  It also shows that the RN4220 strains have two or three 
copies of each flanking region; indicating they are SCOs.  
 
Multiple copies of one of the flanking regions resulted from the suicide plasmid 
only inserting itself into one of the flanking regions, i.e., if a suicide plasmid 
inserts itself in the upstream region as a single event, the entire plasmid inserts 
itself on the chromosome (a single cross over, SCO).   Two copies of the 
downstream region will be present on the chromosome until a second homologous 
recombination event has taken place between the two downstream regions. This 
second recombination event leads to the excision of the gene (or genes) flanked by 
the two regions on the chromosome and insertion of the genes and flanked by the 
homologous regions on the suicide plasmid, see Figure 3-7. 
 
The agr flanking regions of the RN6390B ǻagr::ermB transformants were 
sequenced. This showed that both flanking regions were defined, i.e., they were 
neither absent nor were there any additional nucleotides in the flanking regions 
(see appendix C for sequence alignment.).  One strain, ROJ37, was selected for 
further studies. The ǻagr deletion from ROJ37 was introduced into RN4220 by 
ĭ11 transduction yielding the RN4220 ǻagr strain ROJ39 (Figure 3-7).  
 
108 
To assay for the deletion of the agr locus through loss of AIP production all ǻagr 
strain supernatants were tested for AIPs using an established ȕ-lactamase assay 
(Novick et al., 1995;McDowell et al., 2001) and were found negative for AIP 
production (supernatant tested by Siti Hanna Muharram, data not shown).  To 
introduce the reporter genes, plasmids p'agr-dual and p'agr-lux (Figure 3-6) were 
transformed into ROJ39 (RN4220 ǻagr::ermB) and plated on LB 10 µg/ml 
tetracycline.  This resulted in the ǻagr::ermB P3agr-luxABCDE (ROJ48) or 
ǻagr::ermB P3agr-gfp-luxABCDE (ROJ51) single cross over reporter strain.  ĭ11 
lysates were made from both and transduced into RN6390B yielding RN6390B 
ǻagr P3agr-luxABCDE (ROJ134) and RN6390B ǻagr P3agr-gfp-luxABCDE 
(ROJ137).  Each of these strains contains the entire AIP reporter plasmid which 
has been integrated on the chromosome via a single homologous recombination 
event.  Attempts to force a second recombination event were not successful 
consequently the single cross over strain was used for further studies. 
 
The two RN4220 derived reporter stains (ROJ48, lux only and ROJ51, gfp-lux) 
and one of the RN6390B derived strains (ROJ134, lux only) were tested for 
reporter activity by transforming plasmid pAgrC1agrA (Table 2-2) and running 
bioluminescence assays (section 2.16) with and with out the addition of 270 nM 
AIP-1.  From these tests the bio-reporter ROJ48 was chosen for the study as it had 
the highest signal to background ratio (See Figure 3-9). 
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Figure 3-9: Activation of the bioreporters A) ROJ48 (RN4220 ǻagr::ErmB P3agr-luxABCDE), 
B) ROJ51 (RN4220 ǻagr::ErmB P3agr-gfp-luxABCD and C) ROJ134 (RN6390B ǻagr::ErmB 
P3agr-luxABCD) by AIP-1. Light output and OD were recorded via a Lucy1 (an automated 
bioluminometerphotometer, Anthos, Salzburg, Austria) every 30 min. The ratio between the 
maximum light output of the reporter activated with AIP-1 and the non activated reporter is 
shown in D. 
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3.2.3.2 Validation of the AIP-bioreporter 
 
Before the newly constructed AIP bioreporter S. aureus ROJ48 could be used for 
the AgrC structure-activity studies, we needed to make sure that the data obtained 
from this reporter were comparable with that obtained using the established P3agr 
E-lactamase reporter (Novick et al., 1995;McDowell et al., 2001).  For this 
purpose two wild type agrC genes (agrC1, and agrC4) were introduced on low-
copy vectors together with agrA (pAgrC1agrA and pAgrC4agrA respectively, 
Table 2-2) into S. aureus ROJ48.  
 
The resulting strains were then tested for P3agr activation by a range of 
concentrations of both AIP-1 and AIP-4 and the antagonistic effect (ala
5
)AIP-1, 
figures 3-10 and 3-11 and Table 3-3. EC50 and IC50 obtained and compared with 
the values reported in the literature.  
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Figure 3-10: AIP dependent activation of ROJ48 containing A) pAgrC1agrA activated by 
AIP-1 curve B) pAgrC4agrA activated by AIP-4 C) pAgrC1agrA activated by AIP-4 and D) 
pAgrC4agrA activated by AIP-1. Top part is activation plotted over time in the presence or 
absence (ala
5
)AIP-1 from 0nM to 10µM underneath is the corresponding does response 
curves . 
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Figure 3-11: AIP dependent competitive inhibition of ROJ48 containing either A) 
pAgrC1agrA or B) pAgrC4agrA. Top part is activation plotted over time in the presence or 
absence (ala
5
)AIP-1 from 0nM to 100nM underneath is the corresponding does response 
curves. The reporter was activated with ten times EC50 of either AIP-1 or AIP-4, 60 nM and 
90 nM respectively. 
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For a comparison of previously published EC50 and IC50s with the data obtained 
from ROJ48 see Table 3-3. 
 
 
Table 3-3: Summary of EC50 and IC50 values for AIP-1 and AIP-4 used as an agonist for 
either AgrC1 or AgrC4 respectively in activation assays and (ala
5
)AIP-1 an antagonist in 
competitive inhibition assays.  
 
 Published agrP3::luxABCDE 
 EC50 IC50 EC50 IC50 
 AIP-1 AIP-4 (ala
5
)AIP-1 AIP-1 AIP-4 (ala
5
)AIP-1 
AgrC1 
10.2 ± nM3) 
19 ± nM
2) 
28 ± nM1) 
62 ± nM
1) 
5n ± 2 nM
1) 
33 nM
2) 
6 ± nM 107 ± nM 7 ±1 nM 
AgrC4 26 ± µM1) 13 ± nM1) 3 ± 2 nM1) 3.5 ± µM 9 ± nM 11 ± 2 nM 
1) Lyon et al (2002), 2)McDowell et al. (2001), 3) Mayville et al., (1999) 
 
The data in Table 3-3 show that AIPs activated their native AgrCs in the low 
nanomolar range and that (ala
5
)AIP-1 inhibits both AgrC1 and AgrC4.  This 
shows that ROJ48 AIP-bioreporter has a high degree of selectivity and sencitivity 
and is activated and inhibited at similar AIP concentrations to those obtained using 
a ȕ-lactamase reporter. 
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However, the advantage of using ROJ48 is that there is no background agr activity 
and no additional reagents are required 
 
 
 
3.2.4 Role of the predicted extra-cellular loops in group specific 
activation and inhibition of AgrC 
3.2.4.1 Introduction 
To identify the amino acids important for group specific activation and inhibition 
of AgrC, it was decided to base the analysis on a comparison of AgrC1 and AgrC4 
as they are the most closely related AgrC receptors and their AIPs differ with only 
one amino acid. Figure 3-2, show that there are six amino acids that differ in the 
first extra-cellular loop, three in the second and the third extra-cellular loop is 
identical in AgrC1 and AgrC4.  Since the second loop has the least variable it was 
decided to use this as the starting point for the investigation.  
 
Plasmid constructs carrying agrC and agrA similar to the those used for the 
validation of ROJ48 (see section 3.2.3.2) were used.  A total of 14 constructs were 
made using AgrC1 and AgrC4 as backbones and changing one, two or all three 
amino acids that differ between the two groups using site-directed mutagenesis 
(primers listed in Table 2-3).  These modified AgrC AgrA constructs under the 
control of the P2agr promoter were introduced into ROJ48 as described in section 
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2.8.4 and 2.16.  EC50s and IC50s for these constructs were determined for AIP-1, 
AIP-4 and (ala
5
)AIP-1.  
 
3.2.4.2 Contribution of the second extra-cellular loop of AgrC4 to 
AIP-dependent activation 
Using AgrC4 as the AgrC backbone the three different amino acids in the second 
extra-cellular loop were changed to those  of group 1; 
101
T to 
101
A, 
104
T to 
104
V and 
107
S to 
107
V. 
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Figure 3-12: Amino acids changed in the second extracellular loop of AgrC4. 
 
Subsequently single and double mutations were made and assayed to determine 
the contribution of each amino acid to AgrC activation. The results are shown 
below in Figure 3-13 to Figure 3-15 and summarised in Table 3-4. 
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Figure 3-13: Dose response curves for activation of ROJ48 bio-reporter via AgrC4 loop2 gr1 
(AgrC4T101AT104VS107V) by A) AIP-1 or B) AIP-4. AIP concentrations ranged from 0nM 
to 10µM. Error bars represent standard deviations where n=3. 
 
From the data used to plot Figure 3-13, EC50s were calculated for AIP-1 and AIP-
4 acting on AgrC4loop2gr1 (Table 3-4) using Prism2 (GraphPad, San Diego, 
USA).  The EC50 for AIP-1 was calculated to be 33 nM and the EC50 for AIP-4 
was calculated to be 170 nM. This shows a clear shift towards group 1 behaviour 
with a 107-fold increase in EC50 for AIP-1 and a 19 fold decrease for AIP-4.  This 
shows that the second extra-cellular loop of AgrC is important for group specific 
activation.  
 
To further investigate the respective roles of the three amino acids that differ 
between AgrC1 and AgrC4 in loop2, a series of single and double mutations were 
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made in AgrC4. The effect of AIP-1 and AIP-4 on the activation of these mutated 
AgrC4s was tested using the bioreporter ROJ48 (Figure 3-14 and Figure 3-15). 
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Table 3-4 Activation of native and mutated AgrC group 1 and 4 by AIP-1 and AIP-4 
respectively (EC50 nM; n=3), and the fold increase or decrease observed for the activation of 
mutated AgrC. Ĺ indicates an increased activation of the mutated AgrC (decrease in 
the EC50). Ļ indicates a decreased ability to activate the mutated AgrC (increase in 
the EC50). ĺ indicates no difference in the ability to activate the mutated AgrC. 
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Native and mutated AgrC4 EC50 (nM) Fold increase / 
decrease in 
activity 
 AIP-1 AIP-4 AIP-1 AIP-4 
AgrC4 (wild type) 3542 ± 997 9 ± 1 - -
T101A V104T V107S (loop2 gr1) 33 ± 2 170 ± 12 107 Ĺ 19 Ļ
T101A 754 ± 47 29 ± 1 4.7 Ĺ 3.2 Ļ
V104T 6357 ± 349 512 ± 57 1.8 Ļ 59 Ļ
V107S 451 ± 30 9 ± 3 7.8 Ĺ ĺ
T101A V104T 12064 ± 1654 587 ± 10 3.4 Ļ 62 Ļ
T101A V107S 407 ± 45 22 ± 3 8.7 Ĺ 2.4 Ļ
V104T V107S 4335 ± 457 551 ± 48 1.2 Ļ 61 Ļ
Native and mutated AgrC1     
AgrC1 (wild type) 6 ± 1 107 ± 20 - -
A101T T104V S107V (loop2 gr4) 110 ± 7 94 ± 7 18 Ļ 1.1 Ĺ
A101T 30 ± 2 22 ± 5 5 Ļ 4.8 Ĺ
T104V 235 ± 38 269 ± 49 39 Ļ 2.5 Ļ
S107V 150 ± 15 408 ± 4 25 Ļ 3.8 Ļ
A101T T104V 47 ± 2 15 ± 2 7.8 Ļ 7 Ĺ
A101T S107V 99 ± 10 19 ± 3 16.5 Ļ 5.6 Ĺ
T104V S107V 120 ± 16 466 ± 9 20 Ļ 4.3 Ļ
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Figure 3-14: Dose response curves for activation of ROJ48 via AgrC4 carrying single amino 
acid mutations in loop2. A) AgrC4T101A activated by AIP-1 B) AgrC4T101A activated by 
AIP-4 C) AgrCV104T activated by AIP-1 D) AgrC4V104T activated by AIP-4 E) 
AgrC4V107S activated by AIP-1 F) AgrC4V107S activated by AIP-4. Added AIP 
concentration ranged from 0nM to 10µM in a total. Error bars represent standard deviations 
where n=3. 
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Figure 3-15: Dose response curves for activation of the ROJ48 via AgrC4 carrying double 
amino acid mutations in loop2. A) AgrC4T101AV104T activated by AIP-1 B) 
AgrC4T101AV104T activated by AIP-4 C) AgrCT101AV107S activated by AIP-1 D) 
AgrC4T101AV107S activated by AIP-4 E) AgrC4V104TV107S activated by AIP-1 F) 
AgrC4V107SV104T activated by AIP-4. Added AIP concentration ranged from 0nM to 
10µM. Error bars represent standard deviation where n=3. 
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From the data used to plot Figure 3-14 and Figure 3-15, EC50s were calculated for 
AIP-1 and AIP-4 acting on AgrC4 with single or double mutations in the second 
extra-cellular loop (Table 3-4).  From the EC50s it can be seen that changing the 
valine at position 104 to a threonine (V104T) resulted in a 1.8 fold decrease in 
EC50 when using AIP-1 to activate AgrC and a 57 fold decrease for AIP-4.  
 
A similar result was obtained if the valines at positions 104 and at position 107 
were changed to threonine and serine, respectively. The EC50 for AIP-1 decreased 
1.2 fold from 3542 nM to 4335 nM and for AIP-4 decreased by 61 fold from 9 nM 
to 551 nM (Table 3-4).  If the valine for threonine substitution at position 104 was 
combined with changing the threonine at position 101 to an alanine, the decrease 
in EC50 was even more pronounced, resulting in a 3.4 fold decrease in EC50 for 
AIP-1 from 3342 nM to 12064 nM and a 62 fold decrease for AIP-4 from 9 nM to 
587 nM.  In contrast, when the threonine at position 101 was substituted with an 
alanine (T101A) or the valine at position 107 was substituted with a serine 
(V107S), a 4.7 fold increase in the EC50 were obtained (3542 nM to 754 nM) and 
7.8 fold (3542 nM to 451 nM) respectively.  This increase in EC50 for AIP-1 was 
accompanied by a relatively small reduction in the EC50 for the T101A 
substitution and no change for V107S substitution when AIP-4 was the agonist.  
 
These observations suggest that for AgrC4 
104
V plays an important role in 
activation where as it is 
101
T and 
107
V that are key to the group specificity. 
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3.2.4.3 Contribution of the second extra-cellular loop of AgrC1 to 
AIP-dependent activation 
To complete the analysis of the second extracellular loop, a set of mutants using 
AgrC1 as the AgrC backbone were made, complementary to those previously 
described for AgrC4. AIP-1 and AIP-4 dependent activation of these construct 
was tested using ROJ48. The results of these experiments are shown in Figure 
3-16 to Figure 3-18 and data summarised in Table 3-4. 
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Figure 3-16: Dose response curves for activation of the ROJ48 via AgrC1 loop2 gr4 
(AgrC1A101TV104TV107S) by A) AIP-1 or B) AIP-4. Exogenous AIP concentrations ranged 
from 0nM to 10µM. Error bars represent standard deviation where n=3. 
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Figure 3-17: Dose response curves for activation of ROJ48 via AgrC1 carrying a single 
amino acid substitution in loop2 A) AgrC1 A101T activated by AIP-1 B) AgrC1 A101T 
activated by AIP-4 C) AgrC1 T104V activated by AIP-1 D) AgrC1 T104V activated by AIP-4 
E) AgrC1 S107V activated by AIP-1 F) AgrC1 S107V activated by AIP-4. Added AIP 
concentration ranged from 0nM to 10µM. Error bars represent standard deviation where 
n=3. 
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Figure 3-18: Dose response curves for activation of ROJ48 via AgrC1 carrying two amino 
acid substitutions in loop2 A) AgrC1 A101TT104V activated by AIP-1 B) AgrC1 
A101TT104V activated by AIP-4 C) AgrC1 A101TS107V activated by AIP-1 D) AgrC1 
A101TS107V activated by AIP-4 E) AgrC1 T104VS107V activated by AIP-1 F) AgrC1 
T104VS107V activated by AIP-4. Added AIP concentration ranged from 0nM to 10µM. 
Error bars represent standard deviation where n=3 
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The data shown in Figure 3-16 to Figure 3-18 were used to calculate EC50s for the 
different AgrC1 mutations and these are summarised in Table 3-4. 
 
These data shows that changing the second extra-cellular loop of AgrC1 to that of 
AgrC4 does not result in the same significant shift in group specific activity 
observed with AgrC4.  Here we observed little difference in EC50 for AIP-4 acting 
on the hybrid receptor (from EC50 107 nM to 94 nM).  However, as for AgrC1 
there was an 18 fold decrease in the activity of the native AIP (AIP-1) (from EC50 
6 nM to 110 nM). 
 
If the alanine at position 101 is changed to a threonine (A101T) a 5 fold decrease 
in the EC50 from 6 nM to 30 nM for AIP-1, and a 4.8 fold increase for AIP-4 from 
107 to 22 nM for AIP-4 was noted.  This was the only increase in EC50 for AIP-4 
noted for any of the single amino acid substitutions.  A 2.5 fold decrease in EC50 
was observed if the threonine at position 104 was changed to a valine (T104V; 
EC50 107 nM to 269 nM) and a 3.8 fold decrease from 107 nM to 408 nM if the 
serine at position 107 was changed to a valine (S107V).  A similar but much more 
pronounced effect was noted for AIP-1 as an agonist with a 39 fold decrease in 
EC50 from 6 nM to 235 nM for T104Vand  a 25 fold decrease in EC50 from 6 nM 
to 150 nM for S107V.  
 
For double mutations a similar picture was observed where the EC50 for the native 
agonist (AIP-1) was reduced for all constructs: 7.8 fold increase for A101TT104V 
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(EC50 of 6 nM to 47 nM), 16.5 fold for A101T S107V (EC50 of 6 nM to 99 nM), 
and 20 fold for T104V S107V (EC50 of 6 nM to 120 nM). For AIP-4 a 7 fold 
increase in EC50 from 107 nM to 15 nM if both the alanine at position 101 were 
changed to a threonine and the threonine at position 104 was changed to a valine. 
A 5.6 fold increase in EC50 from 107 nM to 19 nM was observed if the alanine at 
position 101 was exchanged for threonine and the serine at position 107 to valine.  
 
This suggests that for AgrC1 
104
T and 
107
S and for AgrC4 
104
V play an important 
role in the activation and that for AgrC1 
101
A and for AgrC4 
101
V and 
107
V is 
important for group specificity. 
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3.2.4.4 Contribution of the predicted first extra-cellular loop 
Since exchanging the second extra-cellular loop did not result in complete change 
of group specificity, an AgrC4 loop1 group1 receptor was constructed to 
investigate the role of the first extra-cellular loop in the group specific agr 
response.  Figure 3-19 shows the dose response curve for activation of AgrC4 and 
AgrC4 loop1 group 1 with AIP-4.  
.  
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Figure 3-19: Dose response curve for the activation of ROJ48 via AgrC4 or AgrC4 loop1 gr1 
activated with AIP-4 at various concentrations ranging from 0 nM to 10 µM. Error bars 
represent standard deviation where n=3 
 
This clearly shows a reduction in EC50 from 9 nM for AgrC4 to 1011 nM for 
AgrC4 loop1 gr4 indicating that the first extra-cellular loop also plays an 
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important role in activation of AgrC by its native ligand.  The AgrC4 loop1 gr1 
construct was also tested with AIP-1 as an activator but showed no activation at a 
concentration of 10 µM (data not shown), unlike wild type AgrC4 for which AIP-
1 is a weak agonist with an EC50 of 3.5µM. This indicates that the first extra-
cellular loop is required for activation of AgrC. 
 
The cross group inhibitor (ala
5
)AIP-1, was used to investigate whether changes in 
the first extra-cellular loop only effected the activation of the receptor or, as with 
changes in the second extra-cellular loop the changes also had impacted on 
inhibition.  For this, a competitive inhibition assay (described in section 3.2.3.2) 
where the AgrC4 loop1 gr1 was activated with ten fold EC50 of AIP-4 and 
(ala
5
)AIP-1 was added in concentrations ranging form 0nM to 10 µM. Results are 
shown in Figure 3-20.  
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Figure 3-20: Dose response curve for the inhibition of ROJ48 via AgrC4 or AgrC4 loop1 
group1 activated with fold EC50 AIP-4. Exogenous concentration of (ala5)AIP-1  ranged from 
0 nM to 10 µM. Error bars represent standard deviation where n=3. 
 
Figure 3-20 shows that the loop change does alter the ability of (ala
5
)AIP-1 to 
inhibit activation, but is still a very potent antagonist indicating that the first extra-
cellular loop is not important for the inhibition of AgrC receptor activation. 
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3.2.5 Forced evolution of new agr group 
To investigate further the effect of the changes made in AgrC1 and AgrC4, 
receptor inhibition assays using the cross group agr inhibitor (ala
5
)AIP-1 were 
carried out. The (ala
5
)AIP-1 compound is a potent inhibitor of all four agr groups 
(McDowell et al., 2001;Lyon et al., 2002). Firstly, a complete loop swap of the 
second AgrC extra-cellular loop was tested (see Figure 3-21).  
 
This showed that (ala
5
)AIP-1 had no antagonistic effect on either AgrC4loop2gr1 
or AgrC1loop2gr4.  When tested as an agonist with these constructs (ala
5
)AIP-1 
was now found to be a potent agonist instead of a potent antagonist with an EC50 
of 389 nM for AgrC4loop2gr1 and an EC50 of 46 nM for AgrC1loop2gr4 (Figure 
3-21). 
 
To try to pinpoint which amino acids were responsible for this reversal of activity, 
assays with (ala
5
)AIP-1 used both as an agonist and an antagonist was carried out 
for all available AgrC mutants (Figure 3-21 to Figure 3-23). 
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Table 3-5: Summary of EC50 and IC50 (nM) for the activation / inhibition of the AgrC4 and 
AgrC1 wild type and mutated receptors. 
 
Native and mutant AgrC4 and AgrC1 
proteins 
Activity in nM 
Activation 
EC50 
Inhibition 
IC50 
AgrC4 (wild type)  11 ± 2 
T101A V104T V107S (loop2 gr1) 389 ± 12  
T101A  73 ± 13 
V104T  16 ± 2 
V107S  4718 ± 318 
T101A V104T  28 ± 5 
T101A V107S  255 ± 15 
V104T V107S  10 ± 3 
AgrC1 (wild type)  7 ± 1 
A101T T104V S107V (loop2 gr4) 46 ± 4  
A101T 120 ± 24  
T104V 556 ± 38  
S107V 4054 ± 785  
A101T T104V 26 ± 1  
A101T S107V 16 ± 1  
T104V S107V 1235 ± 303  
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Figure 3-21: Dose response curves for the inhibition of ROJ48 via A) AgrC1 activated with 
60 nM AIP-1 B) AgrC4 activated with 90 nM AIP-4. (ala
5
)AIP-1 was added at concentrations 
ranging from 0 nM to 10 µM. C) and D) show the dose response curves for activation of 
ROJ48 via AgrC1loop2gr4 (C) and AgrC4loop2gr1 (D) using (ala
5
)AIP-1 as an agonist. 
(ala
5
)AIP-1 was added at concentrations ranging from 0 nM to 10 µM. Error bars represent 
standard deviation where n=3 
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Figure 3-22: Dose response curves of the inhibition of ROJ48 via AgrC4 carrying single or 
double amino acid substitutions in the second extra-cellular loop using (ala
5
)AIP-1 as the 
antagonist. A) AgrC4 T101A, B) AgrC4 V104T, C) AgrC4 V107S D) AgrC4 T101A V104T E) 
AgrC4 T101A V107S F) AgrC4 V104T V107S. All AgrC4 constructs were activated by ten 
10X EC50. Concentration of added (ala5)AIP-1  ranged from 0 nM to 10 µM. Error bars 
represent standard deviation where n=3 
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Figure 3-23: Dose response curves of the activation of ROJ48 via AgrC1 carrying single or 
double amino acid substitutions in the second extra-cellular loop using (ala
5
)AIP-1 and an 
agonist. A) AgrC1 A101T, C) AgrC1 T104V, E) AgrC1 S107V B) AgrC1 A101T D) AgrC1 
T104V F) AgrC1 S107V. Concentration of added (ala
5
)AIP-1  is ranged from 0 nM to 10 µM. 
Error bars represent standard deviation where n=3 
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From these data it is clear that for AgrC1 it is only necessary to change one single 
amino acid to make a receptor that responds to (ala
5
)AIP-1  as an agonist, whereas 
for AgrC4 a change of three amino acids is required.  
 
Altering the serine in position 107 to a valine on its own, or with the threonine at 
position 104 to a valine for AgrC1, makes (ala
5
)AIP-1  a very weak AgrC1 agonist 
with EC50s of 4 µM and 1.2 µM respectively.  Whereas changing either the alanine 
at position 101 to a threonine or the threonine at position 104 to a valine, makes a 
receptor where (ala
5
)AIP-1  is a moderate agonist with an EC50 of 120 nM or 556 
nM respectively.  The most potent agonistic activity of (ala
5
)AIP-1  was seen 
when alanine at position 101 was changed to a threonine together with the serine 
at position 107 to a valine, this makes a receptor where (ala
5
)AIP-1  is a potent 
agonist with an EC50 of 16 nM.  Changing both the alanine at position 101 to a 
threonine and the threonine at position 104 to a valine or all three amino acids 
(A101T T104V S107V) (Figure 3-21 and Figure 3-23) also gives a receptor where 
(ala
5
)AIP-1  is a potent agonist with an EC50 of 26 nM or 46 nM respectively. 
 
For AgrC4 only the full loop change provides a receptor where (ala
5
)AIP-1  
functions as an agonist. Changing the valine at position 104 to a threonine on its 
own and in conjunction with changing the serine at position 107 to a valine, gave 
little or no change in potency of antagonistic activity (ala
5
)AIP-1 with IC50s of 16 
nM and 10 nM respectively using 90 nM AIP-4 to activate the receptor and only a 
slight difference in IC50, from 11 nM to 28 nM, is obtained if both the threonine at 
144 
position 101 was changed to an alanine and the valine at position 104 to a 
threonine.  If the threonine at position 101 was changed to an alanine a larger 
change was noted with an IC50 of 73 nM compared to 11 nM for AgrC4.  However 
changing the valine at position 107 to a serine yielded a receptor where (ala
5
)AIP-
1  was a very weak antagonist with an IC50 of 4.7 µM, whereas changing both the 
threonine at position 101 to an alanine and the valine at position 107 to a serine 
gives a receptor where (ala
5
)AIP-1  is an intermediate antagonist with an IC50 of 
255 nM. 
 
These results show that a single point mutation can make an AgrC receptor 
recognise a potent antagonist as an agonist, essentially creating a fifth agr group. 
For AgrC1 the changing of the alanine at position 101 to a threonine is the key to 
this switch in recognition of agonist. This effect is boosted by changing either the 
threonine at position 104 or the serine at position 107 to valine at the same time.  
For AgrC4 it is the valine at position 107 which is important for the antagonistic 
effect of (ala
5
)AIP-1 and a change of three amino acids is required to make it 
recognise (ala
5
)AIP-1 as an agonist. 
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3.3 Discussion 
 
AgrC belongs to a family of QS peptide histidine protein kinases (HPK).  The 3D 
structure of AgrC has not yet been solved but using different prediction methods 
several different topology models have been proposed where AgrC has either five 
(Lina et al., 1998) or six TMH (Geisinger et al., 2008).   
 
Here eight different software tools have been used to predict the transmembrane 
topology of AgrC and each six transmembrane helices (24 to 18 amino acid 
sequence domains), three extracellular loops and a cytoplasmic histidine-kinase 
domain. The general consensus of these models, and the predictions and large 
scale comparison of different predictions reported by Möller et al (2008), indicates 
that the TMHMM 2.0 program is the most accurate prediction tool available at 
present. The five TMH model proposed by Lina et al (1998) is most likely to be 
incorrect as it is only based on a Kyte-Doolittle hydropathy map and incorporates 
a 12 amino acid residue helix (helix II) which is incapable of spanning the 
membrane.  However, each prediction program predicts six TMH and three 
extracellular loops, the size of the loops differs in number of predicted amino acid 
residues present within each loop.  Loop1 is predicted to contain from 5 to 25 
amino acid residues, loop2 from 2 to 15 amino acid residues and loop3 from 9 to 
20 amino acid residues.   
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PhoA fusion data of AgrC expressed in E. coli have indicated that amino acid 
residues 33, 105 and 176 are located externally and residue 142 is located on the 
cytoplasmic side of the membrane, a finding that is in agreement with the models 
predicted in section 3.2.2 and the HMMTOP 2.0 model proposed by Geisinger et 
al (2008).  Since AIPs interact with AgrC at the cell surface and do not enter the 
cell, and AIP-1 and AIP-4 differ by only one amino acid, it is likely that 
differences in the AgrC1 and AgrC4 sequences will play an important role in the 
group specific AIP recognition.  Using both the TMHMM 2.0 (used here) and the 
Geisinger et al (2008) prediction models for AgrC, the major changes are located 
in the predicted extracellular loops 1 and 2 and whereas extracellular loop3 is 
identical; these differences are likely to account for AIP recognition.   
 
In the prediction by TMHMM 2.0, loop1 consists of 19 amino acid residues for 
both AgrC1 and AgrC4 but differs in 7 amino acids where 3 are conservative 
changes (
38
F ĺ 38L, 42V ĺ 42G and 44S ĺ 44T) and 3 results in the exchange of 
hydrophobic for polar amino acids (
35
L ĺ 35S, 39F ĺ 39Y and 41I ĺ 41T) and 1 
results in the exchange of a polar for a hydrophobic amino acid (
45
T ĺ 45A).  
Alternatively Geisinger proposes a 10 amino acid loop1 (from 
29
G to 
38
F) with 
only two amino acid differences (
35
L ĺ 35S and 38F ĺ 38L).  For extracellular 
loop2 TMHMM 2.0 predicts 9 amino acid residues on the out side (
101
A to 
109
S) 
with 3 amino acids differing between AgrC1 and AgrC4 (
101
A ĺ101T, 104T ĺ 104V 
and 
107
S ĺ 107V), whereas Geisinger predicts 10 amino acid residues on the 
outside (
101
A to 
110
I) with the same amino acids differing.  One of these changes 
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results in the exchange of a polar amino acid to a hydrophobic amino acid (
101
A 
ĺ101T) and the other two results in the exchange of hydrophobic amino acids to 
polar amino acids (
104
T ĺ 104V and 107S ĺ 107V).  This observation is likely to be 
significant as the Asp5 (polar) in AIP-1 is exchanged with a Tyr (hydrophobic) in 
AIP-4.  These differences in the AgrC receptor are likely to play a pivotal role in 
the group specific AIP recognition of AIP-1 and AIP-4. There is, however, a 
discrepancy between the topology model proposed in Geisinger et al (2008) and 
the topology model from the HMMTOP 2.0 program cited to have been used for 
the modelling (Tusnady and Simon, 2001).  The HMMTOP 2.0 predicts the N- 
and C-terminals to be extracellular, where as most other prediction programs 
predict them to be cytoplasmic.  If the model is inverted such that N- and C-
terminal ends are on the cytoplasmic side of the membrane the models still 
correlate, Geisinger et als (2008) model presents loop1 as residues 29-38, loop 2 
as residues 101-110 and loop 3 as residues 169-181, whereas the HMMTOP 2.0 
predict loop1 to be residue 30-39, loop2 to be residue 103-110 and loop3 to be 
residue 169-182. Figure 3-24 show a comparison of the discussed models. 
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Figure 3-24: Comparison of the predicted extracellular loops. A) Prediction using TMHMM 
2.0 used by Jensen et al 2008. B) Geisinger et als (2008) prediction using TMMTOP 2.0. C) 
Prediction obtained in this study using TMMTOP 2.0. 
 
Using the TMHMM 2.0 prediction server the transmembrane topology of AgrC2 
and AgrC3 from S. aureus, AgrC from S. epidermidis, AgrC from S. heamolyticus 
and the AgrC from S. saprophyticus were predicted to have six transmembrane 
helices and three extracellular loops, with the exception of S. aureus AgrC2 and S. 
epidermidis AgrC which were predictied to have four TMH and two extracellular 
loops and seven TMH and three extracellular loops with a N-terminal extracellular 
tail respectively. This difference in AgrC topology could explain why the S. 
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aureus AgrC inhibitor (ala
5
)AIP-1 does not have any antagonistic effect on S. 
epidermidis AgrC activation.  All structures of staphylococcal AgrCs conforms to 
the HPK10 group and are all very similar in predicted topology. This is hinting at 
some common way for AIP to bind to the AgrC for all staphylococci and as the 
macrocyclic ring structure is a common feature, it would make sense if loops 2 
and 3 make up the binding pocket and loop 1 interacts with the tail. 
 
To elucidate the contribution of the extracellular loops 1 and 2 to the group 
specific recognition of AIPs by AgrC, a new AIP-bioreporter wherein AgrC could 
readily be mutated was required.  To achieve this, the agr locus was first deleted 
from S. aureus strain RN4220.  The luxABCDE operon was placed on the 
chromosome under the control of the P3agr promoter. agrC and agrA genes were 
introduced on a plasmid under the control of the P2agr promoter, and the reporter 
activated by the addition of an exogenous AIP.  Figure 3-10 and Figure 3-11 show 
the response of the reporter as a function of exogenous AIP concentration.  Using 
AIP-1 to activate the reporter via AgrC1 and AgrC4 EC50s of 6 ± 1 nM and 3542 ± 
997 nM were obtained, respectively.  Similar data were obtained using AIP-4 to 
activate the reporter via AgrC1 and AgrC4 giving EC50s of 107 ± 10 nM and 9 ± 1 
nM respectively (Table 3-3).  In the presence of the potent cross group inhibitor 
(ala
5
)AIP-1, the respective reporter fusions were strongly inhibited (Figure 3-11) 
with IC50 values of 7 ± 1nM and 11 ± 2 nM respectively (Table 3-3).  These data 
are consistent with that previously published using the alternative P3agr blaZ 
reporter gene fusion (Mayville et al., 1999;McDowell et al., 2001). 
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Figure 3-25: Mutations and combination of mutations made in the extracellular loop 2 of 
AgrC4 and AgrC1 and the resulting receptors EC50 and IC50 values for activation / 
inhibition with AIP-1 AIP-4 and (ala
5
)AIP-1. All values are in nM and taken from Table 3-4 
and 3-5. 
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EC50 = 6
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EC50 = 1235
nM
nM
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To elucidate the contribution of the AgrC extracellular loop2 to group specific 
AIP recognition of AIP-1 and AIP-4, first the three differing amino acid residues 
in AgrC4 loop2 were exchanged to those of AgrC1 loop2 (i.e., at position 101, 
104 and 107) and introduced into the S. aureus bioreporter ROJ48.  This resulted 
in a 107 fold increase in EC50 for AIP-1 and a ~19 fold decrease for AIP-4, see 
Table 3-4 A similar but less pronounced change in EC50s was seen if the three 
differing amino acid residues inAgrC1 loop2 were changed to those of AgrC4 
loop2 with a 1.1 fold increase in EC50 for AIP-4 and an 18 fold decrease in EC50 
for AIP-1, see Table 3-4.  These results indicate that the differential recognition of 
AIP-1 and AIP-4 by their cognate receptors, depends to a large extent on 
extracellular loop2.   
 
To explore the relative importance of the individual amino acid residues at 
position 101, 104 and 107, a series of single and double mutants in both AgrC1 
and AgrC4 were made. Table 3-4 shows that changing the threonine in position 
101 to an alanine, the valine in position 107 to a threonine, or both of them 
together accounts for the increase in EC50 for AIP-1 where as changing the valine 
in position 104 to a threonine results in a decrease in EC50 for both AIP-1 and 
AIP-4, Table 3-4.  Similar changes in the EC50s are observed when changing 
either one or two of the differing amino acids at a time in AgrC1 to those of 
AgrC4. Where changing the alanine in position 101 to a threonine gives an 
increase in the EC50 for AIP-4 but a decrease for AIP-1 both on its own and in 
combination with changing the threonine in position 104 to a valine or the serine 
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in position 107 to a valine.  A decrease in EC50 is also seen for both AIP-1 and 
AIP-4 if the threonine in position 104 is changed to a valine.  
 
The difference from using AgrC4 as a backbone is that when the serine at position 
107 is changed to a valine an increase in EC50 for AIP-4 would be expected since 
the reverse change for AgrC4 gave an increase in EC50 for AIP-1, however here a 
decrease in the EC50 for both AIP-1 and AIP-4 is observed (Table 3-4).  These 
observations suggest that the amino acid residue at position 101 is key to the 
differential recognition of AIP for both AgrC1 and AgrC4 and that the amino acid 
residue at 107 also is key for the differential recognition for AgrC4 whereas 
position 104 is essential for the efficient activation of both AgrCs by both AIP.  
 
These data are consistent with the results obtained for chimeric AgrC1-4 and 
AgrC4-1 proteins by Wright et al (Wright, III et al., 2004).  Here the authors fused 
N-terminal and C-terminal domains from AgrC1 and AgrC4 at position 86-93, 
which are identical in AgrC1 and AgrC4, so that the AgrC4-1 chimera 
incorporates the extracellular loop2 from AgrC1 and AgrC1-4 incorporates the 
extracellular loop2 from AgrC4.  Wright et al (2004) found that AgrC4-1 exhibits 
an EC50 of 26 nM for AIP-1 and EC50 of 120 nM for AIP-4 which is in good 
agreement with the EC50s of 33 nM and 170 nM, respectively, for the AgrC4 
mutant protein in which all three amino acids were changed to those of AgrC1.  
However, the EC50s for the AgrC1-4 reported by Wright et al (2004) does not 
correlate with the EC50s presented here for the mutated AgrC1 protein where all 
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three differing amino acid residues were changed to those of AgrC4, Wright et al 
(2004) reported an EC50 of 1220 nM for AIP-1 acting on the AgrC1-4 and an EC50 
of 6 nM for AIP-4, here the comparative EC50s are 110 nM for AIP-1 and 94 for 
AIP-4.  
 
Geisinger et al (2008) have recently published a detailed study of AgrC1 and 
AgrC4 group specific recognition of AIP-1 and AIP-4.  Some of their data 
corroborates the date presented here in, that the second extracellular loop of AgrC 
plays an important role in the group specific recognition of AIPs and, apart from 
residue 101, 104 and 107, they also identified residue 116 as contributing to the 
differential AIP recognition.  However, the data differ with respect to the impact 
of V107S and V104T V107S single and double mutations on the activation of 
AgrC4 by AIP-1.  There are no obvious explanations for these differences. 
 
The contribution of the extracellular loop1 predicted by TMHMM 2.0 was 
investigated by exchanging the seven differing amino acid residues (position 35, 
38, 39, 41, 42, 44 and 45) in AgrC4 to those of AgrC1 and introducing the 
mutated AgrC4 into the bioreporter ROJ48.  Figure 3-19 shows that the EC50 for 
AIP-4 is reduced >100 fold, where as AIP-1 does not activate the AgrC4 loop1 
mutant.  This is probably due to the absence of the molecular features of the 
AgrC1 loop2.  In contrast the change in IC50 for the (ala
5
)AIP-1 when AgrC4 
loop1 is exchanged for the AgrC1 loop1 is very small (AgrC4 IC50 11 nM 
mutated AgrC4 IC50 30 nM, Figure 3-20).  These data indicate that the putative 
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extracellular loop1 plays a critical role in AgrC activation. Although the tripeptide 
exocyclic tail (the message region of the AIP) of AIP-1 and AIP-4 are identical 
in their orientation with respect to the macrocyclic part of the AIP is likely to be 
different, and loop1 may very well be involved in the recognition of this address 
region (Chan et al., 2004).   
 
Alternatively, the change of amino acid residues in the extracellular loop1 may 
result in structural differences leading to the loss of activity, or the changes could 
have led to conformational or topology changes in loop1 which could influence 
the molecular composition of the flanking transmembrane domains.  The data for 
the changes in the extracellular loop1 together with that from the changes in the 
extracelluar loop2 suggest that it is the interaction between the AgrC loop2 and the 
cognate AIP thiolactone domain that may be the rate-limiting step. 
 
 It has been shown that replacement of  aspartic acid in the fifth position of AIP-1 
with alanine creates an inhibitor of all four S. aureus agr groups (McDowell et al., 
2001;Scott et al., 2003;Wright, III et al., 2004). In addition Wright et al (2004) 
observed that the (ala
5
)AIP-1 could not activate either the AgrC1-4 or the AgrC4-
1 chimera (Wright, III et al., 2004).  Here, by simply changing the alanine in 
position 101 of AgrC1 to the corresponding threonine of AgrC4 the specificity of 
(ala
5
)AIP-1 has been changed from a potent inhibitor to an activator.  In contrast 
changing the threonine in position 101 of the AgrC4 to the corresponding alanine 
of AgrC1 do not change the specificity of (ala
5
)AIP-1 (see Table 3-5).  Changing 
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the alanine in position 101 to a threonine in conjunction with changing either the 
threonine in position 104 or the serine in position 107 to a valine results in an 
increase in the potency of (ala
5
)AIP-1 as an agonist. However, if all three changes 
are made at the same time (A101T, T104V and S107V) the activity of (ala
5
)AIP-1 
as an agonist is almost completely lost. Hence, to function as a potent agonist for 
AgrC1, (ala
5
)AIP-1 requires the exchange of a non-polar amino acid in position 
101 to a polar amino acid and the retention of a polar amino acid residue in either 
position 104 or 107, but benefits from exchanging one of them for a non-polar 
(hydrophobic) amino acid residue.  
 
Structure activity studies of AIP-1 have established that the intact macrocycle (the 
address region) is essential for binding to AgrC while the N-terminal tail (the 
message region) is required for activation of AgrC (Chan et al., 2004).  NMR 
studies of AIP-1 and (ala
5
)AIP-1 have shown that the structural difference that 
converts AIP-1 from an activator to an inhibitor of AgrC1 is the orientation of the 
exocyclic tail with respect to the marcrocycle (Chan et al., 2004).  Since the 
macrocycle alone can function as a weak inhibitor these data suggest that the 
activation of AgrC1 mutants could be a consequence of the receptor adopting a 
partially activated conformation.  However since that the macrocycle on its own is 
only a very weak activator of AgrC1 A101T this indicated that the tripeptide tail 
plays an important role in receptor activation.  At a genetic level it is interesting 
that the change in specificity of the AgrC1 receptor requires only one single base 
change (G to A) to modify the codon for alanine (GCA) to that of threonine 
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(ACA). The agrD1 gene also only requires one (A to C) mutation to modify the 
codon for aspartic acid to alanine to create (ala
5
)AIP-1 (GAC to GCC).  Hence, for 
such a new agr system to evolve naturally only two complementary point 
mutations would be required to make a fully functional agr system, and a new agr 
group.  The natural cause of agr divergence is, at present, not known (Dufour et 
al., 2002), although competitive interference between different S. aureus agr 
groups has been reported (Fleming et al., 2006). 
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4 Visualisation of the AgrC protein 
4.1 Introduction 
Full length AgrC has not previously been purified either in its native form from S. 
aureus or as a recombinant protein from any other organism. However, Lina et al 
(1998) raised rabbit anti-sera against a fusion of maltose binding protein (MBP) 
and the cytoplasmic C-terminal domain of AgrC (from 
173
S to the stop codon). 
This antisera recognized a 46 kDa band on Western blots which was absent from 
an isogenic agr null mutant. Apart from these data, the only structural information 
for AgrC is that predicted using transmembrane topology programmes (Lina et al., 
1998;Geisinger et al., 2008)and from PhoA fusions expressed in E. coli. (Lina et 
al., 1998). Consequently, a method for overexpressing and purifying functional 
AgrC would greatly assist attempts to solve the structure of AgrC and aid 
characterisation of the specific AIP binding site(s). 
 
In this chapter, the expression and identification of AgrC in both E. coli and 
S.aureus was attempted using Western blot, photo-activatable probes and green 
fluorescent protein (Gfp) fusions. 
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4.2 Results 
 
4.2.1 Tagging AgrC for purification and identification of the AIP 
binding site(s) 
 
Initially the plan was to tag AgrC with a His-tag or using the Impact system (This 
systems utilize engineered protein splicing elements (inteins) fused to a chitin 
binding domain as affinity tags. Which allows purification in a single 
chromatographic step) such that it could be affinity purified before and after 
reaction with photo-activatable AIP derivatives (Figure 4-2).  After purification, 
the native AgrC or AgrC-AIP complex would be proteolytically cleaved and 
subjected to mass spectrometry such that MS fragments bearing the covalently 
attached AIP could be identified and their structure determined to identify the key 
AgrC amino acid residues involved in AIP binding. 
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Figure 4-1: Use of photoactivatable AIP for detection of binding site in AgrC. Blue star 
denominates photoactivatable group either in the macrocyclic ring or in the tail. Green line is 
covalent bonds formed by the photoactivation.  
 
The photoactivatable AIPs to be used were N-4-(4-benzoylphenoxy)butyryl(des-
Tyr
1
) and 4-benzoyl-L-phenylalanine (synthesised by Dr Weng Chan;). 
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Figure 4-2: Photoactivatable AIPs A) N-4-(4-benzoylphenoxy)butyryl(des-Tyr
1
)AIP-1 B) 4-
benzoylPhe
6
)AIP-1. 
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To construct tagged AgrC proteins, a 6 x His-tagged agrC gene (primers Table 
2-3) was introduced into the E. coli-S.aureus shuttle expression vector, pSK5632 
(Grkovic et al., 2003). This proved more difficult than anticipated, and cloning the 
tagged agrC directly into pSK5632 proved impossible. The 6 x His-tagged agrC 
was, therefore, cloned into a Topo-vector for sub-cloning into an alternative 
expression vector. This strategy proved successful until the sub-cloning step where 
again no clones were obtained. An alternative method of tagging was then tried, 
the Impact (NEB, UK) (primers Table 2-3), but also proved unsuccessful. Both 
cloning strategies were attempted using several different E. coli host strains 
including JM109 and TOP10F as well as C41 and C43 which are E. coli strains 
specifically developed for expressing  toxic recombinant membrane proteins 
(Miroux and Walker, 1996).  None of these host/vector combinations successfully 
yielded tagged AgrC protein. 
 
4.2.2 Visualisation of AgrC using Western blot and SDS PAGE 
gel electrophoresis 
After unsuccessfully attempting to tag and express AgrC in both E. coli and S. 
aureus, Western blot analysis using an antiserum raised in rats against an MBP- 
C-terminal AgrC fusion (MBP-AgrCser173, constructed by Dr Alan Cockayne) 
was used to visualise AgrC (section 2.15) and identify the corresponding band on 
a Coomassie blue stained SDS-PAGE gel for subsequent use with the the 
photoactivatable AIPs. 
162 
 
 
 
 
kDa
kDa
kDa
kDa
1 2 3 1 2 3
 
Figure 4-3: Lane 1) Biorad Precision Plus Protein Standard. Lane 2 and 3) Crude membrane 
extract from; 2) ROJ40 (RN4220 ǻagr) and 3) ROJ134  (RN4220 ǻagr) pAgrC1agrA. (A) 
Coomasie blue stained gel B) Western blot, film exposed for 30 s  
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Figure 4-3 shows that either the primary, secondary or both antibodies conjugates 
reacted with multiple staphylococcal proteins. To determine whether the problem 
was only due to one or both of the antibodies, a western blot probed only with the 
secondary antibody was performed (Figure 4-4) .  
Lane: 1       2         3       4
 
Figure 4-4: Crude membrane prep Western blot probed with just rabbit-anti-rat-HRP 
secondary antibody. Lane 1) Biorad low range SDS-PAGE Standard 2) ROJ40 3) RN6090B 
4) ROJ40 (ala
5
)AIP-1. 
 
As the secondary antibody alone recognised many different staphylococcal 
proteins (Figure 4-4) the antiserum was absorbed with ROJ38 (RN6390B ǻagr) or 
ROJ40 (RN4220 ǻagr) whole cells and incubating either for 2 h at room 
temperature or overnight at 4°C. To clean up the crude membrane protein 
preparation, Elugent extraction was undertaken in the hope that AgrC would be 
selectively extracted (section 2.11). 
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Figure 4-5: Western blot of both crude membrane prep and Elugent extract using 
absorbed antibodies. Lane 1) Biorad low range SDS-PAGE Standard  2) RN6390B 3) ROJ38 
4) ROJ38 pAgrC1agrA and 5) ROJ38 pAgrC1agrA with 100nM AIP. Black arrows indicates 
putative AgrC protein 
 
On the western blot shown in Figure 4-5 AIP-1 was added to strains carrying the 
plasmids pAgrC1AgrA to induce the transcription of agrC from the P2agr 
promoter. There are two bands (approximately ~60 kDa and ~50kDa) present in 
the lane 2; wild type S. aureus RN6390B that are absent in lane 3; S. aureus 
ROJ38 (RN6390B ǻagr) which is also visible in lanes 4 and 5; ROJ38 
pAgrC1AgrA with out and with AIP-1 that may be AgrC, however one protein 
band appears to be too large (AgrC is predicted to be 49 kDa). Both bands are also 
visible in lanes 2,4 and 5 but absent from lane 3 with the Elugent extracts. 
165 
Unfortunately these can not be identified on a Coomassie blue stained SDS-PAGE 
gel (Figure 4-6).  
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Figure 4-6: Coomasie blue stained 12% acrylamide gel of crude membrane prep (lane 2-5) 
and Elugent extract (lane 6-9). Lane 1) Biorad low range SDS-PAGE Standard, 2 & 6) 
RN6390B 3 & 7) ROJ38 4 & 8) ROJ38 pAgrC1agrA and 5 & 9) ROJ38 pAgrC1agrA with 
100nM AIP. Black arrows indicates AgrC candidates observed in blot Figure 4-5. Red arrow 
indicates band submitted for MALDI-TOF protein identification. 
 
How ever, there is a band that is visible in S. aureus RN6390B (lane 2; red arrow), 
which is absent in the lane 3 and 7 but present in lanes 2,4,5,6,8 and 9. Even 
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though this band appears to be too small to be AgrC (~38 kDa) it was submitted 
for MALDI-TOF. To ensure there was enough protein a new gel was run with 
three lanes of membrane preparations from RN6390B and ROJ38 pAgrC1agrA 
with 100nM AIP-1 and two lanes of Elugent extract from ROJ38 pAgrC1agrA 
with 100nM AIP-1. The protein identification results were: RN6390B and ROJ38 
pAgrC1agrA samples gave were mixed bands making identification uncertain. 
The only staphylococcal protein positively identified was Pseudouridine synthase 
(Rsu). The ROJ38 pAgrC1agrA Elugent extract gave a confident match as a 
hypothetical protein gene code MW1525 from S .aureus strain MW2. 
 
Since none of the bands sent for mass spectrometry proved to be AgrC, the 
photoactivatable AIP strategy was abandoned. 
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4.2.3 AgrC-Gfp fusions 
 
To investigate whether AgrC is localised to a specific region in the cell, both C-
terminal and N-terminal AgrC-Gfp (green fluorescent protein) fusions were 
constructed in the same plasmid backbone as that used for the AIP bioreporter 
assays (pSKermp2), where the fusion is under the control of the P2agr promoter 
(for primers Table 2-3). 
 
pGfp-AgrC1A
10358 bp
gfp
agrA
ermB
bla
rep
par
cat
agrC1
BamHI (1)
HindIII (2776)
EcoRI (742)
EcoRI (7084)
EcoRI (7587)
EcoRI (9942)
EcoRI (10121)
 
Figure 4-7: Plasmid map of pGfp-AgrC1A 
 
Unfortunately attempts to generate the C-terminal fusion proved unsuccessful, 
however, transformants for the N-terminal fusion were obtained (plasmid pGfp-
AgrC1A, Figure 4-7). Restriction mapping of the plasmid proved difficult but the 
insert size was correct (plasmid sent for sequencing, but no results have been 
received yet) and since the transformants grew on all the antibiotics (the plasmids 
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carried resistance genes to ampicillin, chloramphenicol and erythromycin) it was 
decided to transform the fusions into S. aureus RN4220 and ROJ39 (RN4220 
ǻagr) for further study.  
 
Microscopy of E. coli JM109/ pGfp-AgrC1A show that the fusion is uniformly 
distributed in E. coli. However, the E. coli cells showed signs of being slightly 
division deficient, with many cells being abnormally elongated; these were also 
the cells that fluoresced the strongest (Figure 4-8E). 
 
Figure 4-8A-C shows that in S. aureus RN4220 AgrC is uniformly distributed 
throughout the cell. To test whether the AgrC-Gfp fusion was functional it was 
transformed into ROJ39 and grown with and with out AIP-1 (Figure 4-8D). A few 
differences in fluorescing cells were observed, however, the difference was small. 
The pGfp-Agr plasmid was also transformed into S. aureus ROJ48 and used in a 
bioluminescence assay to determine whether the fusion was functional. This, 
however, did not show any agr activity even at 10 µM AIP-1.  
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Figure 4-8: Light and fluorescent micrographs of N-terminal gfp-agrC fusions. A) cut outs of 
Bright field images B) is fluorescence images and C) merge of bright field and fluorescence 
images of RN4220 with pGfp-AgrC. D) Merge of bright field and fluorescence microscopy 
pictures of ROJ39 with pGfp-AgrC grown with out (left) and with AIP-1 (right) E)  E. coli 
JM109 with pGfp-AgrC 
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4.3 Discussion 
Attempts at tagging and purifying AgrC unfortunately failed, most likely due to 
the toxicity of  AgrC for E. coli. Alternatives to solve this problem could be to use 
a different  vector / host expression system such as the lactobacillus pNZ8020 
expression vector (de Ruyter et al., 1996) or a yeast expression system.  
Lina et al (1998) showed western blots using antibodies raised in New Zealand 
with rabbits against the C-terminal domain of AgrC (Lina et al., 1998), however, 
this did not prove reproducible with the antibodies raised in rats in our laboratory. 
Preliminary data generated using Gfp tagging of AgrC revealed that AgrC is 
uniformly distributed through out S. aureus and, since it is fluorescent, the Gfp 
protein must have folded correctly when fused to AgrC. A C-terminal fusion also 
needs to be made where AgrC will hopefully still be active verifying that AgrC-
Gfp has inserted correctly into the membrane. Use of this fusion for confocal 
microscopy would verify AgrCs localisation in the membrane. The Gfp tagged 
AgrC could also be used for co-immunoprecipitation to further study AgrC AIP 
interactions using the available photoactivatable AIPs. 
 
172 
5 AgrB-D interactions and identification of a novel 
protein potientially interacting with AgrB 
5.1 Introduction 
 
AgrD is the precursor molecule for functional AIP.  To yield the functional AIP 
three events are necessary; two endopeptidase events removing the 24 amino acid 
residue N-terminal amphipathic leader and the C-terminal charged tail and the 
formation of the thioester bond between Į-carboxyl group of the C-terminal amino 
residue the thiol group on the central cysteine to form a macrocyclic and the 
functional AIP will need to be secreted.   
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Figure 5-1: Steps involved in the production and secretion of functional AIP. 1) Removal of 
the  N-terminal leader 2) removal of the C-terminal tail 3) formation of the macrocycle. 
 
AgrB has been hypothesised to process the AgrD polypeptide and secrete 
functional auto inducing peptide (AIP) (Ji et al., 1995;Ji et al., 1997).  It is, 
however, very unlikely that AgrB can perform all of these steps on its own, thus it 
has been hypothesised that AgrB requires the help of other proteins to fulfil this 
role (Garvis et al., 2002;Novick, 2003), either for the cleaving of the AgrD 
polypeptide, forming the macrocycle to yield the functional AIP or with the 
secretion of the active AIP (Ji et al., 1995;Mayville et al., 1999).  AgrB has been 
shown to have peptidase activity and cleave AgrD to remove the C-terminal tail 
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(Zhang et al., 2002;Qiu et al., 2005), and recently Kavanaugh et al. (2007) 
demonstrated that type 1 signal peptidase likely cleaves off the N-terminal leader. 
5.1.1 Two hybrid systems 
Two hybrid systems are yeast or bacterial systems used to look for protein-protein 
interactions (some systems can also be used for protein-DNA interactions). They 
work by fusing the proteins of interest inframe to each domain of a two domain 
protein and if the fusions interact the function of the protein is restored leading to 
a screenable event. 
5.1.1.1 Yeast two hybrid systems 
The Matchmaker yeast two hybrid system, chosen to show direct interaction 
between AgrB and AgrD and for the library screening for interaction between 
AgrB and other protein(s), if any, that might be involved in the processing or 
secretion of the AIP, is based on the GAL4 regulatory system, where the GAL4  
protein binds to the UAS (upstream activating sequence) and activates the 
transcription of the target gene. The separation of GAL4 into two distinct 
domains, a DNA binding domain (BD) and an activating domain (AD), is 
exploited by fusing the library DNA fragments or your gene of interest (here 
agrB) in frame to either the binding domain or the activating domain.  If the two 
proteins of interest interact, the functionality of the GAL4 protein is restored and 
the reporter genes are transcribed (Figure 5-2). 
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Figure 5-2: Principle of a yeast two hybrid system; the DNA binding domain (BD) fused to 
the bait protein (AgrB) binds to the UAS. And if there are interactions between AgrB and 
the library protein fused to the activating domain (AD) the activating domain will be 
positioned so that transcription of the reporter genes can be initiated from the promoter 
leading. This enables the yeast Saccharomyces cerevisiae PJ69-4A to grow on minimal plates 
missing nutrients otherwise required to grow on minimal medium and to the transcription of 
the lacZ gene.  
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5.1.1.2 Bacterial two hybrid systems 
The principle of restoring the function of a protein by fusing proteins of interest to 
two distinct domains of the same protein and the activity of this protein is restored 
of the proteins of interest is interacting is also utilised in a bacterial two-hybrid 
system. Here, instead of restoring the activator GAL4, it is the CyaAs (adenylate 
cyclase) activity that is restored. CyaA is involved in a signal transduction cascade 
converting AMP (adenine mono-phosphate) into cAMP (cyclic AMP). An 
adenylate cyclase-deficient E. coli strain (E. coli lacks CaM (calmodulin) or CaM-
related proteins which are required for CyaA function) is used as a reporter strain.  
The proteins investigated are fused to either the T25 or the T18 fragment of CyaA 
and if interactions occur, the two domains are brought together and CyaA function 
is restored leading to the production of cAMP.  As cAMP is required for E. coli to 
ferment maltose or lactose, this interaction can be visualised using MacConkey 
plates supplemented with maltose, LB X-gal or by growth selection on minimal 
media plates supplemented with maltose or lactose as sole carbon source. 
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5.2 Results  
5.2.1 Yeast two hybrid system library screening 
5.2.1.1 Interactions between AgrB and AgrD 
 
As direct interactions between AgrB and AgrD have not yet been definitively 
demonstrated agrB and agrD were cloned in-frame into pGBT9 and pGAD424 
respectively and transformed into S. cerevisiae PJ69-4A.  No colonies were 
recovered that show any potential interactions.  To rule out the possibility that 
AgrB and / or AgrD is not functional in yeast putative AgrB /AgrD interactions 
were investigated using a bacterial two hybrid system (Karimova et al., 1998).  
AgrB and AgrD was cloned into the plasmids pKT25 and pUT18 and transformed 
into the E. coli strain BTH101 (Karimova et al., 1998).  However, no interactions 
between AgrB and AgrD were found. 
5.2.1.2 Yeast two hybrid system library screening 
To facilitate fishing for novel proteins interacting with AgrB, a genomic DNA 
library was made by digesting gDNA from S.aureus strain Newman with EcoRI 
and ligating it into the plasmid pGBT9 creating pGBT9-SA-gDNA-Lib, a BD-
library hybrid, a library of all S. aureus Newman protein fused to the binding 
domain of GAL4 (Constructed by Alan Cockayne).  The bait fusion of the two 
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hybrid system was made by fusing agrB in frame into pGAD424 using EcoRI and 
BamHI creating pGAD424-AgrB, an AD-AgrB hybrid.  
 
The two plasmids were co-transformed into the S. cerevisiae PJ69-4A carrying the 
reporter genes HIS3 under the control of the GAL1 promoter, the reporter gene 
ADE2 under the control of the GAL2 promoter, and a lacZ reporter under the 
control of the GAL7 promoter. In minimal media this strain requires tryptophan, 
leucine, methionine, uracil, adenine and histidine for growth.  The leucine and 
tryptophan dependency is used for selection as pGBT9 carries the complementary 
tryptophan gene (TRP1) and pGAD424 carries the complementary leucine gene 
(LEU2).  The presence of three reporters all responding to the same inducer gives 
the opportunity to select for interactions more or less stringently, see Table 5-1.  
 
Table 5-1: Yeast medium used for selection of interactions between proteins in the yeast two 
hybrid system. 
Yeast Minimal Medium with: Stringency 
Methionine, uracil and adenine Least stringent 
Methionine, uracil and histidine  
Methionine and uracil Most stringent 
 
To select for co-transformants the yeast was plated at 30°C for 72 h on Yeast 
Minimal Medium (YMM) with methionine uracil, and adenine, selecting not only 
for the presence of the two plasmids but also for interactions with AgrB.  
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150 co-transformants were streaked on to three sets of plates; YMM X-gal with 
methionine, uracil and adenine, YMM with methionine uracil and histidine, and 
YMM with methionine and uracil. The plates were incubated at 30°C and growth 
and colour were followed for 72 h, see Figure 5-3.  
 
After 72 h 70 co-transformants showed potential interactions between AgrB-AD 
and the gDNA-BD fusions by growth on one of the two growth selective mediums 
and by turning blue on the X-gal plates (Figure 5-3).  These were re-streaked on to 
YMM methionine, uracil, histidine, adenine and leucine and incubated at 30ºC for 
48 h. The purpose of this was to ensure each strain only contains one copy of 
pGBT9-SA-gDNA-Lib plasmid. 
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Figure 5-3: Yeast PJ69-4A containing plasmids pGBT9-SA-gDNA-Lib and pGAD424-AgrB 
plated on three different selective plates selecting for protein-protein interactions with AgrB. 
YMM methionine and uracil (most stringent) YMM methionine uracil and histidine and 
YMM X-gal methionine uracil and adenine (Least stringent for growth, blue if interactions 
are present). Photos were taken every 24 h for 72 h to document growth and colour change.  
After 72 h streaks that were blue on the X-gal medium and grew on one of the two growth 
selective medias were considered potential candidates for interactions between AgrB-AD and 
the protein expressed by the library plasmid. Potential candidates are shown in red boxes. 
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Plasmids from each of the 70 strains were isolated and the library insert was 
amplified by PCR, using primers pGBT9f and pGBT9r (Table 5-2).  The resulting 
PCR products were purified and digested with the frequent cutting restriction 
enzyme HaeIII.  The digests and their parent PCR products were then run on a 1% 
analytical agarose gels.  PCR products of the same size and with the same 
digestion patters were presumed to be identical.  Pairs of identical PCR products 
were sent off for sequencing (Figure 5-4).  
 
Sequences (appendix B) were blasted against the S. aureus genome to identify 
which gene the library insert originated from (see Table 5-2.) 
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1     39    3      68    5     49     9       63
20    46    31    53     60    69     61
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Figure 5-4: PCR products sent for sequencing on the left hand side of each double lane and 
the HaeIII digest on the right hand side of each double lane of  PCR products. Numbers 
above the lanes indicate the number given to the potential interaction during the YTH 
screening. 
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Table 5-2: List of genes of interest that showed up when sequences were blasted against 
Staphylococcus aureus genome using blastn (http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi). 
Only results with the highest scores and e-values are shown. Score: The higher the score the 
better a match the blasted sequence matches the sequence in the database. E-value: Is the 
expectation value and is number of different alignents with scores equivalent to or better 
than the score that are expected to occur in a database search by chance. Hence, the lower 
the E value, the more significant the score 
Sequence 
no 
Blast result (Features in subject sequence) Score, e-value 
1 & 39 RGD-containing lipoprotein 954 , 0.0 
3 & 68 imidazolonepropionase 567 , 6e-159 
5 & 49 glucose-6-phosphate 1-dehydrogenase 650 , 0.0 
9 & 63 SA0619 (hypothetical protein, similar to low-
affinity inorganic phosphate transporter) 
710 , 0.0 
20 & 46 SA0958 (myo-inositol-1(or 4)-
monophosphatase homolog) 
464 , 5e-128 
31 & 53 glucose-6-phosphate 1-dehydrogenase 975 , 0.0 
60 & 69 glucose-6-phosphate 1-dehydrogenase 975 , 0.0 
61 SA0211 (conserved hypothetical protein) 2044 , 0.0 
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Due to the way the genomic library was constructed, the above candidates 
potentially interacting with AgrB were not necessarily transcribed in frame, i.e., 
the fusion protein might not be transcribed in the same reading frame as the 
original gene giving rise to a nonsense protein.  Each sequence was compared at 
the fusion site to its original gene, using the sequence analysis software VectorNTI 
(Invitrogen, USA) to determine which candidates was transcribed in the correct 
reading frame.  The result of this analysis is shown in Table 5-3. 
 
Table 5-3: Potential interactions transcribed in frame with the fusion 
Sequence no. S.A. gene no S.A. geneproduct 
1 & 39 SA0201 RGD-containing lipoprotein 
20 & 46 SA0958 SA0958 (myo-inositol-1(or 4)-
monophosphatase homolog) 
3 & 68 SA2121 Imidazolonepropionase 
 
5.2.2 Verification of candidate genes involvement in agr 
function 
 
The proteins listed in Table 5-3 were only potential candidates for interactions 
with AgrB and these interactions require verification using alternative assays.  
Ideally this would be done by purifying the proteins and using a method such as 
surface plasmon resonance (SPR).  However, since AgrB is a large membrane 
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protein which is difficult to express and purify, it was decided to make in frame 
knock out mutants of the three candidate genes and test these mutants for 
production of AIP, Į-haemolysin and protein A production.  This would tell us 
whether or not the protein in question contributed AIP production / secretion and 
agr function. This is work in progress. 
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5.3 Discussion 
Identifying direct interactions between AgrB and AgrD, for this there could be 
several reasons for the lack of interactions; (1.) they do not interact, (2.) the 
binding domain and the activating domain from GAL4 are too bulky to allow for 
the small AgrD to gain access to AgrB, (3.) AgrB processes AgrD too quickly for 
there to be any detectable interactions or (4.) the proteins are not functional in 
yeast / E. coli. 
Three different proteins that potentially interact with AgrB were identified using a 
yeast two-hybrid system.  Two of the three SA0958 (gene no from S. aureus strain 
N315) and hutI are unlikely to have a direct function in quorum sensing let alone 
AIP production. SA0958 is a myo-inositol-1(or 4)-monophosphatase homolog 
which is involved in the inositol phosphate metabolism and belongs to a family of 
bivalent metal-ion dependant phosphatases.  HutI is an imidazolonepropionase and 
is a part of the histidine utilisation operon.  Rlp, the third protein found, is a RGD-
containing lipoprotein predicted to belong to the SBP_bac_5 super family.  
 
This is a family of ABC-type di-peptide periplasmic transporter components.  As 
Rlp is a hypothetical protein of a predicted function, it is plausible that it could 
transport polypeptides instead of just dipeptides.  Hence, a hypothesis for AIP 
synthesis could be AgrB cleaves the charged C-terminal and makes the cyclic 
thiolactone then transports the intermediate product size out, in conjunction with 
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Rlp and once outside the cell SpsB (S. aureus signal peptidase 1) cleaves the N-
terminal yielding a functional AIP (figure 5-5).  
 
 
 
Charged TailAmphipathic Leader AIP
Rlp?
AgrB
1
3
2 SpsB
Membrane
 
 
Figure 5-5: Hypothesis on the production and secretion of AIP. 1) C-terminal tail is cleaved 
of by AgrB 2) AgrB forms the macrocycle and exports the intermediate to the cell surface in 
conjunction with Rlp 3) SpsB cleaves off the active AIP. 
 
There is one flaw in this hypothesis and that is that SpsB have only been shown to 
cleave AgrD1 and the cleavage site does not appear to be present on other AgrD 
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sequences. This, however, could a group specific event and SpsB (or other 
peptidases) in other agr groups have a different recognition sequence. 
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6 General discussion 
S. aureus is an opportunistic pathogen that usually does not present a danger to 
healthy individuals.  Over the past four decades, antibiotic resistant strains have 
steadily become more and more of a problem in health care settings and within the 
last two decades aggressive, highly virulent strains have also emerged in 
community settings, infecting young healthy individuals.  As it is highly adaptable 
and capable of horizontal transfer of antibiotic resistance genes, new ways of 
combating the organism are urgently needed.  One proposed way is through 
virulence inhibition.  S. aureus infection / virulence can be divided into two steps: 
1) Establishing the infection through invasion and adherence to the host tissue 
utilizing numerous cell wall associated adhesion factors (MSCRAMMs), and 2) 
Spreading and exo-toxin production.  The switch between these two phases is 
mainly controlled by the agr locus and it has been shown that the agr deficient 
mutants have a less virulent phenotype than agr wild type (Cheung et al., 
1994;Bunce et al., 1992).  It has also been shown that blocking the agr response 
by co-administrating AIP-2 with S. aureus group I attenuates the infection 
(Mayville et al., 1999).  These properties of S. aureus infections make the agr 
response a good potential target for anti-virulence drugs.  
 
S. aureus is divided into four agr groups with each group producing a unique AIP 
which is recognised by the sensor domain of the AgrC histidine kinase and can 
cross inhibit the other groups AgrCs.  Therefore, in order to make an agr inhibitor 
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that would be effective in a possible clinical setting, it would need to inhibit all 
four groups.  One such inhibitor, (ala
5
)AIP-1 was made by McDowell et al 
(McDowell et al., 2001) and in vitro, even at low concentrations, strains from all 
four agr groups show an agr negative phenotype.  However, very little is known 
about the detailed mechanism involved in the group specific agr response, and a 
greater understanding of this could help to make better virulence inhibitors. 
 
In this study I have tried to elucidate first, the potential transmembrane topology 
of AgrC in order to get a better idea of which amino acid residues are available to 
interactions with the AIP, and secondly to elucidate the role of individual amino 
acids in the group specific agr recognition of AIP by the AgrC receptor.  For this, 
agr groups I and IV were chosen as they are the most closesly related of the four 
groups, differing by only one residue in the AIP.  There are a multitude of 
topology prediction tools available online for using different methods and 
algorithms with varying degrees of success, but the general trend was a topology 
for AgrC consisting of six TMH and three extracellular loops with both 
cytoplamic N- and C-terminals.  This is in contrast to previous published 
prediction for AgrC by Lina et al where AgrC1 was predicted to have 5 TMH and 
a extracellular N-terminal and cytoplamic C-terminal (Lina et al., 1998), but is in 
agreement with a more recently published topology by Geisinger et al (Geisinger 
et al., 2008).  It was also shown that most staphylococcal AgrCs seem to have the 
same general topology, with only S. epidermidis having seven TMH and an 
extracellular N-terminal, but still three extracellular loops. 
192 
 
Having a good idea of the transmembrane topology of AgrC and knowledge of 
which amino acid residues are available for interactions with the AIP on the 
extracellular surface of S. aureus, the next step was to try to elucidate the 
individual residues role in the group specific response.  For this an AIP bioreporter 
based on the luxABCDE bioluminescence cassette was built in an agr negative 
version of the transformable S. aureus strain RN4220.  Into this reporter strain 
various versions of agrC1 and agrC4, both wild type and mutated, were 
introduced on a plasmid and expressed from the P2agr promoter in conjunction 
with agrA.  The effectiveness of AIP-1 and AIP-4 in activating these different 
AgrC receptors was then measured in a bioluminescence assay.  The data collected 
from these assays indicate that the second extracellular loop is responsible for the 
group specific recognition of AIP-1 and AIP-4 by AgrC1 and AgrC4, more 
specifically the residue at position 101 and 107 is important for the differential 
recognition of AIP-1 and AIP-4 for AgrC4 and AgrC1, however the role of 
residue 107 for AgrC1 is not as significant as for AgrC4, hence residue 101 may 
play a larger role here.  I have also shown that the first extracellular loop plays an 
important role in activation of AgrC but less so in the inhibition of AgrC.  The 
finding that the second extracellular loop is responsible for the group specific AIP 
recognition are in agreement with Wright et als findings using chimeric AgrC 
receptors (Wright, III et al., 2004) and most of the findings are in agreement with 
the recently published data from Geisinger et al that also found that residues 100 
and 116 play a role in the group specific recognition of AIP-1 and AIP-4. 
193 
 
To study the effects of mutations in the AgrC receptor on the inhibition by 
possible virulence-inhibiting drugs, the S. aureus agr inhibiting (ala
5
)AIP-1 was 
tested against the available AgrC mutants.  The data from this part of the study 
surprisingly showed that (ala
5
)AIP-1 is a moderate activator of the AgrC4 loop2 
gr1 mutant and that it is a weak to potent activator of all the AgrC1 mutants, 
showing most potent activation of the AgrC1A101TS107S (the two residues 
suggested to be responsible of the group specific AIP recognition of AgrC1 and 
4).  By changing just the residue at position 101, (the residue that seems to play 
the largest role in the group specific recognition of AIP-1), made the AgrC1 
receptor recognise (ala
5
)AIP-1 as a fairly potent agonist.  This has never before 
been observed. Then, Wright et al observed that (ala
5
)AIP-1 activated their 
AgrC1-3 and AgrC4-3 chimera but the AgrC1-4 or AgrC4-1 chimera was not 
activated by (ala
5
)AIP-1 (Wright, III et al., 2004).  
 
This part of the study has given a more detailed insight to how the activation of 
AgrC occurs and can hopefully help in rational design of anti-virulence drugs 
down the line. Also, it has demonstrated that the theory that all S. aureus agr 
groups originate from the same ancestor is plausible as only two point mutations 
would be necessary to make a new group whos AIP activates its own AgrC and 
cross inhibits other groups AgrC.  This discovery also raises the question that 
resistance to potential AIP analogue anti-virulence drugs would also render them 
ineffective.  This is, however, unlikely: 1) if AgrC is mutated so that it recognises 
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the drug as an agonist instead of an antagonist the agr system would be 
continuously switched on and all the exo-toxins would be continuously expressed, 
which is very energy expensive for S. aureus. 2) The adhesins and immune 
evasions normally associated with the early part of an S. aureus infection would 
not be expressed which would make S. aureus easily detected by the immune 
system and  S. aureus would be less able to establish itself in the host.  It would 
not, therefore, be advantageous for the bacteria to develop resistance in this way. 
Other resistance mechanisms are of course possible but since anti-virulence drugs 
do not directly select for resistance this must be presumed to be fairly unlikely. 
There is, however, a potential down side to inhibiting the agr system in 
Staphylococcus. The inhibition of agr can lead to biofilm formation or thicker 
biofilms which is more persistent to both the immune response and antibiotics. 
However, as agr have only been shown to be expressed for a matter of hours in the 
beginning of an infection and that several groups have shown that agr is required 
for the establishment of a fully robust infection (Booth et al., 1995;Abdelnour et 
al., 1993;Gillaspy et al., 1995), the role of anti-agr drugs seems limited to the first 
hours of the infection. At first this does not seem to have much application, but 
with the emergence of highly virulent community associated MRSA and MSSA 
strains that can lead to the death of the infected person within 48 h, preventing the 
expression of toxins and thereby buying the patient and doctors a bit more time to 
treat the infection with conventional antibiotics could prove a very benficial. On 
the other hand blocking agr would lead to the continuation of the production of 
adhesins and immune adversins, and could lead to more biofilm formation which 
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could result in chronic infection. An argument for using agr activators in the case 
of biofilm infection could also be made. Activating agr under these circumstances 
could lead to the dispersion of the biofilm and allow conventional antibiotics to 
work. Here again there is the problem that this treatment could have undesirable 
effects, as it would most likely lead to high toxin production and subsequent toxic 
shock.  
The role of agr in biofilm formation has, however, been questioned by (Johnson et 
al., 2008) who showed that agr mutants produce less biofilm under iron restricted 
conditions, which at least some areas of the human body can be assumed to be, 
giving a potential case for the use of anti-agr drugs against biofilms. 
As there seems to be a case both for and against this type of treatment in S. aureus 
infections, only time and further research will show whether this will be a fruitful 
road to take 
 
A research problem that has been identified and attempted to be resolved in this 
study is the visualisation of AgrC.  Lina et al are the only group ever to show a 
western blot of AgrC (Lina et al., 1998) and AgrC has never been purified.  Here 
we tried to recreate Lina et als western blot of AgrC using recombinant C-
terminal part of AgrC to raise AgrC-anti-sera in rats.  This, however, proved 
unsuccessful probably because the rats used had been in contact with S. aureus 
from the environment, and cleaning up the antibodies with whole cell protein 
preps from agr negative S. aureus did not prove more successful.  From personal 
communication with Professor Paul Williams and conversations with people at 
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staphylococcal conferences, it is apparent that many people have tried to tag and 
purify AgrC over recent years unsuccessfully. Our attempt, with 6X-HIS tag and 
the NEB Impact system also proved unsuccessful. Work on several other 
methods of visualising AgrC is currently in progress in the group, including 
expressing HIS-tagged AgrC from its native promoter and gfp tagging both the N-
terminal and C-terminal end of AgrC for microscopy purposes.  
Another possible target for anti agr drugs could be AgrB which is required for 
AIP production. Qiu et al have showed that AgrB specifically cleaves off the C-
terminal charged tail of AgrB (Qiu et al., 2005), and Kavanaugh et al (2007) have 
showed a possible role for SspB in the processing of AgrB (Kavanaugh et al., 
2007).  However, all steps have not yet been clarified in the production of AIP.  
To investigate if any other proteins are directly involved in the processing of AgrD 
into AIP a yeast two hybrid system was used to screen for proteins that potentially 
interact with AgrB.  Three proteins were found, but only Rlp, a predicted ABC 
dipeptide transporter, appeared to be a real possibility.  If this potential transporter 
is involved in AIP production, it is possibly in the secretion of AIP, it could prove 
a potential target for anti agr drugs inhibiting the secretion of AIP and its 
accumulation in the extracellular space and preventing it from activating AgrC.  
Currently we are working on knocking rlp out in S. aureus in order to test if it has 
any influence on AIP production.  
 
Since the golden heydays of new antibiotics in the 1950s only four new classes 
have emerged, two in the sixties and then none until oxazolidione in 2000 and 
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lipopetides in 2003 (Moreillon, 2008). Most new antibiotics and those in clinical 
trails are members of already known classes and it can therefore be assumed that 
resistance to these drugs will be a problem sooner or later.  Williams P (Williams, 
2002) suggested targeting the quorum sensing systems, and thereby the virulence, 
of S. aureus as a way of circumventing existing resistance mechanisms.  Various 
other anti-virulence strategies are also being pursued, these include; anti-toxin-
antibodies or toxin target homologues neutralising toxins by blocking their 
function, targeting toxin transcription factors, anti-adherence drugs mimicking the 
host target or blocking the pilus assembly(in pili producing bacteria), targeting 
secretion and anti-QS anti TCS drugs are among the strategies being perused 
(Reviewed in (Cegelski et al., 2008).  Besides the advantage of reduced chance of 
resistance, anti-virulence drugs also have the advantage of not killing off the 
natural micro-flora and opening the door for secondary infections. There are, 
however, a number of potential problems that need to be overcome when 
developing these drugs. Largest of these seem to be pharmacodynamics and the 
potential for an inmmune systems response to the drug. As many of the current 
drugs are peptides or relatively large molecules they tend to have relatively poor 
pharmacodynamics, as they often will have problems being taken up or defused 
through barriers and are susceptible to digestive and metabolic breakdown. Also 
large molecules may be detected by the immune system and could be neutralised 
by antibodies as a consequence hereof or initiate an adverse immune response 
(Patrick, 2001). It would also be over optimistic not to consider the possibility that 
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resistance to these drugs could arise, even though they would not actively select 
for this resistance by killing non resistant cells. 
   
The research presented in this thesis help give a better understanding of the 
mechanisms involved in agr QS on a molecular level and have given a small clue 
more on how AgrD is processed into AIP and secreted. These findings will aid 
hopefully in the design of anti-virulence drugs in the future. 
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Appendix A 
TMHMM 2.0 
 
HELP with output formats  
 
# Newman_agrC1 Length: 430 
# Newman_agrC1 Number of predicted TMHs:  6 
# Newman_agrC1 Exp number of AAs in TMHs: 142.64221 
# Newman_agrC1 Exp number, first 60 AAs:  40.58505 
# Newman_agrC1 Total prob of N-in:        0.90392 
# Newman_agrC1 POSSIBLE N-term signal sequence 
Newman_agrC1 TMHMM2.0 inside      1     6 
Newman_agrC1 TMHMM2.0 TMhelix      7    29 
Newman_agrC1 TMHMM2.0 outside     30    48 
Newman_agrC1 TMHMM2.0 TMhelix     49    71 
Newman_agrC1 TMHMM2.0 inside     72    77 
Newman_agrC1 TMHMM2.0 TMhelix     78   100 
Newman_agrC1 TMHMM2.0 outside    101   109 
Newman_agrC1 TMHMM2.0 TMhelix    110   132 
Newman_agrC1 TMHMM2.0 inside    133   144 
Newman_agrC1 TMHMM2.0 TMhelix    145   167 
Newman_agrC1 TMHMM2.0 outside    168   181 
Newman_agrC1 TMHMM2.0 TMhelix    182   204 
Newman_agrC1 TMHMM2.0 inside    205   430 
 
# plot in postscript, script for making the plot in gnuplot, data for plot 
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Toppred 
Algorithm specific parameters:  
 
Full window size : 21 
Core window size : 11 
Wedge window size: 5 
Using hydrophobicity file: GES-scale 
 
Cutoff for certain transmembrane segments: 1.00 
Cutoff for putative transmembrane segments: 0.60 
Critical distance between 2 transmembrane segments: 2 
 
Critical loop length:  60 
 
Kingdom: procaryote 
 
Using cyt/ext file: CYTEXT-scale 
 
 
Sequence : unknown  (430 res) 
MELLNSYNFVLFVLTQMILMFTIPAIISGIKYSKLDYFFIIVISTLSLFLFKMF
DSASLI 
ILTSFIIIMYFVKIKWYSILLIMTSQIILYCANYMYIVIYAYITKISDSIFVIFPS
FFVV 
YVTISILFSYIINRVLKKISTPYLILNKGFLIVISTILLLTFSLFFFYSQINSDEA
KVIR 
QYSFIFIGITIFLSILTFVISQFLLKEMKYKRNQEEIETYYEYTLKIEAINNEM
RKFRHD 
YVNILTTLSEYIREDDMPGLRDYFNKNIVPMKDNLQMNAIKLNGIENLKV
REIKGLITAK 
ILRAQEMNIPISIEIPDEVSSINLNMIDLSRSIGIILDNAIEASTEIDDPIIRVAFI
ESE 
NSVTFIVMNKCADDIPRIHELFQESFSTKGEGRGLGLSTLKEIADNADNVL
LDTIIENGF 
FIQKVEIINN 
 
Found: 6 segments 
 
Candidate membrane-spanning segments: 
 
 Helix Begin - End   Score Certainity 
     1     8 - 28    2.092 Certain 
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     2    54 - 74    1.886 Certain 
     3    84 - 104   1.004 Certain 
     4   109 - 129   2.219 Certain 
     5   149 - 169   2.438 Certain 
     6   182 - 202   2.417 Certain 
 
Total of 1 structures are to be tested 
 
HEADER    START   STOP    LEN PROB   HP  DARGLYS  DCYTEXT 
DNCHARGE DNNEGPOS 
TOPOLOGY   1                  1.00         1.00    -0.35     -2.00     1.00 
TOPOLOGY                                   N-in     N-in     N-out 
CYT_LOOP      1      7      7              0.00  (  0.25) 
TRANSMEM      8     28     21 1.00 2.09 
EXT_LOOP     29     53     25              3.00  (  0.52) 
TRANSMEM     54     74     21 1.00 1.89 
CYT_LOOP     75     83      9              2.00  (  0.24) 
TRANSMEM     84    104     21 1.00 1.00 
EXT_LOOP    105    108      4              1.00  ( -0.19) 
TRANSMEM    109    129     21 1.00 2.22 
CYT_LOOP    130    148     19              4.00  (  0.43) 
TRANSMEM    149    169     21 1.00 2.44 
EXT_LOOP    170    181     12              2.00  ( -0.15) 
TRANSMEM    182    202     21 1.00 2.42 
CYT_LOOP    203    430    228           ( 26.00)   -0.35 
TMpred 
TMpred output for AgrC1  
[ISREC-Server] Date: Thu Sep 18 15:45:06 2008  
 
tmpred -par=matrix.tab -html -min=17 -max=33 -def -
in=wwwtmp/.TMPRED.6553.6779.seq -out=wwwtmp/.TMPRED.6553.6779.out -
out2=wwwtmp/.TMPRED.6553.6779.out2 -
out3=wwwtmp/.TMPRED.6553.6779.txt >wwwtmp/.TMPRED.6553.6779.err 
Sequence: MEL...INN, length: 430 
Prediction parameters: TM-helix length between 17 and 33  
 
1.)Possible transmembrane helices  
The sequence positions in brackets denominate the core region. 
Only scores above 500 are considered significant. 
Inside to outside helices :   6 found 
      from        to    score center 
   9 (   9)  27 (  27)   2110     19 
  53 (  53)  72 (  72)   2198     62 
  79 (  79) 103 (  99)   1952     90 
 110 ( 112) 128 ( 128)   2285    120 
 149 ( 151) 168 ( 168)   2620    159 
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 185 ( 185) 205 ( 202)   2707    194 
 
Outside to inside helices :   6 found 
      from        to    score center 
   9 (   9)  30 (  27)   1687     19 
  53 (  53)  72 (  72)   2321     61 
  74 (  80) 102 (  97)   1365     89 
 113 ( 113) 132 ( 129)   2464    121 
 149 ( 149) 168 ( 168)   2518    159 
 184 ( 184) 205 ( 205)   2548    194 
 
 
2.) Table of correspondences  
Here is shown, which of the inside->outside helices correspond to which of the 
outside->inside helices. 
Helices shown in brackets are considered insignificant. 
A "+"-symbol indicates a preference of this orientation. 
A "++"-symbol indicates a strong preference of this orientation. 
  
           inside->outside | outside->inside 
     9-  27 (19) 2110 ++   |     9-  30 (22) 1687       
    53-  72 (20) 2198      |    53-  72 (20) 2321  +    
    79- 103 (25) 1952 ++   |    74- 102 (29) 1365       
   110- 128 (19) 2285      |   113- 132 (20) 2464  +    
   149- 168 (20) 2620  +   |   149- 168 (20) 2518       
   185- 205 (21) 2707  +   |   184- 205 (22) 2548       
 
 
3.) Suggested models for transmembrane topology 
These suggestions are purely speculative and should be used with extreme caution 
since they are based on the assumption that all transmembrane helices have been 
found. 
In most cases, the Correspondence Table shown above or the prediction plot that 
is also created should be used for the topology assignment of unknown proteins. 
 
2 possible models considered, only significant TM-segments used 
 
-----> STRONGLY prefered model: N-terminus inside 
 6 strong transmembrane helices, total score : 14015 
 # from   to length score orientation 
 1    9   27 (19)    2110 i-o 
 2   53   72 (20)    2321 o-i 
 3   79  103 (25)    1952 i-o 
 4  113  132 (20)    2464 o-i 
 5  149  168 (20)    2620 i-o 
 6  184  205 (22)    2548 o-i 
218 
 
------> alternative model 
 6 strong transmembrane helices, total score : 12760 
 # from   to length score orientation 
 1    9   30 (22)    1687 o-i 
 2   53   72 (20)    2198 i-o 
 3   74  102 (29)    1365 o-i 
 4  110  128 (19)    2285 i-o 
 5  149  168 (20)    2518 o-i 
 6  185  205 (21)    2707 i-o 
 
 
 
You can get the prediction graphics shown above in one of the following formats:  
GIF-format  
Postscript-format  
numerical format  
 
Back to ISREC home page 
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Tmap  
Results from TMAP prediction: 
 
Predictions for the sequence is given below. 
A PostScript file showing the P values plotted against sequence positions can be 
downloaded by clicking here. 
 
Please cite Persson, B. & Argos, P. (1994) J. Mol. Biol. 237, 182-192. and 
Persson, B. & Argos, P. (1996) Prot. Sci. 5, 363-371. 
Please notify me via E-mail if the server does not behave properly. 
 
Thank you for using TMAP!  
Bengt Persson 
 
RESULTS from program TMAP, edition 51 
 
Numbers give: a) number of transmembrane segment 
              b) start of TM segment (alignment position / residue number) 
              c) end of TM segment (alignment position / residue number) 
              d) length of TM segment within parentheses 
 
NO CERTAIN TOPOLOGY PREDICTION (contributions:  6 in  6 out  K out R 
in) 
 
PREDICTED TRANSMEMBRANE SEGMENTS FOR SEQUENCE 
/var/www/html/temp/1221747504.99968.msf 
 
  TM  1:   11 -   39  (29.0) 
  TM  2:   50 -   78  (29.0) 
  TM  3:   83 -  106  (24.0) 
  TM  4:  112 -  140  (29.0) 
  TM  5:  150 -  178  (29.0) 
  TM  6:  188 -  216  (29.0) 
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PREDICTED TRANSMEMBRANE SEGMENTS FOR PROTEIN  
 
  TM  1:   11 -   39 (29) 
  TM  2:   50 -   78 (29) 
  TM  3:   83 -  106 (24) 
  TM  4:  112 -  140 (29) 
  TM  5:  150 -  178 (29) 
  TM  6:  188 -  216 (29) 
 
SOSUI  
SOSUI Result 
 
 
Query title : >Newman_agrC1  
Total length : 430 A. A.  
Average of hydrophobicity : 0.493721  
 
 
This amino acid sequence is of a MEMBRANE PROTEIN  
which have 7 transmembrane helices. 
No. N terminal transmembrane region C terminal type length
1 6 SYNFVLFVLTQMILMFTIPAIIS 28 PRIMARY 23 
2 34 KLDYFFIIVISTLSLFLFKMFDS 56 PRIMARY 23 
3 60 IILTSFIIIMYFVKIKWYSILLI 82 PRIMARY 23 
4 85 SQIILYCANYMYIVIYAYITKIS 107 PRIMARY 23 
5 110 IFVIFPSFFVVYVTISILFSYII 132 PRIMARY 23 
6 148 KGFLIVISTILLLTFSLFFFYSQ 170 PRIMARY 23 
7 182 YSFIFIGITIFLSILTFVISQFL 204 PRIMARY 23 
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PHDhtm  
******************************************************************
********** 
*                                                                          * 
*    PHD: Profile fed neural network systems from HeiDelberg               * 
*    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~               
* 
*                                                                          * 
*    Prediction of:                                      * 
*  secondary structure,         by PHDsec     * 
*  solvent accessibility,       by PHDacc     * 
*  and helical transmembrane regions,     by PHDhtm      
*                                                                          * 
*    Author:                       
* Burkhard Rost           
*       EMBL, 69012 Heidelberg, Germany        * 
*       Internet: Rost@EMBL-Heidelberg.DE        
*                                                                          * 
*    All rights reserved.                                                  * 
*                                                                          * 
******************************************************************
********** 
*                                                                          * 
*    The network systems are described in:                             * 
*                                                                          * 
*    PHDsec:    B Rost & C Sander: JMB, 1993, 232, 584-599.      
*      B Rost & C Sander: Proteins, 1994, 19, 55-72.      
*    PHDacc:   B Rost & C Sander: Proteins, 1994, 20, 216-226.     * 
*    PHDhtm:   B Rost et al.:     Prot. Science, 1995, 4, 521-533.    
*                                                                          * 
******************************************************************
********** 
*                                                                          * 
*    Some statistics                                                       * 
*    ~~~~~~~~~~~~~~~                                                       * 
*                                                                          * 
*    Percentage of amino acids:                                            * 
*    +--------------+--------+--------+--------+--------+--------+         * 
*    | AA:          |    I   |    L   |    S   |    F   |    N   |         * 
*    | % of AA:     |   17.4 |   10.5 |    8.1 |    7.7 |    6.3 |         * 
*    +--------------+--------+--------+--------+--------+--------+         * 
*    | AA:          |    E   |    K   |    Y   |    V   |    T   |         * 
*    | % of AA:     |    6.0 |    5.8 |    5.1 |    5.1 |    5.1 |         * 
*    +--------------+--------+--------+--------+--------+--------+         * 
*    | AA:          |    D   |    M   |    A   |    R   |    G   |         * 
*    | % of AA:     |    4.4 |    3.5 |    3.5 |    3.0 |    2.8 |         * 
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*    +--------------+--------+--------+--------+--------+--------+         * 
*    | AA:          |    Q   |    P   |    H   |    C   |    W   |         * 
*    | % of AA:     |    2.3 |    2.1 |    0.5 |    0.5 |    0.2 |         * 
*    +--------------+--------+--------+--------+--------+--------+         * 
*                                                                          * 
*    Percentage of helical trans-membrane predicted:                       * 
*    +--------------+--------+--------+                                    * 
*    | SecStr:      |    H   |    L   |                                    * 
*    | % Predicted: |   46.3 |   53.7 |                                    * 
*    +--------------+--------+--------+                                    * 
*                                                                          * 
******************************************************************
********** 
*                                                                          * 
*    PHD output for your protein                                           * 
*    ~~~~~~~~~~~~~~~~~~~~~~~~~~~                                           * 
*                                                                          * 
*    Thu Sep 18 16:19:06 2008                                              * 
*    Jury on:        4    different architectures (version   8.94_69  ).   * 
*    Note: differently trained architectures, i.e., different versions can * 
*    result in different predictions.                                      * 
*                                                                          * 
******************************************************************
********** 
*                                                                          * 
*    About the protein                                                     * 
*    ~~~~~~~~~~~~~~~~~                                                     * 
*                                                                          * 
*    HEADER                                                                * 
*    COMPND                                                                * 
*    SOURCE                                                                * 
*    AUTHOR                                                                * 
*    SEQLENGTH   430                                                       * 
*    NCHAIN        1 chain(s) in Newman_agrC1 data set                     * 
*    NALIGN        8                                                       * 
*    (=number of aligned sequences in HSSP file)                           * 
*                                                                          * 
*                                                                          * 
*    protein:       Newman_        length      430                         * 
*                                                                          * 
---  
--- ------------------------------------------------------------ 
--- PhdTopology prediction of transmembrane helices and topology 
--- ------------------------------------------------------------ 
---  
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--- PhdTopology REFINEMENT AND TOPOLOGY HEADER: 
ABBREVIATIONS 
---  
--- NHTM_BEST    : number of transmembrane helices best model 
--- NHTM_2ND_BEST: number of transmembrane helices 2nd best model 
--- REL_BEST     : reliability of best model (0 is low, 9 high) 
--- HTMTOP_PRD   : topology predicted ('in': intra-cytoplasmic) 
--- HTMTOP_RID   : difference between positive charges 
--- HTMTOP_RIP   : reliability of topology prediction (0-9) 
--- MOD_NHTM     : number of transmembrane helices of model 
--- MOD_STOT     : score for all residues 
--- MOD_SHTM     : score for HTM added at current iteration step 
--- MOD_N-C      : N  -  C  term of HTM added at current step 
---  
--- ALGORITHM REF: The refinement is performed by a dynamic pro- 
--- ALGORITHM    : gramming-like procedure: iteratively the best 
--- ALGORITHM    : transmembrane helix (HTM) compatible with the 
--- ALGORITHM    : network output is added (starting from the  0 
--- ALGORITHM    : assumption, i.e.,  no HTM's  in the protein). 
--- ALGORITHM TOP: Topology is predicted by the  positive-inside 
--- ALGORITHM    : rule, i.e., the positive charges are compiled 
--- ALGORITHM    : separately  for all even and all odd  non-HTM 
--- ALGORITHM    : regions.  If the difference (charge even-odd) 
--- ALGORITHM    : is < 0, topology is predicted as 'in'.   That 
--- ALGORITHM    : means, the protein N-term starts on the intra 
--- ALGORITHM    : cytoplasmic side. 
---  
--- PhdTopology REFINEMENT HEADER: SUMMARY 
 MOD_NHTM MOD_STOT MOD_SHTM MOD_N-C  
        1    0.618    0.902   183 -   201  
        2    0.663    0.891   108 -   132  
        3    0.700    0.891   148 -   167  
        4    0.732    0.890    42 -    59  
        5    0.777    0.887    64 -    88  
        6    0.811    0.881    14 -    32 
---  
--- PhdTopology REFINEMENT AND TOPOLOGY HEADER: SUMMARY 
--- NHTM_BEST    : 6 
--- NHTM_2ND_BEST: 5 
--- REL_BEST     : 3 
--- HTMTOP_PRD   : in 
--- HTMTOP_RID   : -3.438 
--- HTMTOP_RIP   : 3 
---  
--- PhdTopology REFINEMENT AND TOPOLOGY PREDICTION: SYMBOLS 
--- AA           : amino acid in one-letter code 
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--- PHD htm      : HTM's predicted by the PHD neural network 
---                system (H=HTM, ' '=not HTM) 
--- Rel htm      : Reliability index of prediction (0-9, 0 is low) 
--- detail       : Neural network output in detail 
--- prH htm      : 'Probability' for assigning a helical trans- 
---                membrane region (HTM) 
--- prL htm      : 'Probability' for assigning a non-HTM region 
---          note: 'Probabilites' are scaled to the interval 
---                0-9, e.g.,, prH=5 means, that the first  
---                output node is 0.5-0.6 
--- subset       : Subset of more reliable predictions 
--- SUB htm      : All residues for which the expected average 
---                accuracy is > 82% (tables in header). 
---          note: for this subset the following symbols are used: 
---             L: is loop (for which above ' ' is used) 
---           '.': means that no prediction is made for this, 
---                residue as the reliability is:  Rel < 5 
--- other        : predictions derived based on PHDhtm 
--- PHDFhtm      : filtered prediction, i.e., too long HTM's are 
---                split, too short ones are deleted 
--- PHDRhtm      : refinement of neural network output  
--- PHDThtm      : topology prediction based on refined model 
---                symbols used: 
---             i: intra-cytoplasmic 
---             T: transmembrane region 
---             o: extra-cytoplasmic 
---  
--- PhdTopology REFINEMENT AND TOPOLOGY PREDICTION 
                  ....,....1....,....2....,....3....,....4....,....5....,....6 
         AA      
|MELLNSYNFVLFVLTQMILMFTIPAIISGIKYSKLDYFFIIVISTLSLFLFKMF
DSASLI| 
         PHD htm |           
HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
HHHH| 
         Rel htm 
|999988877640356788888888877776555556677777777777777777777777| 
 detail:  
         prH htm 
|000000011125678899999999988888777778888888888888888888888888| 
         prL htm 
|999999988874321100000000011111222221111111111111111111111111| 
 subset: SUB htm 
|LLLLLLLLL......HHHHHHHHHHHHHH........HHHHHHHHHHHHHHHHHHH
HHHH| 
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         PHDRhtm |             HHHHHHHHHHHHHHHHHHH         
HHHHHHHHHHHHHHHHHH | 
         PHDThtm 
|iiiiiiiiiiiiiTTTTTTTTTTTTTTTTTTToooooooooTTTTTTTTTTTTTTTTTTi| 
                  ....,....7....,....8....,....9....,....10...,....11...,....12 
         AA      
|ILTSFIIIMYFVKIKWYSILLIMTSQIILYCANYMYIVIYAYITKISDSIFVIFPS
FFVV| 
         PHD htm 
|HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
HHHHHHHHHHHHHHH| 
         Rel htm 
|777777777777777777777777777777777777777777766667777777777777| 
 detail:  
         prH htm 
|888888888888888888888888888888888888888888888888888888888888| 
         prL htm 
|111111111111111111111111111111111111111111111111111111111111| 
 subset: SUB htm 
|HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH....H
HHHHHHHHHHHH| 
         PHDRhtm |   HHHHHHHHHHHHHHHHHHHHHHHHH                   
HHHHHHHHHHHHH| 
         PHDThtm 
|iiiTTTTTTTTTTTTTTTTTTTTTTTTToooooooooooooooooooTTTTTTTTTTTT
T| 
                  ....,....13...,....14...,....15...,....16...,....17...,....18 
         AA      
|YVTISILFSYIINRVLKKISTPYLILNKGFLIVISTILLLTFSLFFFYSQINSDEA
KVIR| 
         PHD htm |HHHHHHHHHHHHHHHHHHH 
HHHHHHHHHHHHHHHHHHHHHHHHHHHHHH          | 
         Rel htm 
|777777777877776530010124555677777777777788888776302356766532| 
 detail:  
         prH htm 
|888888888988888765545567777888888888888899999888653321111233| 
         prL htm 
|111111111011111234454432222111111111111100000111346678888766| 
 subset: SUB htm 
|HHHHHHHHHHHHHH..............HHHHHHHHHHHHHHHHHHH.......L.....| 
         PHDRhtm |HHHHHHHHHHHH               
HHHHHHHHHHHHHHHHHHHH             | 
         PHDThtm 
|TTTTTTTTTTTTiiiiiiiiiiiiiiiTTTTTTTTTTTTTTTTTTTTooooooooooooo| 
                  ....,....19...,....20...,....21...,....22...,....23...,....24 
226 
         AA      
|QYSFIFIGITIFLSILTFVISQFLLKEMKYKRNQEEIETYYEYTLKIEAINNEM
RKFRHD| 
         PHD htm |HHHHHHHHHHHHHHHHHHHHHHHH                                    | 
         Rel htm 
|257788888877777888877653056788999999999999999999999999999999| 
 detail:  
         prH htm 
|678899999988888999988876421100000000000000000000000000000000| 
         prL htm 
|321100000011111000011123578899999999999999999999999999999999| 
 subset: SUB htm 
|..HHHHHHHHHHHHHHHHHHH......LLLLLLLLLLLLLLLLLLLLLLLLLLLL
LLLLL| 
         PHDRhtm |  HHHHHHHHHHHHHHHHHHH                                       | 
         PHDThtm |ooTTTTTTTTTTTTTTTTTTTiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii| 
                  ....,....25...,....26...,....27...,....28...,....29...,....30 
         AA      
|YVNILTTLSEYIREDDMPGLRDYFNKNIVPMKDNLQMNAIKLNGIENLKV
REIKGLITAK| 
         PHD htm |                                                            | 
         Rel htm 
|999999999999999999999999999999999999999999999999999999998899| 
 detail:  
         prH htm 
|000000000000000000000000000000000000000000000000000000000000| 
         prL htm 
|999999999999999999999999999999999999999999999999999999999999| 
 subset: SUB htm 
|LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL
LLLLLL| 
         PHDRhtm |                                                            | 
         PHDThtm |iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii| 
                  ....,....31...,....32...,....33...,....34...,....35...,....36 
         AA      
|ILRAQEMNIPISIEIPDEVSSINLNMIDLSRSIGIILDNAIEASTEIDDPIIRVAFI
ESE| 
         PHD htm |                               HHHHHH                  HHHHH| 
         Rel htm 
|999999999999999999999988753212101122136677788888888875123210| 
 detail:  
         prH htm 
|000000000000000000000000123343455566531111100000000012466655| 
         prL htm 
|999999999999999999999999876656544433468888899999999987533344| 
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 subset: SUB htm 
|LLLLLLLLLLLLLLLLLLLLLLLLL...............LLLLLLLLLLLLL.......| 
         PHDRhtm |                                                            | 
         PHDThtm |iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii| 
                  ....,....37...,....38...,....39...,....40...,....41...,....42 
         AA      
|NSVTFIVMNKCADDIPRIHELFQESFSTKGEGRGLGLSTLKEIADNADNVL
LDTIIENGF| 
         PHD htm |HHHHHH                                                      | 
         Rel htm 
|122331158889999999999999999999999999999999999999999999999999| 
 detail:  
         prH htm 
|566665420000000000000000000000000000000000000000000000000000| 
         prL htm 
|433334579999999999999999999999999999999999999999999999999999| 
 subset: SUB htm 
|........LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL
LL| 
         PHDRhtm |                                                            | 
         PHDThtm |iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii| 
                  ....,....43...,....44...,....45...,....46...,....47...,....48 
         AA      |FIQKVEIINN| 
         PHD htm |          | 
         Rel htm |9999999999| 
 detail:  
         prH htm |0000000000| 
         prL htm |9999999999| 
 subset: SUB htm |LLLLLLLLLL| 
         PHDRhtm |          | 
         PHDThtm |iiiiiiiiii| 
---  
--- PhdTopology REFINEMENT AND TOPOLOGY PREDICTION END 
---  
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DAS 
Potential transmembrane segments 
Start Stop Length ~ Cutoff 
9 27 19 ~ 1.7 
10 26 17 ~ 2.2 
37 51 15 ~ 1.7 
38 50 13 ~ 2.2 
57 74 18 ~ 1.7 
59 72 14 ~ 2.2 
76 103 28 ~ 1.7 
79 88 10 ~ 2.2 
95 101 7 ~ 2.2 
110 132 23 ~ 1.7 
111 131 21 ~ 2.2 
148 167 20 ~ 1.7 
150 166 17 ~ 2.2 
183 202 20 ~ 1.7 
184 201 18 ~ 2.2 
 
 
The DAS curve for your query:  
229 
 
The DAS curve of the query is also available in PostScript format.  
230 
You may wish to compare your curve with those obtained for the test set. It gives 
you an idea about the confidence of the prediction.  
 
 
MEMSAT  
THE TOPOLOGY RESULT OF YOUR SEQUENCE 
 
 
The results that may be important to you 
are printed at the bottom of your 
browser,  
The first section after the FINAL 
PREDICTION is the topology of the 
protein The second is the visual location 
of the predicted transmembrane helix 
The third is the fasta sequence of your 
protein  
 
Any Suggestion On the Web 
Please Mail to 
yzhai@biomail.ucsd.edu 
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COMMERCIAL USE OF THIS PROGRAM IS FORBIDDEN 
 
Newman_agrC1 
430 residues read from file. 
 
Helix 1 from 184 (in) to 205 (out) : 10028 
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
----------------------------------------------------------------------------------------------------------------------
Score = -35.667000 
Helix 1 from 184 (out) to 205 (in) : 10136 
----------------------------------------------------------------------------------------------------------------------
OOOOXXXXXXXXXXXXXXIIII+++++++++++++++++++++++++++++++++++++++++++++
+++++++++++++++++ 
Score = -20.294000 
Helix 1 from   9 (in) to  27 (out) : 3261 
Helix 2 from  35 (out) to  51 (in) : 3437 
Helix 3 from  58 (in) to  74 (out) : 2511 
Helix 4 from  81 (out) to 103 (in) : 2601 
Helix 5 from 110 (in) to 132 (out) : 5463 
Helix 6 from 149 (out) to 168 (in) : 5833 
Helix 7 from 182 (in) to 205 (out) : 5498 
Helix 8 from 216 (out) to 232 (in) : -8175 
231 
Helix 9 from 241 (in) to 257 (out) : -5566 
Helix 10 from 268 (out) to 285 (in) : -6740 
Helix 11 from 295 (in) to 313 (out) : -5191 
Helix 12 from 321 (out) to 337 (in) : -1626 
Helix 13 from 351 (in) to 368 (out) : -2052 
Helix 14 from 384 (out) to 400 (in) : -5963 
Helix 15 from 407 (in) to 423 (out) : -3174 
++++++++IIIIXXXXXXXXXXXOOOO-------OOOOXXXXXXXXXIIII++++++IIIIXXXXXXX
OOOOXXXXXXXXXIIII++++++++IIIIXXXXXXXXXOOOO----------OOOOXXXXXXXXXX
Score = -100000.000000 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 236 (in) to 252 (out) : -4560 
Helix 9 from 268 (out) to 285 (in) : -6740 
Helix 10 from 295 (in) to 313 (out) : -5191 
Helix 11 from 321 (out) to 337 (in) : -1626 
Helix 12 from 351 (in) to 368 (out) : -2052 
Helix 13 from 384 (out) to 400 (in) : -5963 
Helix 14 from 407 (in) to 423 (out) : -3174 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++IIIIXXXXXXXX
OOOOXXXXXXXXXIIII++++++IIIIXXXXXXXXXOOOO------- 
Score = -100000.000000 
Helix 1 from   9 (in) to  27 (out) : 3261 
Helix 2 from  35 (out) to  51 (in) : 3437 
Helix 3 from  58 (in) to  74 (out) : 2511 
Helix 4 from  81 (out) to 103 (in) : 2601 
Helix 5 from 110 (in) to 132 (out) : 5463 
Helix 6 from 149 (out) to 168 (in) : 5833 
Helix 7 from 182 (in) to 205 (out) : 5498 
Helix 8 from 236 (out) to 252 (in) : -5005 
Helix 9 from 295 (in) to 313 (out) : -5191 
Helix 10 from 321 (out) to 337 (in) : -1626 
Helix 11 from 351 (in) to 368 (out) : -2052 
Helix 12 from 384 (out) to 400 (in) : -5963 
Helix 13 from 407 (in) to 423 (out) : -3174 
++++++++IIIIXXXXXXXXXXXOOOO-------OOOOXXXXXXXXXIIII++++++IIIIXXXXXXX
OOOOXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++IIIIXXXXX
Score = -100000.000000 
Helix 1 from   9 (out) to  27 (in) : 3774 
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Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 295 (in) to 313 (out) : -5191 
Helix 9 from 321 (out) to 337 (in) : -1626 
Helix 10 from 351 (in) to 368 (out) : -2052 
Helix 11 from 384 (out) to 400 (in) : -5963 
Helix 12 from 407 (in) to 423 (out) : -3174 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
OOOOXXXXXXXXXIIII++++++IIIIXXXXXXXXXOOOO------- 
Score = -100000.000000 
Helix 1 from   9 (in) to  27 (out) : 3261 
Helix 2 from  35 (out) to  51 (in) : 3437 
Helix 3 from  58 (in) to  74 (out) : 2511 
Helix 4 from  81 (out) to 103 (in) : 2601 
Helix 5 from 110 (in) to 132 (out) : 5463 
Helix 6 from 149 (out) to 168 (in) : 5833 
Helix 7 from 182 (in) to 205 (out) : 5498 
Helix 8 from 236 (out) to 252 (in) : -5005 
Helix 9 from 319 (in) to 337 (out) : -1705 
Helix 10 from 351 (out) to 368 (in) : -2798 
Helix 11 from 406 (in) to 422 (out) : -2831 
++++++++IIIIXXXXXXXXXXXOOOO-------OOOOXXXXXXXXXIIII++++++IIIIXXXXXXX
OOOOXXXXXXXXXIIII+++++++++++++++++++++++++++++++++++++++++++++++++++
Score = -100000.000000 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 319 (in) to 337 (out) : -1705 
Helix 9 from 351 (out) to 368 (in) : -2798 
Helix 10 from 406 (in) to 422 (out) : -2831 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
OOOOXXXXXXXXXXIIII+++++++++++++++++++++++++++++++++++++IIIIXXXXXXXX
Score = -100000.000000 
Helix 1 from   9 (in) to  30 (out) : 3980 
Helix 2 from  56 (out) to  72 (in) : 4350 
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Helix 3 from  79 (in) to 103 (out) : 3285 
Helix 4 from 110 (out) to 132 (in) : 5667 
Helix 5 from 149 (in) to 168 (out) : 5860 
Helix 6 from 182 (out) to 205 (in) : 5466 
Helix 7 from 319 (in) to 337 (out) : -1705 
Helix 8 from 351 (out) to 368 (in) : -2798 
Helix 9 from 406 (in) to 422 (out) : -2831 
++++++++IIIIXXXXXXXXXXXXXXOOOO-------------------------OOOOXXXXXXXXXIIII+++
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
OOOOXXXXXXXXXXIIII+++++++++++++++++++++++++++++++++++++IIIIXXXXXXXX
Score = -100000.000000 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 319 (in) to 337 (out) : -1705 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
Score = -100000.000000 
Helix 1 from   9 (in) to  30 (out) : 3980 
Helix 2 from  56 (out) to  72 (in) : 4350 
Helix 3 from  79 (in) to 103 (out) : 3285 
Helix 4 from 110 (out) to 132 (in) : 5667 
Helix 5 from 149 (in) to 168 (out) : 5860 
Helix 6 from 182 (out) to 205 (in) : 5466 
Helix 7 from 319 (in) to 337 (out) : -1705 
++++++++IIIIXXXXXXXXXXXXXXOOOO-------------------------OOOOXXXXXXXXXIIII+++
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
Score = -100000.000000 
Helix 1 from   9 (out) to  30 (in) : 4166 
Helix 2 from  56 (in) to  72 (out) : 4318 
Helix 3 from 110 (out) to 132 (in) : 5667 
Helix 4 from 149 (in) to 168 (out) : 5860 
Helix 5 from 182 (out) to 205 (in) : 5466 
Helix 6 from 319 (in) to 337 (out) : -1705 
--------OOOOXXXXXXXXXXXXXXIIII+++++++++++++++++++++++++IIIIXXXXXXXXXO
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
Score = -100000.000000 
Helix 1 from   9 (in) to  30 (out) : 3980 
Helix 2 from  56 (out) to  72 (in) : 4350 
Helix 3 from 110 (in) to 132 (out) : 5463 
Helix 4 from 149 (out) to 168 (in) : 5833 
234 
Helix 5 from 182 (in) to 205 (out) : 5498 
++++++++IIIIXXXXXXXXXXXXXXOOOO-------------------------OOOOXXXXXXXXXIIII+++
----------------------------------------------------------------------------------------------------------------------
Score = 16.868000 
Helix 1 from   9 (out) to  30 (in) : 4166 
Helix 2 from 110 (in) to 132 (out) : 5463 
Helix 3 from 149 (out) to 168 (in) : 5833 
Helix 4 from 182 (in) to 205 (out) : 5498 
--------OOOOXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++
----------------------------------------------------------------------------------------------------------------------
Score = 10.220000 
Helix 1 from 110 (in) to 132 (out) : 5463 
Helix 2 from 149 (out) to 168 (in) : 5833 
Helix 3 from 182 (in) to 205 (out) : 5498 
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
----------------------------------------------------------------------------------------------------------------------
Score = 0.360000 
Helix 1 from 110 (out) to 132 (in) : 5667 
Helix 2 from 182 (in) to 205 (out) : 5498 
-------------------------------------------------------------------------------------------------------------OOOO
------------------------------------------------------------------------------------------------------------------ 
Score = -8.163000 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 217 (in) to 234 (out) : -7586 
Helix 9 from 241 (out) to 257 (in) : -6320 
Helix 10 from 268 (in) to 285 (out) : -6744 
Helix 11 from 295 (out) to 313 (in) : -5146 
Helix 12 from 321 (in) to 337 (out) : -1881 
Helix 13 from 351 (out) to 368 (in) : -2798 
Helix 14 from 384 (in) to 400 (out) : -6639 
Helix 15 from 407 (out) to 423 (in) : -4021 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII+++++++++++IIIIXXXXXXXXXXOOOO------OOOOXX
OOOOXXXXXXXXXIIII+++++++ 
Score = -100000.000000 
Helix 1 from   9 (in) to  27 (out) : 3261 
Helix 2 from  35 (out) to  51 (in) : 3437 
Helix 3 from  58 (in) to  74 (out) : 2511 
Helix 4 from  81 (out) to 103 (in) : 2601 
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Helix 5 from 110 (in) to 132 (out) : 5463 
Helix 6 from 149 (out) to 168 (in) : 5833 
Helix 7 from 182 (in) to 205 (out) : 5498 
Helix 8 from 216 (out) to 232 (in) : -8175 
Helix 9 from 241 (in) to 257 (out) : -5566 
Helix 10 from 268 (out) to 285 (in) : -6740 
Helix 11 from 295 (in) to 313 (out) : -5191 
Helix 12 from 321 (out) to 337 (in) : -1626 
Helix 13 from 351 (in) to 368 (out) : -2052 
Helix 14 from 406 (out) to 422 (in) : -3101 
++++++++IIIIXXXXXXXXXXXOOOO-------OOOOXXXXXXXXXIIII++++++IIIIXXXXXXX
OOOOXXXXXXXXXIIII++++++++IIIIXXXXXXXXXOOOO----------OOOOXXXXXXXXXX
Score = -100000.000000 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 236 (in) to 252 (out) : -4560 
Helix 9 from 268 (out) to 285 (in) : -6740 
Helix 10 from 295 (in) to 313 (out) : -5191 
Helix 11 from 321 (out) to 337 (in) : -1626 
Helix 12 from 351 (in) to 368 (out) : -2052 
Helix 13 from 406 (out) to 422 (in) : -3101 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++IIIIXXXXXXXX
OOOOXXXXXXXXXIIII++++++++ 
Score = -100000.000000 
Helix 1 from   9 (in) to  27 (out) : 3261 
Helix 2 from  35 (out) to  51 (in) : 3437 
Helix 3 from  58 (in) to  74 (out) : 2511 
Helix 4 from  81 (out) to 103 (in) : 2601 
Helix 5 from 110 (in) to 132 (out) : 5463 
Helix 6 from 149 (out) to 168 (in) : 5833 
Helix 7 from 182 (in) to 205 (out) : 5498 
Helix 8 from 236 (out) to 252 (in) : -5005 
Helix 9 from 295 (in) to 313 (out) : -5191 
Helix 10 from 321 (out) to 337 (in) : -1626 
Helix 11 from 351 (in) to 368 (out) : -2052 
Helix 12 from 406 (out) to 422 (in) : -3101 
++++++++IIIIXXXXXXXXXXXOOOO-------OOOOXXXXXXXXXIIII++++++IIIIXXXXXXX
OOOOXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++IIIIXXXXX
Score = -100000.000000 
236 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 295 (in) to 313 (out) : -5191 
Helix 9 from 321 (out) to 337 (in) : -1626 
Helix 10 from 351 (in) to 368 (out) : -2052 
Helix 11 from 406 (out) to 422 (in) : -3101 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
OOOOXXXXXXXXXIIII++++++++ 
Score = -100000.000000 
Helix 1 from   9 (in) to  27 (out) : 3261 
Helix 2 from  35 (out) to  51 (in) : 3437 
Helix 3 from  58 (in) to  74 (out) : 2511 
Helix 4 from  81 (out) to 103 (in) : 2601 
Helix 5 from 110 (in) to 132 (out) : 5463 
Helix 6 from 149 (out) to 168 (in) : 5833 
Helix 7 from 182 (in) to 205 (out) : 5498 
Helix 8 from 236 (out) to 252 (in) : -5005 
Helix 9 from 319 (in) to 337 (out) : -1705 
Helix 10 from 351 (out) to 368 (in) : -2798 
++++++++IIIIXXXXXXXXXXXOOOO-------OOOOXXXXXXXXXIIII++++++IIIIXXXXXXX
OOOOXXXXXXXXXIIII+++++++++++++++++++++++++++++++++++++++++++++++++++
Score = -100000.000000 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
Helix 8 from 319 (in) to 337 (out) : -1705 
Helix 9 from 351 (out) to 368 (in) : -2798 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
OOOOXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++++++++++
Score = -100000.000000 
Helix 1 from   9 (in) to  30 (out) : 3980 
Helix 2 from  56 (out) to  72 (in) : 4350 
Helix 3 from  79 (in) to 103 (out) : 3285 
Helix 4 from 110 (out) to 132 (in) : 5667 
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Helix 5 from 149 (in) to 168 (out) : 5860 
Helix 6 from 182 (out) to 205 (in) : 5466 
Helix 7 from 319 (in) to 337 (out) : -1705 
Helix 8 from 351 (out) to 368 (in) : -2798 
++++++++IIIIXXXXXXXXXXXXXXOOOO-------------------------OOOOXXXXXXXXXIIII+++
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
OOOOXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++++++++++
Score = -100000.000000 
Helix 1 from   9 (out) to  27 (in) : 3774 
Helix 2 from  35 (in) to  51 (out) : 3682 
Helix 3 from  58 (out) to  74 (in) : 3229 
Helix 4 from  87 (in) to 103 (out) : 2848 
Helix 5 from 110 (out) to 132 (in) : 5667 
Helix 6 from 149 (in) to 168 (out) : 5860 
Helix 7 from 182 (out) to 205 (in) : 5466 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++ 
Score = 36.574000 
Helix 1 from   9 (in) to  30 (out) : 3980 
Helix 2 from  56 (out) to  72 (in) : 4350 
Helix 3 from  79 (in) to 103 (out) : 3285 
Helix 4 from 110 (out) to 132 (in) : 5667 
Helix 5 from 149 (in) to 168 (out) : 5860 
Helix 6 from 182 (out) to 205 (in) : 5466 
++++++++IIIIXXXXXXXXXXXXXXOOOO-------------------------OOOOXXXXXXXXXIIII+++
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++ 
Score = 31.547000 
Helix 1 from   9 (out) to  30 (in) : 4166 
Helix 2 from  56 (in) to  72 (out) : 4318 
Helix 3 from 110 (out) to 132 (in) : 5667 
Helix 4 from 149 (in) to 168 (out) : 5860 
Helix 5 from 182 (out) to 205 (in) : 5466 
--------OOOOXXXXXXXXXXXXXXIIII+++++++++++++++++++++++++IIIIXXXXXXXXXO
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++ 
Score = 25.369000 
Helix 1 from   9 (in) to  30 (out) : 3980 
Helix 2 from 110 (out) to 132 (in) : 5667 
Helix 3 from 149 (in) to 168 (out) : 5860 
Helix 4 from 182 (out) to 205 (in) : 5466 
++++++++IIIIXXXXXXXXXXXXXXOOOO-------------------------------------------------------------
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++ 
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Score = 15.639000 
Helix 1 from 110 (out) to 132 (in) : 5667 
Helix 2 from 149 (in) to 168 (out) : 5860 
Helix 3 from 182 (out) to 205 (in) : 5466 
-------------------------------------------------------------------------------------------------------------OOOO
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++ 
Score = 8.526000 
Helix 1 from 110 (in) to 132 (out) : 5463 
Helix 2 from 149 (out) to 168 (in) : 5833 
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
OOOOXXXXXXXXXXXXIIII+++++++++++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++++++++++++++++++++++++++++++++++ 
Score = -3.605000 
 1 helices (+) : Score = -35.667 
 1 helices (-) : Score = -20.294 
 2 helices (+) : Score = -3.605 
 2 helices (-) : Score = -8.163 
 3 helices (+) : Score = 0.36 
 3 helices (-) : Score = 8.526 
 4 helices (+) : Score = 15.639 
 4 helices (-) : Score = 10.22 
 5 helices (+) : Score = 16.868 
 5 helices (-) : Score = 25.369 
 6 helices (+) : Score = 31.547 
 6 helices (-) : Score = -100000 
 7 helices (+) : Score = -100000 
 7 helices (-) : Score = 36.574 
 8 helices (+) : Score = -100000 
 8 helices (-) : Score = -100000 
 9 helices (+) : Score = -100000 
 9 helices (-) : Score = -100000 
10 helices (+) : Score = -100000 
10 helices (-) : Score = -100000 
11 helices (+) : Score = -100000 
11 helices (-) : Score = -100000 
12 helices (+) : Score = -100000 
12 helices (-) : Score = -100000 
13 helices (+) : Score = -100000 
13 helices (-) : Score = -100000 
14 helices (+) : Score = -100000 
14 helices (-) : Score = -100000 
15 helices (+) : Score = -100000 
15 helices (-) : Score = -100000 
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FINAL PREDICTION 
================ 
1: (out) 9-27 (3.77) 
2: 35-51 (3.68) 
3: 58-74 (3.23) 
4: 87-103 (2.85) 
5: 110-132 (5.67) 
6: 149-168 (5.86) 
7: 182-205 (5.47) 
 
--------OOOOXXXXXXXXXXXIIII+++++++IIIIXXXXXXXXXOOOO------OOOOXXXXXXX
OOOOXXXXXXXXXXXXXXXXIIII++++++++++++++++++++++++++++++++++++++++++
++++++++++++++++++++ 
MELLNSYNFVLFVLTQMILMFTIPAIISGIKYSKLDYFFIIVISTLSLFLFKMFDSASLIILTSFI
YTLKIEAINNEMRKFRHDYVNILTTLSEYIREDDMPGLRDYFNKNIVPMKDNLQMNAIKLN
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HMMTOP 2.0 
 
Protein: Newman_agrC1 
Length:  430 
N-terminus: OUT  
Number of transmembrane helices: 6 
Transmembrane helices: 7-30 39-62 79-103 110-133 150-169 182-205  
 
Total entropy of the model:  17.0116 
Entropy of the best path:  17.0140 
 
The best path: 
 
     seq  MELLNSYNFV LFVLTQMILM FTIPAIISGI KYSKLDYFFI 
IVISTLSLFL    50 
     pred OOooooHHHH HHHHHHHHHH HHHHHHHHHH iiiiiiiiHH 
HHHHHHHHHH  
 
     seq  FKMFDSASLI ILTSFIIIMY FVKIKWYSIL LIMTSQIILY 
CANYMYIVIY   100 
     pred HHHHHHHHHH HHoooooooo ooooooooHH HHHHHHHHHH 
HHHHHHHHHH  
 
     seq  AYITKISDSI FVIFPSFFVV YVTISILFSY IINRVLKKIS TPYLILNKGF   
150 
     pred HHHiiiiiiH HHHHHHHHHH HHHHHHHHHH HHHooooooo 
oooooooooH  
 
     seq  LIVISTILLL TFSLFFFYSQ INSDEAKVIR QYSFIFIGIT IFLSILTFVI   
200 
     pred HHHHHHHHHH HHHHHHHHHi iiiiiiiiii iHHHHHHHHH 
HHHHHHHHHH  
 
     seq  SQFLLKEMKY KRNQEEIETY YEYTLKIEAI NNEMRKFRHD 
YVNILTTLSE   250 
     pred HHHHHooooo oooooooooo OOOOOOOOOO OOOOOOOOOO 
OOOOOOOOOO  
 
     seq  YIREDDMPGL RDYFNKNIVP MKDNLQMNAI KLNGIENLKV 
REIKGLITAK   300 
     pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO 
OOOOOOOOOO  
 
     seq  ILRAQEMNIP ISIEIPDEVS SINLNMIDLS RSIGIILDNA IEASTEIDDP   
350 
241 
     pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO 
OOOOOOOOOO  
 
     seq  IIRVAFIESE NSVTFIVMNK CADDIPRIHE LFQESFSTKG 
EGRGLGLSTL   400 
     pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO 
OOOOOOOOOO  
 
     seq  KEIADNADNV LLDTIIENGF FIQKVEIINN   430 
     pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO  
 
 
 
If you are going to use these results in your work, please cite:  
G.E Tusnády and I. Simon (1998) J. Mol. Biol. 283, 489-506.  
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Appendix B 
 
>1 
GAAAATGCAGGATTTAACGTGAAGATGAATATCCAACCAGATTATGGT
AGCTATCGTACACAACGTCAAGCCGGCAATTATGATATCCAAATTGAT
GACTGGATGACAGTGTTTGGTGACCCGAACTATGCTATGACGGCATTA
TTTAGTTCTACAGGATCAAATAGTTTATTGAAAGATAAACATGTAGAC
CAGTTGTTAAATAAAGCTTCTACTCAAAATGAAGCAGATGTTAAACAA
ACATATAAGCAAATTGAAGATGAAGTTGTATTTGATAAAGGGTATATG
GCGCCTTTATATGGATCAAAAAAGAATTTAGTATATGACAATAAAGTG
TTAGATAAAAATAGTGTTGGATTGCCAAATTCACGTGCATTAATATGG
CAACAATTTGATTACAACAATAGTAGAGAACGAGATACGCGGCCACTT
GTGATGACACAACAAGATGGTGAAATTCCTACATTGGATCCAATACGT
T 
 
>39 
GAAAATGCAGGATTTAACGTGAAGATGAATATCCAACCAGATTATGGT
AGCTATCGTACACAACGTCAAGCCGGCAATTATGATATCCAAATTGAT
GACTGGATGACAGTGTTTGGTGACCCGAACTATGCTATGACGGCATTA
TTTAGTTCTACAGGATCAAATAGTTTATTGAAAGATAAACATGTAGAC
CAGTTGTTAAATAAAGCTTCTACTCAAAATGAAGCAGATGTTAAACAA
ACATATAAGCAAATTGAAGATGAAGTTGTATTTGATAAAGGGTATATG
GCGCCTTTATATGGATCAAAAAAGAATTTAGTATATGACAATAAAGTG
TTAGATAAAAATAGTGTTGGATTGCCAAATTCACGTGCATTAATATGG
CAACAATTTGATTACAACAATAGTAGAGAACGAGATACGCGGCCACTT
GTGATGACACAACAAGATGGTGAAATTCCTACATTGGATCCAATACGT
T 
 
>3 
AAAGTGTCTAATCGTTTAGCTGAGAAATATGATTTAGACATGAAACAT
ACTTTCCTAGGGCCTCATGCTGTACCTAAAGAGGCAAGTTCAAATGAG
GCATTTTTAGAAGAAATGATTGCGTTACTTCCGGAAGTAAAACAATAT
GCAGACTTTGCGGATATTTTCTGTGAAACAGGTGTATTTACAATAGAA
CAATCGCAACATTATATGCAAAAAGCCAAAGAAGCAGGTTTTAAAGTG
AAAATACATGCGGATGAAATTGATCCGTTAGGCGGACTGGAATTAG 
 
>68 
AAAGTGTCTAATCGTTTAGCTGAGAAATATGATTTAGACATGAAACAT
ACTTTCCTAGGGCCTCATGCTGTACCTAAAGAGGCAAGTTCAAATGAG
GCATTTTTAGAAGAAATGATTGCGTTACTTCCGGAAGTAAAACAATAT
GCAGACTTTGCGGATATTTTCTGTGAAACAGGTGTATTTACAATAGAA
CAATCGCAACATTATATGCAAAAAGCCAAAGAAGCAGGTTTTAAAGTG
AAAATACATGCGGATGAAATTGATCCGTTAGGCGGACTGGAATTAG 
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>5 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGATTTAATTGATGAAGCAAGTTCTAAAGTAAGACTTAAGAGTCA
TACGACACCTAATAATTTAAAAGAAATTGAACAAGAAATTGAAAAAGT
TAAAAATGAAAAAGATGCCGCAGTACATGCTCAAGAGTTTGAAAATGC
TGCTAACCTGCGTGATAAACAAACAAAACTTGAAAAGCAATATGAAG
AAGCTAAAAATGAATGGAAGAATGCACAAAATGGCATGTCAACTTCAT
TGTCAGAAGAAGATATTGCTGAAGTTATTGCAGGATGGACAGGTATCC
CATTAACTAAAATCAATGAAACAGAATCTGAAAAACTTCTTAGTCTAG
AAGATACATTACATGAGAGAGTTATTGGGGCAAAAAGATGCTGTTAAT
TCAATCAGTAAAGCGGTTAGACGTGCCCGTGCAGGGGTTAAAAGATCC
TAAACGACCAATTCCCGGGGA 
 
>49 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGATTTAATTGATGAAGCAAGTTCTAAAGTAAGACTTAAGAGTCA
TACGACACCTAATAATTTAAAAGAAATTGAACAAGAAATTGAAAAAGT
TAAAAATGAAAAAGATGCCGCAGTACATGCTCAAGAGTTTGAAAATGC
TGCTAACCTGCGTGATAAACAAACAAAACTTGAAAAGCAATATGAAG
AAGCTAAAAATGAATGGAAGAATGCACAAAATGGCATGTCAACTTCAT
TGTCAGAAGAAGATATTGCTGAAGTTATTGCAGGATGGACAGGTATCC
CATTAACTAAAATCAATGAAACAGAATCTGAAAAACTTCTTAGTCTAG
AAGATACATTACATGAGAGAGTTATTGGGGCAAAAAGATGCTGTTAAT
TCAATCAGTAAAGCGGTTAGACGTGCCCGTGCAGGGGTTAAAAGATCC
TAAACGACCAATTCCCGGGGA 
 
 
244 
 
 
 
 
 
 
 
 
 
 
 
 
 
>9 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGCAGTACCAAGCCCCATTGCTGTCGCACAGGCAAATTTTACCCA
TAACTGTGGTTCAACACTGCCATCATTCTGTACATTAGCGACAATCAAT
GCCAACGTAATAATACCCATTGATTTTTGCGCATCATTCGTACCGTGAG
AGAATGATTGTAACGCTGCTGTGAAAATTTGGAAAAATCTAAAGTTAC
GATTCGCTCTTGTTAAATTTGCATTTTTAAAGATAACTTTAAAAATTGA
ATACATCAAGAAACCAACACAAAATGCGATAATCGGTGAAACGATTA
ATACAATAATAATTTTTGTGAAACCTTGGTAATGTAACACTCCAAATG
AGCCTTCAGATGCGATTGCTGCACCCG 
 
>63 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGCAGTACCAAGCCCCATTGCTGTCGCACAGGCAAATTTTACCCA
TAACTGTGGTTCAACACTGCCATCATTCTGTACATTAGCGACAATCAAT
GCCAACGTAATAATACCCATTGATTTTTGCGCATCATTCGTACCGTGAG
AGAATGATTGTAACGCTGCTGTGAAAATTTGGAAAAATCTAAAGTTAC
GATTCGCTCTTGTTAAATTTGCATTTTTAAAGATAACTTTAAAAATTGA
ATACATCAAGAAACCAACACAAAATGCGATAATCGGTGAAACGATTA
ATACAATAATAATTTTTGTGAAACCTTGGTAATGTAACACTCCAAATG
AGCCTTCAGATGCGATTGCTGCACCCG 
245 
 
 
 
 
 
 
 
 
>20 
ATGGAGCAAAATTTAACAATTGAAACAAAGTCAAATCCGAATGACCTT
GTTACAAATGTAGATAAAGCAACAGAAGATTTCATTTTTGATACAATT
TTAGAAACATATCCCAATCATCAAGTATTAGGTGAAGAAGGGCATGGT
CATGACATCGATACTTCCAAAGGTACGGTATGGATTGTTGACCCAATA
GACGGTACATTGAATTTTGTTCATCAACAAGAAAATTTCGCAATTT 
 
>46 
ATGGAGCAAAATTTAACAATTGAAACAAAGTCAAATCCGAATGACCTT
GTTACAAATGTAGATAAAGCAACAGAAGATTTCATTTTTGATACAATT
TTAGAAACATATCCCAATCATCAAGTATTAGGTGAAGAAGGGCATGGT
CATGACATCGATACTTCCAAAGGTACGGTATGGATTGTTGACCCAATA
GACGGTACATTGAATTTTGTTCATCAACAAGAAAATTTCGCAATTT 
 
>31 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGTTCTATCATTCGCTTTTTTTCTAGACTATATTATGAAATTATATT
TTACAATGCCCAAAACTATTTTAATAATCATTGAACAAATGGGTGTAT
AATTTATAGAAATAATGTAGAATAAAAATAAATGATTGAATTAATTGG
AGTGAAAGTTTTGGACGTTATCAAGCAAATACAACAGG 
 
>53 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGTACACGTCCAAACTTTTTTATAGCAATTATTTGCTTATAAGTTA
ATAATTGAACTTTTTAAAATATTGTCTCATACTTTAAAAATCCAGTTTC
TCACTCATTACCTTCATCCATCTCGAACAAATATTCTCACACCATTATC
246 
AATAAGGTTGACTTAGTTGAGAATACAAATCTTCTTTTTTTACATTTTTT
ACATTAAAATCAAGATATTAAATATAGACACAACCTTTTAAATCATCA
ACTACAAAATCCATTATCAAAGCACTTTATATTATCTTTCTTTATTTTAA
AAGTAATCATTCACTTTACAAAGTTATCCAGTTGACTATTCTGGATCAA
AATGTAATAATGCTAACTAAGAGATTAGAATTATTATAATTAAGCGCA
AT 
 
>60 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGTTCTATCATTCGCTTTTTTTCTAGACTATATTATGAAATTATATT
TTACAATGCCCAAAACTATTTTAATAATCATTGAACAAATGGGTGTAT
AATTTATAGAAATAATGTAGAATAAAAATAAATGATTGAATTAATTGG
AGTGAAAGTTTTGGACGTTATCAAGCAAATACAACAGG 
 
>69 
TCTTACTCAATGAGCGCTCAAGATAAAATGAATACTGTAGATGCATAT
GAAAATCTATTATTTGATTGTCTTAAAGGTGATGCCACTAACTTCACGC
ACTGGGAAGAATTAAAATCAACATGGAAATTTGTTGATGCAATTCAAG
ATGAATGGAATATGGTTGATCCAGAATTCCCTAACTATGAATCAGGTA
CTAATGGTCCATTAGAAAGTGATTTACTACTTGCTCGTGATGGTAACCA
TTGGTGGGACGATATTCAATAATTGAATTAAAACGCACATGTTAAACA
AAAATAAATGAGCGAATGACAAGGATTGATTACGAATCAAGTAAATC
AATTGTTCTATCATTCGCTTTTTTTCTAGACTATATTATGAAATTATATT
TTACAATGCCCAAAACTATTTTAATAATCATTGAACAAATGGGTGTAT
AATTTATAGAAATAATGTAGAATAAAAATAAATGATTGAATTAATTGG
AGTGAAAGTTTTGGACGTTATCAAGCAAATACAACAGG 
 
>61 
AGCAAACAACCGAATCAAATTAATGATTGGGGAACATTTGATCATACT
AAATTTGATGTCGATGATCATGTTACTAGTTATATGACATTTGCCAATC
GAGCAAGCATGCAGTTTGAATGTTCGTGGTCTGCAAATATCAAAGAAG
ATAAGGTTCACGTTAGTTTATCAGGAGAAGATGGCGGTATCAATTTAT
TTCCATTTGAAATATATGAGCCCCGCTTTGGAACTATTTTTGAAAGCAA
AGCTAATGTTGAGCATAACGAAGACATTGCTGGTGAGAGACAGGCGC
GTAACTTTGTCAATGCGTGTTTAGGGATAGAAGAGATTGTGGTGAAAC
CGGAAGAAGCACGCAATGTAAATGCCCTTATAGAAGCGATTTATCGTA
GCGATCTTGATAACAAGAGCATACAACTTTAATGATTATCATATATGA
TACAAAATTCTCAATATAAAAAGAAGGAGTGCTTTTCAATGAAAATAG
GTGTATTTTCAGTATTATTTTACGATAAAAATTTTGAAGATATGTTAGA
TTATGTCTCAGAATCTGGATTGGATATGATTGAAGTTGGAACAGGTGG
247 
TAACCCAGGAGATAAATTTTGTAAGTTAGATGAGTTGTTAGAAAATGA
AGACAAGCGCCAAGCATTTATGAAGTCAATCACAGACAGAGGCTTACA
AATAAGTGGTTTCAGTTGTCATAACAATCCAATTTCTCCAGATCCGATA
GAAGCGAAAGAAGCCGATGAAACGTTACGTAAAACAATCCGTTTAGC
AAATCTATTAGACGTGCCAGTTGTTAATACATTTTCTGGCATTGCAGGA
TCAGATGATACCGCTAAAAAGCCTAATTGGCCTGTTACACCTTGGCCA
ACAGCCTACTCTGAAATTTATGATTATCAGTGGAATGAAAAGTTGATA
CCATATTGGCAAGATTTAGCTGAGTTTGCAAAAGAGCAAGATGTAAAA
ATTGCCATAGAGTTGCATGCAGGATTTTTAGTGCATACACCATATACA
ATGTTGAAGTTACGTGAGGCTACAAATGAATATATCGGTGCTAACTTA
GATCCTAGTCATCTATGGTGGCAAGGTATTGACC 
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RNAIII
252 
253 
agrA
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